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ABSTRACT 
ASSOCIATIONS BETWEEN VITAMIN D STATUS, ADIPOSITY, AND 
INFLAMMATORY BIOMARKERS IN YOUNG WOMEN (18 – 30 YEARS) 
SEPTEMBER 2014 
ADOLPHINA A. ADDO-LARTEY, B.Sc., UNIVERSITY OF GHANA, LEGON 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Supervised by: Dr. Alayne Ronnenberg  
Calcium and vitamin D intakes have been linked with reduced adiposity in older 
adults and in obese women (body mass index, BMI, ≥ 30 kg/m2). However, very little 
is known about the extent of these associations in apparently healthy, non-obese, 
young women. Emerging research also suggest that vitamin D insufficiency (serum 
25-hydroxyvitamin D, 25-OHD, < 75 nmol/L) and increased adiposity may be 
associated with higher levels of inflammatory biomarkers in obese/older adults, and 
chronically ill patients. We conducted a cross-sectional analysis among 270 (18- to 
30-year old) female participants in the UMass Amherst Vitamin D Status Study (n = 
270) to assess the extent to which dietary intakes of calcium and vitamin D are 
associated with obesity markers. We also evaluated the association between serum 25-
OHD concentrations and both adiposity and inflammatory biomarkers. Study 
participants were mostly Caucasians (84.5%) with normal BMI, although about half 
of women had high adiposity (total body fat ‘TBF’≥ 32%). Women reporting 
adequate intakes of calcium (≥ 1000 mg/day) but low intakes of vitamin D (< 600 
IU/day) were more than twice as likely to have a high percentage of TBF compared to 
women with adequate intakes of both calcium and vitamin D. In addition, women 
vii 
  
with lower calcium intake from supplements were twice as likely to have a waist 
circumference ≥ 80 cm (OR = 2.04; 95% CI: 1.04 – 3.99) compared to women in the 
highest tertile of calcium intake. The magnitude of this association is important since 
among young women 18-30 years old, a waist circumference greater than 80 cm 
indicates central obesity and suggests increased visceral adiposity, which contributes 
to hyperlipidemia and other obesity-related chronic conditions. Among all women, 
total vitamin D, food vitamin D, and supplemental vitamin D intake were not 
associated with serum 25-OHD concentration (P > 0.05). However, among 
supplement users only, intake of vitamin D supplements was positively correlated 
with serum 25-OHD levels (ß = 0.03 ± 0.01 nmol/L, P = 0.05). These findings support 
the notion that serum levels of 25-OHD are influenced by other factors besides the 
vitamin D content of foods, including the use of vitamin D supplements. Serum 25-
OHD concentration tended to be correlated with hs-CRP levels (r = 0.14, P = 0.06), 
but was not significantly associated with adiposity and inflammatory biomarkers. 
Among women with low 25-OHD (< 75 nmol/L), serum 25-OHD level was inversely 
associated with IL-2 and GM-CSF concentrations, and marginally associated with IL-
6 and IL-7 concentrations. Additional prospective studies in more heterogeneous 
populations will help to characterize the relationship between vitamin D status, 
inflammation and obesity. 
 
  
viii 
  
TABLE OF CONTENTS 
 Page 
ACKNOWLEDGEMENTS .................................................................................................v 
ABSTRACT………. ........................................................................................................ ..vi 
LIST OF TABLES.. .......................................................................................................... xii 
LIST OF FIGURES ...........................................................................................................xv 
 
 INTRODUCTION ...............................................................................................................1 
 CHAPTER 
 1. LITERATURE REVIEW ................................................................................................3 
  1.1 Background on Calcium and Vitamin D ............................................................3 
  1.1.2 Absorption, Transport, Metabolism and Excretion.............................6 
   1.1.2.1 Calcium Absorption and Transport ......................................6 
   1.1.2.2 Calcium Metabolism and Excretion.....................................9 
   1.1.2.3 Vitamin D Absorption and Transport ................................10 
   1.1.2.4 Vitamin D Metabolism and Excretion ...............................11 
  1.1.3 Functions and Mechanisms of Action...............................................12 
  1.1.4 Assessment of Nutritional Status ......................................................13 
  1.1.5 Food Sources and Recommended Dietary Intakes ...........................17 
  1.2 Relationship between Dietary Calcium, Vitamin D and Adiposity .................23 
  1.2.1 Dietary Calcium and Adiposity ........................................................23 
  1.2.2 Dietary Vitamin D and Adiposity .....................................................33 
  1.3 Relationship between Adiposity and Serum 25-OHD Concentration .............34 
  1.4 Cytokines and Immune Function .....................................................................40 
   1.4.1 C-Reactive Protein and Inflammation ..............................................45 
  1.5 Vitamin D and Inflammation ...........................................................................49 
  1.6 Relationship between Serum 25-OHD, Adiposity and Inflammation .............50 
 
 
ix 
  
 2. SPECIFIC AIMS AND HYPOTHESES .......................................................................56 
  2.1 Calcium, Vitamin D Intakes and Adiposity in Young Women .......................56 
2.1.1 Specific Aims ....................................................................................56 
2.1.2 Hypotheses ........................................................................................56 
  2.2 Serum 25-OHD Concentration and Adiposity in Young Women ...................57 
2.2.1 Specific Aims ....................................................................................57 
2.2.2 Hypotheses ........................................................................................58 
  2.3 Serum 25-OHD, Adiposity and Inflammation in Young Women ...................58 
2.3.1 Specific Aims ....................................................................................58 
2.3.2 Hypotheses ........................................................................................59 
  2.4 Additional Covariates ......................................................................................60 
  2.5 Human Subjects Proctection ............................................................................62 
  2.6 Permission to Access Data ...............................................................................62 
 
 3. ASSOCIATIONS BETWEEN CALCIUM, VITAMIN D INTAKES AND 
OBESITY MARKERS IN YOUNG WOMEN (18 - 30 YEARS)  ...................................63 
  3.1 Introduction ......................................................................................................64 
  3.2 Materials and Methods .....................................................................................66 
3.2.1 Study Design and Population ............................................................66 
3.2.2 Anthropometry and Lifestyle Factors ...............................................67 
3.2.3 Dietary Assessment ...........................................................................69 
3.2.4 Statistical Analysis ............................................................................69 
  3.3 Results ..............................................................................................................72 
  3.4 Discussion ........................................................................................................74 
  3.5 Conclusions and Significance ..........................................................................80 
  3.6 References ........................................................................................................82 
 
x 
  
 4. ASSOCIATIONS BETWEEN SERUM 25-HYDROXYVITAMIN D 
CONCENTRATION AND ADIPOSITY MEASURES IN YOUNG WOMEN  
 (18 - 30 YEARS)  ............................................................................................................116 
  4.1 Introduction ....................................................................................................117 
  4.2 Materials and Methods ...................................................................................119 
4.2.1 Study Design and Population ..........................................................119 
4.2.2 Assessment of Serum 25-OHD Status ............................................119 
4.2.3 Dietary Assessment .........................................................................120 
4.2.4 Assessment of Covariates ...............................................................120 
4.2.5 Statistical Analysis ..........................................................................122 
  4.3 Results ............................................................................................................124 
  4.4 Discussion ......................................................................................................125 
  4.5 Conclusions and Significance ........................................................................131 
  4.6 References ......................................................................................................132 
 
 5. ASSOCIATIONS BETWEEN SERUM 25-HYDROXYVITAMIN D 
CONCENTRATION, ADIPOSITY AND INFLAMMATORY BIOMARKERS  IN 
YOUNG WOMEN (18 - 30 YEARS)  ............................................................................158 
  5.1 Introduction ....................................................................................................159 
  5.2 Materials and Methods ...................................................................................161 
5.2.1 Study Design and Population ..........................................................161 
5.2.2 Assessment of Serum 25-OHD Status ............................................161 
5.2.3 Assessment of Inflammatory Biomarkers  ......................................162 
5.2.4 Assessment of Covariates ...............................................................162 
5.2.5 Statistical Analysis ..........................................................................164 
  5.3 Results ............................................................................................................166 
  5.4 Discussion ......................................................................................................168 
5.4.1 Serum 25-OHD and Cytokine Levels .............................................169 
xi 
  
5.4.2 Serum 25-OHD and C-Reactive Protein .........................................172 
5.4.3 Adiposity and Inflammation ...........................................................173 
  5.5 Conclusions and Significance ........................................................................176 
  5.6 References ......................................................................................................178 
 
 6. SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS ................................228 
  6.1 Summary and Conclusions ............................................................................228 
 6.2 Future Directions ...........................................................................................231 
 
 APPENDICES  ................................................................................................................233 
  APPENDIX A. Permission to Access Data .........................................................233 
 
  APPENDIX B. Normality and Distribution of Covariates ..................................235 
 APPENDIX C. Linearity and Spline Model Fit for Dietary Intakes ...................242 
  APPENDIX D. Linearity and Spline Model Fit for Adiposity Measures............278 
  APPENDIX E. Linearity and Spline Model Fit for Serum 25-OHD Levels .......332 
 BIBLIOGRAPHY ............................................................................................................338 
 
 
 
  
xii 
  
LIST OF TABLES 
Table Page 
1. IOM
╧
 Recommended Serum 25-Hydroxyvitamin D (25-OHD) Concentration .........16 
2. Alternate Recommendation of Different Levels of Serum 25-OHD ...........................16 
3. Selected Food Sources of Calcium ..............................................................................18 
4. Selected Food Sources of Vitamin D ...........................................................................19 
5. Recommended Dietary Allowances (RDAs) for Calcium ...........................................20 
6. Recommended Dietary Allowances (RDAs) for Vitamin D .......................................21 
7. Characteristics of Participants (n = 270): UMass Amherst Vitamin D Status Study, 
2006 - 2011 ........................................................................................................................90 
8. Unadjusted Dietary Intakes of Participants..................................................................92 
9a. Variations in Characteristics of Participants by Adequacy of Total Calcium  
 Intake
 Ϫ
, Defined by Recommended Dietary Allowance (RDA)  ................................93 
9b. Variations in Characteristics of Participants by Adequacy of Total Vitamin D  
 Intake
 Ϫ
, Defined by Recommended Dietary Allowance (RDA) .................................95 
10a. Variations in Characteristics of Participants by Total Body Fat (TBF) Percentage ..97 
10b. Variations in Dietary Intakes of Participants by TBF Percentage  ............................99 
11a. Variations in Characteristics of Participants by Body Mass Index (BMI)  .............100 
11b. Variations in Dietary Intakes of Participants by BMI  ............................................102 
12a. Variations in Characteristics of Participants by Waist Circumference (WC)  
        Measurement ............................................................................................................103 
12b. Variations in Dietary Intakes of Participants by WC Measurement ........................105 
13. Correlations between Participant Characteristics and Adiposity Measures ..............106 
 
 
xiii 
  
14. Associations (ß ± SE)
 ϖ
 of Adiposity (Total Body Fat Percentage, Body Mass  
      Index and Waist Circumference) and Other Parameters ............................................107 
15. Crude and Adjusted Indepenent Associtaions with Adiposity ß ± SE)
 ϖ
 in Young  
      Women .......................................................................................................................108 
16. Prevalence Odds Ratio for the Association
 
of Calcium and Vitamin D Adequacy  
 with with Events of Adiposity ...................................................................................111 
17. Association
 
of Calcium and Vitamin D Intakes with Event of High Adiposity ........112 
18. Association
 of Women’s Combined Total Calcium and Vitamin D Intakes  
 with Events of High Adiposity ..................................................................................115 
19. Distribution of Serum 25-Hydroxyvitamin D (25-OHD) Levels ..............................141 
20. Variations in Characteristics of Participants by Serum 25-OHD Levels ...................142 
21. Dietary Intakes of Participants by Serum 25-OHD Levels ........................................144 
22. Mean Serum 25-OHD Levels by Oral Contraceptive Use, Alcohol Intake and   
 Smoking Status ..........................................................................................................145 
23. Mean Serum 25-OHD Levels by Adiposity...............................................................153 
24. Unadjusted and Adjusted Mean Values of Adiposity by Serum 25-OHD Levels .....154 
25. Linear Relationship between
 
Serum 25-OHD Levels and Other Parameters ............156 
26. Linear Relationship between Serum 25-OHD Levels and Adiposity ........................157 
27. Median and Inter-Quartile Range Distribution of Inflammatory Biomarkers ...........190 
28. Variations in Median and Inter-Quartile Range Distribution of Inflammatory  
 Biomarkers by Serum 25-OHD Status .......................................................................191 
29. Variations in Median and Inter-Quartile Range Distribution of Inflammatory  
 Biomarkers by Waist Circumference (WC) Measurement ........................................192 
 
 
xiv 
  
30. Variations in Median and Inter-Quartile Range Distribution of Inflammatory  
 Biomarkers by Body Mass Index (BMI) ...................................................................193 
31. Variations in Median and Inter-Quartile Range Distribution of Inflammatory  
 Biomarkers by Total Body Fat Percentage (TBF %) .................................................194 
32. Median Inflammatory Biomarker Concentration by Categories of Oral  
 Contraceptive Use, Smoking Status and Alcohol Intake ...........................................195 
33. Pearson Product Correlations between Log Transformed Inflammatory Factors .....197 
34. Correlations between Log Transformed Inflammatory Factors and Serum 25-OHD  
 Levels .........................................................................................................................198 
35. Mean Serum 25-OHD Concentration across Categories of High Sensitive C –  
 Reactive Protein (hs-CRP) Measures.........................................................................199 
36. Univariate Linear Relationship between
 
logTransformed Inflammatory  
 Biomarkers and Other Parameters .............................................................................214 
37. Association
 
of Serum 25-OHD Concentrations with log Transformed  
 Inflammatory Biomarkers ..........................................................................................221 
  
xv 
  
LIST OF FIGURES 
Figure Page 
1. Vitamin D Synthesis and Metabolism in Humans ...........................................................4 
2. Role of Vitamin D in Calcium Metabolism .....................................................................7 
3. Proposed Dietary Modulation of Adiposity via 1,25-dihydroxyvitamin D Mediation    
    of Intracellular Calcium Influx ......................................................................................24 
4. Prevalence at Risk for Vitamin D Deficiency by Age and Sex: United States, 2001   
    – 2006.............................................................................................................................35 
5. Age and Season-Adjusted Prevalence at Risk of Deficiency and Inadequacy among   
    Persons aged 1 year and over: United States, 2001-2006 ..............................................35 
6. Mechanisms of Innate and Adaptive Immunity .............................................................41 
7. Activation of Inflammatory Response in Tissues ..........................................................46 
8. CRP Ligand and Receptor Binding in Cells ..................................................................47 
9. Possible Mechanism of CRP Modulating Inflammation ...............................................48 
10. Genes Involved in the Vitamin D Pathway..................................................................50 
11. A DXA Scan in Progress .............................................................................................68 
12. A Dual-Energy X-ray Absorptiometry (DXA) Scan Report Showing Different   
     Body Composition Measures ......................................................................................121 
13. A DXA Scan showing Regional Adiposity Measures ...............................................122 
14. Covariation and Pearson Product Coefficient Correlation of Vitamin D Intake and    
     Serum 25-OHD Concentration ...................................................................................146 
15. Pearson Product Coefficient Correlation of Serum 25-OHD and Body Mass Index.147 
16. Pearson Product Coefficient Correlation of Serum 25-OHD and Waist    
     Circumference .............................................................................................................148 
 
xvi 
  
17. Pearson Product Coefficient Correlation of Serum 25-OHD and Total Body Fat   
      Percentage ..................................................................................................................149 
18. Pearson Product Coefficient Correlation of Serum 25-OHD and Regional    
      Adiposity Measures (Arm and Leg Fat) ....................................................................150 
19. Pearson Product Coefficient Correlation of Serum 25-OHD and Regional    
      Adiposity Measures (Trunk, Android and Gynoid Fat) .............................................151 
20. Pearson Product Coefficient Correlation of Serum 25-OHD and Android to    
      Gynoid Fat ratio (AGF ratio) .....................................................................................152 
21. Lowess Regression Curve for the Association between High Sensitive C -   
      Reactive Protein (hs-CRP) and Serum 25-OHD Concentration ................................200 
22. Lowess Regression Curve for the Association between Interleukin-1β (IL-1β) and    
      Serum 25-OHD Concentration ..................................................................................201 
23. Lowess Regression Curve for the Association between Interleukin-2 (IL-2) and   
     Serum 25-OHD Concentration ...................................................................................202 
24. Lowess Regression Curve for the Association between Interleukin-4 (IL-4) and  
     Serum 25-OHD Concentration ...................................................................................203 
25. Lowess Regression Curve for the Association between Interleukin-5 (IL-5) and  
     Serum 25-OHD Concentration ...................................................................................204 
26. Lowess Regression Curve for the Association between Interleukin-6 (IL-6) and   
     Serum 25-OHD Concentration ...................................................................................205 
27. Lowess Regression Curve for the Association between Interleukin-7 (IL-7) and  
     Serum 25-OHD Concentration ...................................................................................206 
28. Lowess Regression Curve for the Association between Interleukin-8 (IL-8) and  
     Serum 25-OHD Concentration ...................................................................................207 
 
xvii 
  
29. Lowess Regression Curve for the Association between Interleukin-10 (IL-10) and   
      Serum 25-OHD Concentration ..................................................................................208 
30. Lowess Regression Curve for the Association between Interleukin-12 (IL-12p70)   
      and Serum 25-OHD Concentration ............................................................................209 
31. Lowess Regression Curve for the Association between Interleukin-13 (IL-13) and   
     Serum 25-OHD Concentration ...................................................................................210 
32. Lowess Regression Curve for the Association between Granulocyte Macrophage   
     Colony Stimulating Factor (GM-CSF) and Serum 25-OHD Concentration ..............211 
33. Lowess Regression Curve for the Association between Tumor Necrosis Factor   
     Alpha (TNF-α) and Serum 25-OHD Concentration ...................................................212 
34. Lowess Regression Curve for the Association between Interferon Gamma (IFN-γ)    
     and Serum 25-OHD Concentration .............................................................................213 
 
 
 
  
1 
   
 
INTRODUCTION 
Recent estimates from the World Health Organization show that about 1.4 billion 
people worldwide are overweight and at least 500 million are obese (WHO, 2008). 
Data from the Centers for Disease Control and Prevention indicate that in 2009 – 
2010, more than one-third (35.7%) of U.S. adults were obese (body mass index, BMI, 
> 30 kg/m
2
), (CDC/NCHS, 2012). The prevalence of obesity in young women, ages 
20 to 39 years was also considerably high (31.9 %), (Flegal et al., 2012). This 
emerging obesity pandemic is worrisome, mostly because obesity is an independent 
risk factor for several obesity-related health problems, including cardiovascular 
disease (CVD), metabolic syndrome, type II diabetes mellitus (T2DM), and some 
kinds of cancers (Flegal et al., 2012; CDC/NCHS, 2012). 
Although obesity is generally associated with sedentary lifestyle and increased 
caloric intake (energy imbalance), micronutrient status may also influence obesity risk 
(Holick, 2006). The preponderance of available literature suggest that there is an 
inverse relationship between intakes of calcium/vitamin D and markers of adiposity, 
including BMI, waist circumference (WC), and total body fat percentage (% TBF), 
particularly in older and/or obese women (Zemel, 2000; Lin et al., 2000; Davies et al., 
2000; Buchowski et al., 2002; Zemel 2003; Zemel et al., 2004; Jacqmain et al., 2003; 
Tidwell and Valliant, 2011). Most of the studies that have examined the role of 
dietary calcium and vitamin D intake in adiposity have relied on proxies such as BMI, 
waist-to-hip-ratio and skinfold measurement (Zemel, 2000; Lin et al., 2000; Davies et 
al., 2000; Buchowski et al., 2002) because they are easily obtained and non-invasive. 
However, the use of these proxy measures may underestimate true body fat 
  
2 
   
percentage, especially among young women who are physically active (Roche et al., 
1981; Wellens et al., 1996; Flegal et al., 2009). In contrast, dual energy x-ray 
absorptiometry (DXA) is considered a more accurate method of estimating percentage 
body fat (Haarbo et al., 1991; Bolanowski and Nilsson, 2001) and its use among 
young women has been previously validated (Bolanowski and Nilsson, 2001).  
Studies in both obese and non-obese adults, as well as  post-menopausal 
women and ill-patients, show that serum 25-hydroxyvitamin D [25-OHD] 
concentration is inversely associated with inflammatory biomarkers such as C-
reactive protein (CRP) and cytokines e.g., interleukins 4, 6, and 10 (Varghese et al., 
2012; Park et al., 2005; Bellia et al., 2011). Abdominal obesity (android to gynoid 
ratio) is also independently positively associated with CRP and IL-6 levels in obese 
adults (Kim et al., 2008). However, there is an important gap in our understanding 
about the extent of these associations in apparently healthy, non-obese, young women.  
This lack of knowledge is problematic because an understanding of the modifiable 
dietary and lifestyle factors that contribute to increased adiposity and/or inflammation 
is important for the prevention and early intervention of chronic conditions such as 
metabolic syndrome, T2DM, and coronary heart disease. This dissertation used cross-
sectional data from 270 healthy young women participating in the UMass Amherst 
Vitamin D Status study to evaluate the extent to which vitamin D status and adiposity 
measures are associated with inflammatory biomarkers in young women, ages 18 to 
30 years.  
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CHAPTER 1 
LITERATURE REVIEW 
1.1 Background on Calcium and Vitamin D 
Calcium is the most abundant mineral in the body, representing about 1.5 - 2% of total 
body weight. Calcium is essential in living organisms, mainly in cell physiology, 
where movement of calcium ion (Ca
2+
) into and out of the cytoplasm functions as a 
signal for many cellular processes (Pietrobon et al., 1990; Chattopadhyay et al., 
1996). Calcium is required for nerve transmission and muscle stimulation (Karakia 
1997; Utichel et al., 1992; Onimaru et al., 2003). It also plays a role in promoting 
cross-linking by binding to Gla- or hydroxyaspartate residues in pro-clotting enzymes 
(Stipanuk, 2006). Almost all (99%) body’s calcium is stored in bones and teeth, where 
it works together with phosphorus to maintain skeletal strength and function.  The 
other 1% is distributed in soft tissues, intra- and extracellular fluids and blood. 
Calcium in foods and dietary supplements is mostly in the form of insoluble salts. 
These salts can be solubilized at an acidic pH in the stomach; however, solubilization 
does not necessarily ensure better absorption because free calcium can bind to other 
dietary constituents, limiting its bioavailability.  
Vitamin D is a fat-soluble vitamin that is naturally present in very few foods. 
The term vitamin D refers collectively to two major nutritionally relevant chemical 
forms known as vitamin D2 (ergocalciferol), present in yeast and plants, and vitamin 
D3 (cholecalciferol), which can be found in few foods, but is mainly synthesized from 
7- dehydrocholesterol (7-DHC) in the skin. 7-DHC, also referred to as pro-vitamin D3, 
is an intermediate precursor of cholesterol that is synthesized in the sebaceous gland 
of the skin and is evenly distributed throughout the epidermis and dermis. During 
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exposure to sunlight, 7-DHC absorbs ultraviolet B radiation (UVB) photons with 
wavelengths between 290 and 315 nm. This process causes a transformation of 7-
DHC to pre-vitamin D3, which is then converted to vitamin D via thermal 
transformation (Holick, 1994). Conversion to vitamin D changes the structure of the 
molecule, facilitating its translocation from the skin into the blood stream. Once in the 
bloodstream, vitamin D binds to vitamin D binding protein (DBP), also called α-2-
globulin (Fig 1).  
 
Figure 1. Vitamin D Synthesis and Metabolism in Humans 
 
Source: Holick MF. J Clin Invest 2006; 116: 2062-72. 
 
Cutaneous synthesis of vitamin D is influenced by several factors, especially 
time of day, season of the year, and latitude. At  latitudes above 42
◦
N (Boston) and 
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below 42
◦
S, very little pre-vitamin D3 is synthesized in skin from November through 
February because the incident angle of sunlight at these latitudes during this time of 
year causes blockage of the UVB photons needed to convert  7-DHC to pre-vitamin 
D3 (Webb et al., 1988). This period is extended at more extreme latitudes, such as in 
Edmonton, Canada, (52
◦
N), to include October and March (Webb et al., 1988). 
During spring and summer months, more UVB photons are able to penetrate the 
ozone layer because the sun is directly overhead. For the average fair skinned person, 
spending about 15 to 20 minutes in the midday sun (or when the sun is strongest) in 
minimal clothing (e.g., shorts and a tank top with no sunscreen) will give enough 
radiation to produce about 10,000 IU of vitamin D (Clemens et al., 1982; Holick, 
2010). Excessive exposure to sunlight does not result in vitamin D toxicity because 
any pre-vitamin D3 that is not converted into vitamin D3 is degraded into biologically 
inert photoproducts such as luminsterol and tachysterol (Holick, 1994; Holick, 2006). 
Excessive exposure to sunlight also causes some vitamin D3 to be converted to its 
non-active forms e.g., supersterol I, supersterol II, and 5, 6-trans-vitamin D3 (Holick, 
1994; Holick, 2006). 
Other factors that may influence vitamin D synthesis include age, skin tone, 
clothing, and use of sunscreen. Aging decreases the synthesis of 7-DHC in skin, 
thereby reducing the production of vitamin D3 by approximately 75% by age 70 years 
compared to younger adults (Holick et al., 1989). The skin pigment melanin is a 
natural sunblock that competes with 7-DHC for UVB photons (Clemens et al., 1982). 
Hence, very dark- skinned people require almost ten times more sun exposure to make 
the same amount of vitamin D as light-skinned people (Clemens et al., 1982). Using 
sunscreen and wearing clothing that completely covers the body can also block 
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ultraviolet rays, reducing vitamin D synthesis (Wolpowitz and Gilchrest, 2006). In 
middle aged and older adults living in Boston for example, approximately 5-15 
minutes of skin exposure (hands, arms, and legs) to sunlight two to three times a week 
is recommended for obtaining sufficient amounts of vitamin D  
 
1.1.2 Absorption, Transport, Metabolism and Excretion 
1.1.2.1 Calcium Absorption and Transport 
Calcium absorption occurs in the small intestine. Most adults can absorb 
approximately 30% of the calcium in foods, but the efficiency of absorption tends to 
decrease as calcium intake increases (FNB/IOM, 2010). Absorption of calcium occurs 
in two ways: intracellular (active) absorption in the duodenum and proximal jejunum 
involving an epithelial calcium channel (TRPV6) and the calcium-binding transport 
protein Calbindin D9K (CaBP); and paracellular (passive) absorption that occurs 
throughout the small intestine, but mostly in the ileum and jejunum (Sheikh et al., 
1987). 
Intracellular energy- dependent absorption is the primary mechanism for 
calcium uptake and transport in the body. Calcium is absorbed into the intestinal cell 
across the brush border via a channel (TRPV6) (Fig 2). When activated by 
1,25(OH)2D, the nuclear VDR interacts with specific gene promoter regions in DNA 
and affects transcription of these vitamin D-specific genes, such as increasing 
expression of the enterocyte membrane calcium channel (TRPV6, also called CaT1 
(Wood et al., 2001) and Calbindin-D9K, intracellular Ca
2+
 binding protein that 
facilitates the absorption of calcium (Bronner, 2009). 
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Figure 2. Role of Vitamin D in Calcium Metabolism 
 
Source: http://bigtomato.org/endo/bcp/vitamind.php 
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Calbindin D9K transports calcium across the cytoplasm of the enterocyte to the 
basolateral (serosal) membrane. Calcium leaves the enterocyte with the assistance of a 
Ca
2+ 
- Mg
2+
 ATPase (an enzyme that hydrolyzes ATP and releases energy for 
pumping Ca
2+ 
out of the cell as Mg
2+
 moves in). The Ca
2+ 
- Mg
2+
 ATPase pump is 
also stimulated by vitamin D. Para-cellular calcium absorption, which occurs between 
cells, rather than through them, predominates when high calcium concentrations are 
present in the lumen. This forms a calcium concentration gradient between the lumen 
and the interstitial fluid, allowing for increased diffusion of calcium through tight 
junctions of the intestinal epithelial cells.  
Calcium is absorbed in its ionized form; hence it must be released from the 
insoluble salts in which it is usually found in food and dietary supplements. Even 
though most calcium salts are dissolved in acidic pH of the stomach, some dietary 
calcium may still form insoluble complexes with other dietary components within the 
more alkaline pH of the small intestine, limiting its bioavailability. Fructose, 
oligosaccharides, inulin, and other non-digestible saccharides may enhance para-
cellular calcium absorption (Ziegler and Fomon, 1983), while vitamin D status, age 
and life stage, influence active calcium transport. In vitamin D deficient states, only 
10 - 15% of dietary calcium is absorbed (Holick, 2006; Holick and Garabedian, 2006; 
DeLuca, 2004). In infants and young children, net calcium absorption is as high as 
75% because of the need to build bone (FNB/IOM, 1997).  Calcium absorption 
usually decreases to 15% – 20% in older adults, mostly because of decreased renal 
production of 1,25(OH)2 D. Estrogen deficiency at menopause also decreases vitamin 
D- mediated calcium absorption in the gut (Gallagher et al., 1980; Heaney et al., 
1989; Breslau, 1994).  In a mixed diet, other components in food (e.g., phytic acid and 
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oxalic acid) may bind to calcium and inhibit its absorption (FNB/IOM, 2010). Foods 
such as spinach, collard greens, sweet potatoes, and rhubarb contain high levels of 
oxalic acid while whole-grain products, wheat bran, beans, seeds, nuts, and soy 
isolates contain high amounts of phytic acid (FNB/IOM, 2010), and the extent to 
which these compounds affect calcium absorption varies. For instance, eating spinach 
and drinking milk concurrently reduces the absorption of calcium in milk (Weaver 
and Heaney, 1991), but eating spinach and wheat products at the same time (with the 
exception of wheat bran) does not appear to lower calcium absorption (Weaver et al., 
1991). In general, the effects of these inhibitor-compounds are usually minimal and 
may not significantly impact nutritional status because people tend to eat a variety of 
foods during a meal.  In contrast to the inhibitors described earlier, increased intake of 
dietary protein can facilitate calcium absorption (Kerstetter et al., 2005) due to greater 
trans-cellular calcium absorption (Gaffney-Stromberg et al., 2010). 
 
1.1.2.2 Calcium Metabolism and Excretion 
In order to maintain calcium homeostasis in the body, some of the calcium ingested is 
eliminated from the body in urine and feces, and an average of 60 mg may be lost 
daily through sweat (Charles et al., 1991). This process is necessary. Calcium is 
filtered and reabsorbed by the kidney such that urinary calcium losses range from 
about 100 - 240 mg/day with an average of about 170 mg/day (Charles et al., 1991; 
Calvo et al., 1991). The amount of calcium excreted is also affected by many factors, 
including intakes of sodium, protein, phosphorus, caffeine and alcohol. Caffeine is a 
stimulant found in coffee and tea, and it can modestly reduce calcium absorption 
while increasing its excretion (Barrett-Connor et al., 1994).  A comparison of data 
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from epidemiologic surveys and animal studies showed that for younger adult women 
consuming adequate calcium, moderate caffeine intakes (1 cup of coffee or 2 cups of 
tea per day) may have little or no harmful effects on bone metabolism (Massey and 
Whiting, 1993). Alcohol consumption can also affect calcium status by reducing its 
absorption (Hirsch and Peng, 1996) and by inhibiting enzymes in the liver that help 
convert vitamin D into its pro-active form, 25-OHD (Laitinen et al.,  1990; Turner, 
2000). High sodium or protein intake increases urinary calcium excretion (Weaver et 
al., 1999; Heaney, 1996), although recent reports suggest that high protein intake also 
increases intestinal calcium absorption, thus effectively counteracting its effect on 
calcium excretion (Kerstetter et al., 2005).  
A few observational studies have reported that consumption of carbonated soft 
drinks with high levels of phosphate is associated with reduced bone mass and 
increased fracture risk (bones remodeling may be hampered if calcium is inadequate, 
causing bones to become brittle or less dense) (Calvo, 1993; Heaney and Rafferty, 
2001), although it is possible that this effect is due to replacement of milk with soda 
rather than the intake of phosphorus itself (Calvo, 1993; Heaney and Rafferty, 2001). 
However, these studies did not control for dietary calcium intake in their analysis. 
 
1.1.2.3 Vitamin D Absorption and Transport 
Dietary vitamin D is absorbed from micelles together with fat and bile salts by way of 
passive diffusion in the intestinal cell; about 50% of dietary vitamin D3 is absorbed in 
this manner (Gropper et al., 2008). Although the rate of absorption is most rapid in 
the duodenum, the largest quantity of vitamin D is absorbed in the distal small 
intestinal. Within the intestinal cell, vitamin D is incorporated primarily into 
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chylomicrons, which then enter the lymphatic system with subsequent entry into the 
blood and transport to the liver. Chylomicrons transport about 40% of the 
cholecalciferol in blood, while the rest is bound to DBP for transport to extra hepatic 
tissues. Even though the vitamin D bound to DBP travels primarily to the liver, some 
may be picked up by other tissues, especially muscle and adipose tissue, primarily for 
storage, before hepatic uptake (Gropper et al., 2008).  
 
 
1.1.2.4 Vitamin D Metabolism and Excretion 
Vitamin D is stored in the body’s adipose tissue. Vitamin D obtained from sun 
exposure, food, and supplements is biologically inert and must undergo two 
hydroxylations in the body for activation (Fig 2). The first hydroxylation occurs in the 
liver, where the enzyme 25 hydoxylase (CYP27A) converts vitamin D to 25-
hydroxyvitamin D [25-OHD], also known as calcidiol. The second hydroxylation is 
carried out by the enzyme 1-α-hydroxylase (CYP27B) in the kidney and forms the 
biologically active 1, 25-dihydroxyvitamin D (1, 25(OH)2 D), also known as calcitriol 
(DeLuca, 2004; Holick, 2006; Holick and Garabedian, 2006). Once 1, 25(OH)2 D 
completes its actions in target tissues, it is principally excreted in bile. Excess 
amounts of 1, 25(OH)2 D also induce the expression of the enzyme 25-
hydroxyvitamin D-24-hydroxylase (24-OHase), which enhances calcitriol catabolism 
(Holick, 2007). Both 25-OHD and 1,25(OH)2 D undergo a 24-hydroxylation to form 
24,25-dihydroxyvitamin D and 1,24,25-trihydroxyvitamin D, respectively. These 
hydroxylated metabolites undergo further hydroxylations in their side chain, resulting 
in the cleavage of the side chain between C-23 and C-24 and formation of the 
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biologically inert and water- soluble calcitroic acid, which is subsequently excreted in 
urine.  
 
1.1.3 Functions and Mechanisms of Action 
The major biological function of vitamin D is to promote calcium absorption in the 
gut and to maintain calcium homeostasis with the help of parathyroid hormone (PTH). 
Low concentrations of serum calcium trigger PTH release from the parathyroid 
glands, which then stimulates 1-hydroxylase activity in kidney, converting 25-OHD to 
1, 25(OH)2 D. The active form of vitamin D travels in the blood attached to vitamin D 
Binding protein (DBP). In target tissues, 1,25(OH)2D  binds to the vitamin D receptor 
(VDR), which triggers a conformational change that increases receptor affinity for 
vitamin D response elements (VDRE) on specific  genes. The 1,25(OH)2D together 
with the VDR and VDRE complex then influence transcription of genes to promote 
calcium absorption in the intestine and renal phosphorus-calcium reabsorption in the 
kidneys (Fig 2). Vitamin D is also required for bone growth and bone remodeling by 
osteoblasts and osteoclasts (Cranney et al., 2007).  
Calcium is needed for bone growth, vascular contraction and vasodilation, 
muscle function, nerve transmission, intracellular signaling and hormonal secretion. 
Maintenance of serum calcium and phosphorus concentrations within in their 
physiologic ranges is essential to support normal mineralization of bone and to 
prevent hypercalcemia and hypocalcemic tetany (a disease caused by abnormally low 
concentrations of calcium in the blood). Hypocalcemic tetany is characterized by 
hyper-excitability of the neuromuscular system and results in carpopedal spasms. 
Adequate vitamin D intake also prevents rickets in children and osteomalacia in adults 
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(Wharton and Bishop, 2003; Jones, 2008). Together with calcium, vitamin D helps 
protect older adults from osteoporosis. Most tissues in the body (e.g., gut, kidney, 
gonads, heart, muscle, brain, and skin) have a VDR as well as the capacity to convert 
25-OHD to 1,25(OH)2D (Holick, 2006; Bosse et al., 2009). Recent reports also 
suggest that vitamin D may have additional roles in the body, including modulation of 
cell growth (Holick, 2006; Krishnan and Feldman, 2011), neuromuscular and immune 
function (Marantes et al., 2011; Menant et al., 2012), and reduction of inflammation 
(Norman and Henry, 2006). 
 
1.1.4 Assessment of Nutritional Status 
Although calcium concentration can be accurately measured in blood, measurement of 
serum total and ionic calcium status is inadequate for “true” assessment of calcium 
status because serum calcium concentration is tightly regulated and does not fluctuate 
with changes in dietary intakes. The body uses bone tissue as a reservoir and a source 
of calcium to maintain constant concentrations of calcium in blood, muscle, and 
intercellular fluid (Gropper et al., 2008).  Normal serum calcium concentration 
usually ranges from 8.5 to 10.5 mg/d (Gropper et al., 2008). Low serum calcium 
levels may not also reflect calcium deficiency since serum calcium concentrations are 
tied to serum albumin status (albumin is a protein that binds calcium in plasma). 
Abnormal levels of biochemical measures associated with calcium homeostasis are 
also not necessarily proof of dietary calcium insufficiency, because vitamin D 
deficiency, bone diseases, and other hormonal imbalances can produce similar 
symptoms (Stipanuk, 2006). Calcium status can also be measured using 24-hour urine 
sampling with adjustment for urinary creatinine (Weaver, 1990). Unfortunately, this 
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procedure is not very effective in assessing calcium status either, as some drugs may 
increase (e.g., antacids, anticonvulsants, carbonic anhydrase inhibitor diuretics, loop 
diuretics) or decrease (e.g., adrenocorticosteroids, birth control pills, and thiazide 
diuretics) calcium content in urine (Bringhurst et al., 2007; Wysolmerski et al., 2007). 
Both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels can be 
specifically measured in serum or plasma (Holick, 1990; Chen et al., 1990).  The 
concentration of 25-OHD is considered the best indicator of vitamin D status because 
it represents a summation of total cutaneous production of vitamin D and oral 
ingestion of either vitamin D2 or D3. Serum 25-OHD also has a fairly long circulating 
half-life of about 15 days (Jones, 2008) as compared to 1, 25(OH)2 D, which has a 
relatively short half-life of between 4 to 6 hours. Serum 1, 25(OH)2 D concentrations 
are also closely regulated by PTH, calcium, and phosphate (Jones, 2008); hence, 
levels of 1,25(OH)2D do not typically decrease until vitamin D deficiency is severe 
(Cranney et al., 2007; Holick, 2007). Recent findings suggest that vitamin D3 may be 
more efficient at increasing serum 25-hydroxyvitamin D levels as compared to 
vitamin D2 (Malham et al., 2012). One of the difficulties associated with vitamin D 
status assessment lies in the actual measurement of serum 25-OHD concentration. 
Presently, there is substantial variability among the various assays available (the two 
most common methods being antibody- based or liquid chromatography based) and 
among laboratories that conduct the analyses (Hollis, 2004; Carter, 2009). This means 
that compared with the actual concentration of 25-OHD in a blood sample, a falsely 
low or falsely high value may be obtained depending on the type of assay or the 
laboratory used (Binkley et al., 2004). A standard reference for serum 25-OHD 
assessment became available in July 2009. This standard material permits 
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standardization of values across laboratories and may improve method-related 
variability (NIST, 2009). Table 1 shows the Institute of Medicine (IOM)-proposed cut 
offs for assessing vitamin D sufficiency, deficiency, and toxicity using serum 25-
OHD concentrations.  
While the 25-OHD cutoffs proposed by IOM serve as the “traditional” 
reference limits, many vitamin D researchers suggests that the optimal serum 
concentration of25-OHD is probably much higher than what is officially 
recommended for adults. Table 2 gives the proposed alternate 25-OHD reference 
limits considered “acceptable” by leading researchers in the field (Hollis and Wagner, 
2004; Hollis and Wagner, 2004; Heaney, 2004; Vieth, 2004; Hollis, 2005; Hanley and 
Davison, 2005; Bischoff-Ferrari et al., 2006; Holick, 2009). Serum 25-OHD level 
generally increases in response to increased vitamin D intake, but the relationship is 
not entirely linear (IOM/FNB, 2010). The increase varies, for example, by baseline 
serum levels and the duration of supplementation. For instance, increasing serum 25-
OHD from a baseline of ≥ 50 nmol/L requires more vitamin D than increasing levels 
from a baseline < 50 nmol/L. In persons with 25-OHD > 50 nmol/L, when the dose is 
≥ 1,000 IU/day, the rise in serum 25-OHD is approximately 1 nmol/L for each 40 IU 
of vitamin D intake. In contrast, among subjects with 25-OHD < 50 nmol/L, a dose of 
600 IU/day is associated with approximately 2.3 nmol/L increase in serum 25-OHD 
for each 40 IU of vitamin D consumed (IOM/FNB, 2010). 
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Table 1. IOM
╧
 Recommended Serum 25-Hydroxyvitamin D (25-OHD) 
Concentration 
25-OHD Level 
(ng/mL)* 
25-OHD Level 
(nmol/L)** 
Health Status 
< 12 < 30 Associated with vitamin D deficiency, 
leading to rickets in infants and children and 
osteomalacia in adults 
12 - 20 30 - 50 Generally considered inadequate for bone and 
overall health in healthy individuals 
≥ 20 ≥ 50 Generally considered adequate for bone and 
overall health in healthy individuals 
> 50 > 125 Emerging evidence links potential adverse 
effects to such high levels, particularly > 150 
nmol/L ( > 60 ng/mL) 
╧
Source: Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes 
for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010. 
* Serum concentrations of 25-OHD are reported in both nanomoles per liter (nmol/L) 
and nanograms per milliliter (ng/mL). 
** 1 ng/mL = 2.496 nmol/L 
 
Table 2. Alternate Recommendation of Different Levels of Serum 25-OHD 
25-OHD Level  
(ng/mL)* 
25-OHD Level 
(nmol/L)** 
Health Implications 
< 20 < 50 Deficiency 
20 - 32 50 - 80 Insufficiency 
32 - 100 80 - 250 Sufficiency 
54 - 90 135 - 225 Normal in sunny countries 
> 100 > 250 Excess 
> 150 > 325 Intoxication 
Source: Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal 
health: A review. Altern Med Rev 2005; 10: 94-111. 
* Serum concentrations of 25-OHD are reported in both nanomoles per liter (nmol/L) 
and nanograms per milliliter (ng/mL). 
** 1 ng/mL = 2.496 nmol/L 
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1.1.5 Food Sources and Recommended Dietary Intakes 
In the U.S, the major contributor of dietary calcium for most individuals is dairy foods 
(e.g., milk, yogurt, and cheese) (Briefel, 2004; Miller et al., 2007; FNB/IOM, 2010). 
Plant foods such as Chinese cabbage, kale, broccoli, almonds and soybeans also 
provide substantial amounts of dietary calcium. Most cereals and grains provide very 
little calcium unless they are fortified; however, they can be considered as substantial 
contributors of overall dietary calcium intake because even though they contain small 
amounts of calcium, people tend to consume them frequently. Table 3 shows a list of 
selected food sources and their calcium content. 
Naturally occurring vitamin D is rare in foods. The most significant dietary 
sources of vitamin D are fatty fish ( especially wild salmon, mackerel, and catfish), 
beef or veal liver, and fish oils, including cod- and tuna-liver oils (Cranney et al., 
2007; Ovesen et al., 2003; Chen et al., 2007). Cheese and egg yolk contain small 
amounts of vitamin D3 (Ovesen et al., 2003), and certain mushroom species also 
provide dietary vitamin D2 in variable amounts (Mattila et al., 1994; Calvo et al., 
2004; Philips et al., 2011). Table 4 shows the vitamin D content of some selected 
foods.  
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Table 3. Selected Food Sources of Calcium 
Food Milligrams (mg) per serving 
Yogurt, plain, low fat, 8 ounces 415 
Orange juice, calcium-fortified, 6 ounces 375 
Yogurt, fruit, low fat, 8 ounces 338 - 384 
Mozzarella, part skim, 1.5 ounces 333 
Sardines, canned in oil, with bones, 3 ounces 325 
Cheddar cheese, 1.5 ounces 307 
Milk, nonfat, 8 ounces** 299 
Milk, reduced-fat (2% milk fat), 8 ounces 293 
Milk, buttermilk, 8 ounces 282-350 
Milk, whole (3.25% milk fat), 8 ounces 276 
Tofu, firm, made with calcium sulfate, ½ cup*** 253 
Salmon, pink, canned, solids with bone, 3 ounces 181 
Cottage cheese, 1% milk fat, 1 cup 138 
Ready-to-eat cereal, calcium-fortified, 1 cup 100 - 1,000 
Turnip greens, fresh, boiled, ½ cup 99 
Kale, raw, chopped, 1 cup 90 
Soy beverage, calcium-fortified, 8 ounces 80 - 500 
Chinese cabbage, bok choi, raw, shredded, 1 cup 74 
Broccoli, raw, ½ cup 21 
 
Source: U.S. Department of Agriculture, Agricultural Research Service. 2011. USDA 
National Nutrient Database for Standard Reference, Release 24. Nutrient Data 
Laboratory. Home Page, http://www.ars.usda.gov/ba/bhnrc/ndl. 
** Calcium content varies slightly by fat content; the more fat, the less calcium the 
food contains. 
*** Calcium content is for tofu processed with a calcium salt. Tofu processed with 
other salts does not provide significant amounts of calcium. 
The U.S. Department of Agriculture recommends that persons aged 9 years and older 
eat 3 cups of foods from the milk group per day (ChooseMyPlate.gov, 2011). A cup is 
equal to 1 cup (8 ounces) of milk, 1 cup of yogurt, 1.5 ounces of natural cheese (such 
as Cheddar), or 2 ounces of processed cheese (e.g., American cheese). 
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Table 4. Selected Food Sources of Vitamin D 
Food IUs per serving* 
Cod liver oil, 1 tablespoon 1,360 
Salmon (sockeye), cooked, 3 ounces 447 
Tuna fish, canned in water, drained, 3 ounces 154 
Orange juice fortified with vitamin D, 1 cup  Approx. 137 
Milk, nonfat, reduced fat, and whole, vitamin D-fortified, 1 cup 115 - 124 
Yogurt, fortified with 20% of the DV for vitamin D, 6 ounces  Approx. 80 
Liver, beef, cooked, 3 ounces 42 
Egg, 1 large (vitamin D is found in yolk) 41 
Ready-to-eat fortified cereal, 0.75-1 cup  Approx. 40 
Cheese, Swiss, 1 ounce 6 
 
Source: U.S. Department of Agriculture, Agricultural Research Service. 2011. USDA 
National Nutrient Database for Standard Reference, Release 24. Nutrient Data 
Laboratory.  
* IUs = International Units. 
 
Recommended intakes for calcium and vitamin D are provided in the Dietary 
Reference Intakes (DRIs) developed by the Food and Nutrition Board (FNB).  DRI is a 
general term for a set of reference values used for planning and assessing the nutrient intakes 
of healthy people. These values, which vary by age and gender, include: 
 Recommended Dietary Allowance (RDA): The average daily level of intake sufficient 
to meet the nutrient requirements of nearly all (97% - 98%) healthy individuals. 
 Adequate Intake (AI): established when evidence is insufficient to develop an RDA 
and is set at a level assumed to ensure nutritional adequacy. 
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 Estimated Average Requirement (EAR): The average daily level of intake estimated 
to meet the requirements of 50% of healthy individuals. It is usually used to assess the 
adequacy of nutrient intakes in populations but not individuals. 
 Tolerable Upper Intake Level (UL): maximum daily intake unlikely to cause adverse 
health effects.  
 
Table 5. Recommended Dietary Allowances (RDAs) for Calcium 
Age Male Female Pregnant Lactating 
0 - 6 months* 200 mg 200 mg --- --- 
7 - 12 months* 260 mg 260 mg --- --- 
1 - 3 years 700 mg 700 mg --- --- 
4 - 8 years 1,000 mg 1,000 mg --- --- 
9 - 13 years 1,300 mg 1,300 mg --- --- 
14 - 18 years 1,300 mg 1,300 mg 1,300 mg 1,300 mg 
19 - 50 years 1,000 mg 1,000 mg 1,000 mg 1,000 mg 
51 - 70 years 1,000 mg 1,200 mg --- --- 
71 + years 1,200 mg 1,200 mg --- --- 
 
Source: Committee to Review Dietary Reference intakes for Vitamin D and Calcium, 
Food and Nutrition Board, Institute of Medicine.  Dietary Reference Intakes for 
Calcium and Vitamin D. Washington, DC: National Academy Press, 2010. 
* Adequate Intake (AI) 
 
The RDA for calcium intake provided by the FNB was estimated based on the 
amounts of calcium needed for bone health and to maintain adequate rates of calcium 
retention in healthy people. The effects of inhibitor compounds and differences in 
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absorption of calcium from mixed diets are also factored into the overall estimation of 
calcium RDAs (Table 5). 
 
Table 6. Recommended Dietary Allowances (RDAs) for Vitamin D 
Age Male Female Pregnancy Lactation 
0 - 12 
months* 
400 IU 
(10 mcg) 
400 IU 
(10 mcg) 
--- --- 
1 - 13 years 600 IU 
(15 mcg) 
600 IU 
(15 mcg) 
--- --- 
14 - 18 years 600 IU 
(15 mcg) 
600 IU 
(15 mcg) 
600 IU 
(15 mcg) 
600 IU 
(15 mcg) 
19 - 50 years 600 IU 
(15 mcg) 
600 IU 
(15 mcg) 
600 IU 
(15 mcg) 
600 IU 
(15 mcg) 
51 - 70 years 600 IU 
(15 mcg) 
600 IU 
(15 mcg) 
--- 
 
--- 
> 70 years 800 IU 
(20 mcg) 
800 IU 
(20 mcg) 
--- --- 
 
Source: Committee to Review Dietary Reference intakes for Vitamin D and Calcium, 
Food and Nutrition Board, Institute of Medicine.  Dietary Reference Intakes for 
Calcium and Vitamin D. Washington, DC: National Academy Press, 2010. 
* Adequate Intake (AI) 
 
Fortified foods can provide considerable amounts of vitamin D in a diet. In the 
United States, foods such as milk, yogurt, cheese, margarine, as well as some brands 
of orange juice are often fortified with vitamin D. Milk and orange juice, for example, 
are fortified with about 400-500 IU (10 µg) of vitamin D per quart, providing 100 - 
125 IU per eight ounce glass, while most cereals are fortified with about 40 - 140 IU 
(1 - 3.5 µg) of vitamin D per serving (Calvo et al., 2004). Dairy products such as 
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yogurt may also be fortified with about 40 - 140 IU (1 - 3.5 µg) of vitamin D per 
serving, and recently, some kinds of bread are also being fortified with vitamin D. The 
RDA for vitamin D represents a daily intake that is sufficient to maintain normal 
calcium homeostasis and bone health in healthy individuals with minimal sun 
exposure. RDAs for vitamin D are set listed in Table 6 in both International Units 
(IUs) and micrograms (mcg); the biological activity of 40 IU is equal to 1 mcg. 
Findings from the Continuing Survey of Food Intakes by Individuals (CSFII, 
1994 -1996, 1998), NHANES 1999-2000, and NHANES 2005 – 2006 indicate that 
while vitamin D intake among the general population has steadily increased over the 
years, a high proportion of premenopausal women in the U.S. are still not meeting 
their vitamin D requirements (Bailey et al., 2010; Moore et al., 2005). Mean intake of 
vitamin D from food sources for female ages 19 to 50 years was 152 ± 4 IU/day in 
CSFII, 168 ± 7 IU/day in NHANES 1999-2000, and 160 ± 12 IU/day in NHANES 
2005-2006 (Bailey et al., 2010), but these amounts are still much lower than the 
newly established allowance of 600 IU/day (FNB/IOM, 2010). Results from 
NHANES 2005-2006 also show that among female supplement users (19 - 30 years), 
the mean vitamin D intake from supplemental sources is insufficient (300 ± 28 
IU/day) to meet current recommended dietary allowances (FNB/IOM, 2010). Despite 
the variety of both plant and animal dietary sources of calcium, data from the National 
Health and Nutrition Examination Survey (NHANES 2003 – 2006), indicate that the 
mean daily calcium intake from food sources for young women (19 - 30 years) is 
inadequate (838 ± 25 mg/day) and below the current recommended intake level of 
1000 mg/day for adults females (20 - 39 years) (FNB/IOM, 2010, Bailey et al., 2010). 
Reports from NHAHES 2003 – 2006, also show that among female supplement users 
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(19 - 30 years), the mean daily contribution of calcium from supplemental sources 
averages approximately 283 ± 19 mg/day (Bailey et al., 2010).  
 
1.2 Relationship between Dietary Calcium, Vitamin D and Adiposity 
1.2.1 Dietary Calcium and Adiposity 
In addition to its role in maximizing bone mineral mass in young adults and reducing 
the risk of osteoporosis during menopausal years (Nguyen et al., 2000; Cheng et al., 
2005; Rizzoli et al., 2010; Khadilkar et al., 2012), several epidemiologic studies have 
described an inverse association between dietary calcium intake and measures of 
adiposity (BMI, waist circumference, and abdominal visceral or subcutaneous fat), 
particularly in older or obese women. Zemel and associates pioneered research in the 
role of dietary calcium in energy/weight management when an “accidental” discovery 
was made during a clinical trial investigating the effects of dairy products on 
hypertension in obese African-Americans (Zemel et al., 1990; Zemel, 1994).  They 
found that addition of calcium-rich dairy foods (yogurt) to the daily diet resulted in a 
sustained reduction in intracellular calcium concentrations (Zemel et al., 1990; Zemel, 
1994), and significant reductions in body fat and circulating insulin (Zemel et al., 
2000). Twelve months of yogurt supplementation (sufficient to raise daily calcium 
intake from approximately 400 to 1,000 mg/day) led to significant decreases in body 
fat (from 32.3 ± 2.6 kg to 27.4 ± 3.1 kg, P < 0.01) measured using bioelectrical 
impedance (Zemel et al., 2000).  
Although the exact mechanism explaining the relationship between dietary 
calcium- vitamin D- intake and adiposity is yet to be fully elucidated, Zemel and 
colleagues have hypothesized that the observation could be mediated through plasma 
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concentrations of 1, 25 - dihydroxyvitamin D3 . Since intracellular Ca
2+
 concentration 
can be modulated by calcitropic hormones (1, 25(OH)2D and PTH), Shi et al.,  used 
primary cultures of human adipocytes to measure the effects of 1, 25(OH)2D 
concentration  on  Ca
2+ 
and lipid metabolism (Shi et al., 2001). They observed that 
treating human adipocytes with 1, 25(OH)2D  resulted in a coordinated activation of 
fatty acid synthase and marked inhibition of lipolysis, suggesting that dietary calcium 
could potentially reduce adipocyte mass. Zemel et al., proposed that suppression of 1, 
25(OH)2D activation with high-calcium diets would reduce adipocyte intracellular 
Ca
2+
 concentration, inhibit fatty acid synthase, and activate lipolysis, thus exerting an 
anti-obesity effect (Zemel et al., 2000; Zemel, 2003),(Figure 3). 
 
Figure 3. Proposed Dietary Modulation of Adiposity via 1,25-dihydroxyvitamin D 
Mediation of Intracellular Calcium Influx 
 
Source: Zemel, MB. J Am Coll Nutr 2001; 20: 428-35S. 
Low + 
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Zemel et al. also used transgenic mice expressing the agouti aP2 gene in 
adipocytes to explore how dietary calcium regulates adiposity in vivo (Zemel et al., 
2000). Agouti mice were selected because, in addition to its role in determining coat 
color (Jackson, 1991; Bultman et al., 1992), agouti protein is also known as the 
obesity gene (Jones et al., 1996). Agouti protein in mice is expressed in adipocytes 
(Jones et al., 1996; Xue et al., 1998), where it stimulates the expression and activity 
of fatty acid synthase, through a Ca
2+ 
dependent mechanism
 
(Jones et al., 1996; Xue et 
al., 1998). Human adipocytes have a similar agouti signaling protein called ASIP 
(Bonilla et al., 2005).  
Zemel and associates confirmed their earlier hypothesis by placing the mice on 
a modified diet containing suboptimal calcium (0.4%), sucrose, and fat increased to 
25% of energy with lard. All mice were then individually randomized (not pair fed) to 
one of four groups. Group 1 (basal group) continued this diet with no modifications; 
Group 2 (high calcium group) received the basal diet supplemented with CaCO3 to 
increase dietary calcium by threefold to 1.2%; Group 3 (medium dairy group), 
received a diet in which 25% of the protein was replaced by non-fat dry milk and 
dietary calcium was increased to 1.2%; Group 4 (high dairy group) had 50% of the 
protein replaced by non-fat dry milk, increasing calcium to 2.4%. Food intake and 
spillage was measured daily, and animals were weighed weekly. At the end of six 
weeks, the agouti mice treated with the basal diet had a weight gain of 24%, while  the 
high calcium, medium dairy, and high dairy diets resulted in a weight reduction of 
26%, 29% and 39%, respectively (P < 0.04). The basal diet resulted in a 2.6-fold 
increase in fatty acid synthase activity while the high-calcium-dairy diets stimulated 
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lipolysis (3.4 - 5.2 fold, P < 0.01), with greater effects from the high-dairy diets than 
from the high calcium diet. Assessment of fat mass also showed that all three high 
calcium and dairy diets triggered a 36% reduction in mass of the epididymal, 
abdominal, perirenal, and subscapular adipose tissue compartments (P < 0.001). This 
led Zemel and colleagues to speculate that the augmented effect of calcium from dairy 
sources vs. non-dairy calcium is likely attributable to additional bioactive compounds 
in dairy that work together with calcium to attenuate body fat (Zemel et al., 2003). 
They proposed that branched-chain amino acids, which are abundant in whey proteins 
(Shah, 2000), may act independently or synergistically with calcium to attenuate 
lipogenesis, accelerate lipolysis, and/or affect nutrient partitioning between adipose 
tissue and skeletal muscle (Zemel, 2003; Ha and Zemel, 2003). Whey proteins also 
contain angiotensin-converting enzyme, a metalloproteinase that is central to the 
blood coagulation cascade by converting angiotensin I to angiotensin II, which is 
required for angiotensin receptor activation and vessel constriction (Mullally et al., 
1997; Pihlanto-Leppala et al., 2000; Zamal et al., 2002). Animal studies have shown 
that adipocytes contain an autocrine/paracrine renin-angiotensin system, suggesting 
that adipocyte lipogenesis may be regulated in part by angiotensin II (Morris et al., 
2001).  
Zemel et al., conducted a cross-sectional analysis of NHANES III data (1988 - 
1994) in 380 adult women to determine whether the results from previous animal 
studies are relevant in defining a role for dietary calcium in modulation of adiposity at 
the population level (Zemel et al., 2000). Mean age, body mass index (BMI), and 
percent body fat (assessed using bioelectrical impedance) in this population were 28.7 
± 0.4 years, 25.7 ± 0.4 kg/m
2
, and 32.7 ± 0.6 %, respectively. Mean dietary calcium 
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intake was 720 ± 52 mg/day and calcium intakes by quartiles were 255 ± 20, 484 ± 
13, 773 ± 28, and 1346 ± 113 mg/day, for 1
st
, 2
nd
, 3
rd
, and 4
th
 quartiles respectively. 
After adjusting for energy intake, activity level, age, race, and ethnicity, the odds of 
being in the highest quartile of body fat (42.49 ± 0.44 %) were significantly reduced 
as the quartile of calcium intake increased, with a relative risk of 1.00 for 1
st
 quartile;  
and 0.75, 0.40, 0.16 for  2
nd
, 3
rd
, and 4
th
 quartiles respectively (Ptrend  < 0.001).  
Several observational and  clinical trials have described similar results with 
respect to dietary calcium and BMI or body weight (Flemming and Yanovski, 1994; 
Davies et al., 2000; Buchowski et al., 2002; Jacqmain et al., 2003; Zemel et al., 
2004), total or abdominal fat (Flemming and Yanovski, 1994; Zemel et al., 2005; 
Lovejoy et al., 2001; Jacqmain et al., 2003; Zemel et al., 2004), and prevalence of 
obesity (Fleming and Yanovski, 1994). A cross-sectional analyses of 235 women 
(ages 20 - 65 years) enrolled in the Quebec Family Study showed that calcium intake 
(assessed with 3-day diet records) was negatively correlated with body fat mass (r = -
0.17, P < 0.05) and abdominal adipose tissue (r = -0.17, P < 0.05), estimated using 
computed tomography scans (Jacqmain et al., 2003). These correlations were all 
adjusted for confounding variables such as age, energy intake, dietary fat and protein 
intake, and markers of socioeconomic status. Investigators also reported that 
percentage body fat was significantly lower in women consuming ≥ 600 mg of 
calcium per day (31.3 ± 0.9 vs. 37.3 ± 1.6 %, P < 0.05), as compared to women with 
lower intakes (Jacqmain et al., 2003). Similar results were obtained with respect to 
BMI and waist circumference (WC) in this cohort (BMI 27.0 ± 0.7 vs. 31.8 ± 1.2 
kg/m
2
, P < 0.05; and WC of 82.0 ± 1.6 vs. 93.6 ± 2.6 cm, P < 0.05). While Jacqmain 
et al. study provides important information of the relationship between dietary 
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calcium intake and body fat assessed with computed tomography scans, use of a three 
diet recall may not adequately reflect usual dietary intakes of individuals.  
The HERITAGE Family Study also examined the association between calcium 
intake (derived from a Willett FFQ) and adiposity in 201 Black and 261 Caucasian 
women aged 17 to 65 years (Loos et al., 2004). Participants were healthy but 
sedentary and had a BMI < 40 kg/m
2
.  Percent body fat (% BF), total abdominal fat 
(TAF), abdominal visceral fat (AVF) and abdominal subcutaneous fat (ASF) were 
assessed using computerized tomography scans. Subjects were divided into tertiles of 
energy-adjusted calcium intake and adiposity measures across tertiles were compared 
by ANOVA.  Adiposity measures were also regressed against the energy-adjusted 
calcium intake to test for a linear trend. Their results showed that mean BMI, waist 
circumference (WC), and % BF were significantly higher in Blacks than in White 
women (BMI of 28.4 ± 0.5 vs. 25.0 ± 0.3 kg/m
2
, P < 0.001; WC of 90.2 ± 1.1 vs. 86.2 
± 0.9 cm, P= 0.01; and BF of 36.0 ± 0.7 vs. 30.1 ± 0.6 %, P < 0.001, respectively). 
Self-reported total calcium intake was also significantly higher in White women 
compared with Black women (1060 ± 34 vs. 825 ± 42 mg/day, P < 0.001). Among 
Caucasian women, energy-adjusted calcium intake was negatively correlated with 
BMI (P = 0.02), % BF (P < 0.01), TAF (P = 0.01), AVF (P = 0.03), and ASF (P = 
0.01). In contrast, Black women in the high calcium intake group tended to have a 
higher BMI (P = 0.05) and WC (P = 0.01) and had significantly more FFM (P = 
0.02) compared with Black women in the low calcium intake group. Loos et al’s 
compared the role of dietary calcium in modulating adiposity in black and Caucasian 
women, but their results did not control for vitamin D intake. This is important 
because calcium and vitamin D intake tend to be highly correlated in most diet. It is 
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important that one controls for the effects of vitamin D in order to tease out the 
independent effects of dietary calcium on adiposity. 
Studies in premenopausal African American and Caucasian women have also 
described inverse associations between calcium intakes and adiposity. Lovejoy et al., 
recruited and compared dietary intakes and body fat in 97 Caucasian women (mean 
age 46.7 ± 0.3 years) and 56 African American women (mean age 47.7 ± 0.2 years) 
(Lovejoy et al., 2001). Dietary intakes were assessed with 4-day food records and 
dual-energy X-ray absorptiometry (DXA) was used to measure percent body fat (% 
BF), fat mass (FM), and lean mass (LM). In this 4-year prospective study, dietary 
intakes of calcium were significantly lower in African American women than in 
Caucasian women (518 ± 34 vs. 758 ± 25 mg/day, P < 0.05). Partial correlation 
(adjusted for total energy intake) showed inverse correlations between calcium intake 
and percent body fat (r = -0.01, P > 0.05 in Black women, and r = -0.25, P < 0.05 in 
White women) or BMI (r = -0.13, P > 0.05 in Black women, and r = -0.21, P < 0.05 
in White women). Lovejoy et al’s study adjusted for total energy intake but not 
vitamin D intake. This is important because calcium and vitamin D intake tend to be 
highly correlated in most diets, hence it is important that one controls for the effects 
of vitamin D in order to tease out the independent effects of dietary calcium on 
adiposity. Lovejoy et al also used a four day food record to assess dietary intakes, and 
this may not adequately reflect usual dietary intakes of individuals.  
A prospective analysis of the effect of calcium intake on changes in body 
composition during a two year exercise intervention among 18 - 31 year old 
Caucasian women in the U.S. also showed similar results (Lin et al., 2000).  Fifty four 
sedentary and normal weight women (mean age 24.6 ± 3.3 years) were randomized 
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into either three sessions of resistance exercise plus 60 minutes of jumping rope per 
week or a control group for 24 months. None of the women had participated in more 
than two hours a week of exercise in the year prior to enrollment. Dietary intake was 
assessed with 3-day diet records at baseline and every six months for two years, and 
DXA was used to estimate body fat and lean mass. They observed that mean calcium 
intake was below the recommended allowance of 1000 mg/day for this age group (781 
± 212 mg/day). Total calcium (adjusted for energy intake) was also negatively 
correlated with changes in body weight (r = -0.35, P < 0.05) and body fat (r = -0.34, P 
< 0.05). This prospective study by Lin et al was important in understanding the causal 
relationship between dietary calcium intake and obesity. However, use of a 3-day 
food record to assess dietary intake is a limitation because it may not adequately 
reflect usual patterns of dietary intake. 
In a randomized control trial of 32 obese adults (27 women and 5 men, mean 
age 49 ± 6 years), participants were kept for 24 weeks on balanced deficit diets (500 
kcal/day deficit) and assigned to one of three diets; a standard diet (400 - 500 mg of 
dietary calcium/d supplemented with placebo), a high-calcium diet (standard diet 
supplemented with 800 mg of calcium/day), or high-dairy diet (1200 to 1300 mg of 
dietary calcium/day supplemented with placebo) (Zemel et al., 2004). All subjects had 
an initial BMI between 30.0 - 39.9 kg/m
2
 and a low-calcium diet (500 - 600 mg/d) at 
study entry, and no more than 3 kg weight change over the preceding 12 weeks. 
Participants kept daily diet diaries throughout the study, and compliance with 
treatment was assessed by weekly interview, review of the diet diary, and pill counts. 
Subjects were also asked to maintain their physical activity level and tobacco use at 
pre-study (baseline) levels throughout the study. DXA was used to assess total fat 
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mass, regional fat, and percent lean / fat mass at the beginning of the study and at 
weeks 12 and 24 weeks. The results showed that while all subjects lost some amount 
of weight due to daily energy restriction of 500 kcal/day, subjects on the high-dairy 
diet lost the largest amount (70%) of body weight, followed by the high-calcium diet 
and the low-calcium control diet (26%),(P < 0.01). Quantitatively these losses 
represented 10.9 ± 1.6%, 8.6 ± 1.1%, and 6.4 ± 2.5% of body weight respectively. Fat 
loss also followed a similar trend with subjects losing 14.1 ± 2.4% of their body fat on 
the high-dairy diet and 11.6 ± 2.2% on the high-calcium diet compared to 8.1 ± 2.3% 
on the low-calcium control diet. Finally, changes in abdominal fat, which is indicative 
of central obesity occurred in all subjects, but those on the low-calcium diet lost the 
least amount (5.3 ± 2.3%) of abdominal fat compared to 12.9 ± 2.2% for those on the 
high-calcium diet and 14.0 ± 2.3% for the high-dairy diet (P < 0.025). While this 
clinical trial shed some light on how different calcium diets influence changes in body 
weight, subjects were all older adults and obese (BMI of 30.0 - 39.9 kg/m
2
) at the start 
of the intervention. Participants also had low-calcium diets (500 - 600 mg/d) at the 
start of the intervention. Since the mechanisms underlying how calcium might 
modulate adiposity could vary by BMI, data on these associations in non-obese 
subjects who are not calcium deficient would be useful.   
Another clinical trial examined the effects of dairy rich foods on body weight 
and fat in 34 obese African-American adults (Zemel et al., 2005). In phase one of the 
study, researchers investigated weight maintenance by randomizing subjects to a low 
calcium (500 mg/day)/low dairy (< 1 serving/day) or high dairy (1200 mg Ca/day diet 
including 3 servings of dairy) diet with no change in energy or macronutrient intake. 
In the second phase examining the effect of dairy/calcium on weight loss, subjects 
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were similarly randomized to the low or high dairy diets and placed on a caloric 
restriction regimen (deficit of 500 kcal/day). All subjects were aged 26 to 55 years, 
had an initial BMI of 30 - 40 kg/m
2
, and were on a low calcium (< 600 mg/d) and low 
dairy (< 1 serving/d) diet as determined by food frequency and diet history at study 
entry. Total fat mass (TFM) and percent lean (% LM) and fat mass (% FM) were 
assessed using DXA. The results from phase 1 showed no significant changes in body 
weight over the 24-week period in both groups. Compared to the low-dairy-low-
calcium group, the high dairy diet resulted in significant decreases in total body fat 
(2.16 kg, P < 0.01) and trunk fat (1.03 kg, P < 0.01), with a corresponding increase in 
% LM (1.08 kg, P < 0.04). Phase 2 of the study showed that although both diets 
produced significant changes in body weight and fat loss, weight and fat loss 
were almost 2-fold greater in subjects consuming the high-dairy-high calcium diet 
compared with those  consuming the low-dairy-low calcium diet (P < 0.01). Loss of 
lean body mass was also noticeably reduced in subjects consuming the high-dairy-
high-calcium diet than in those on the low-dairy-low calcium (P < 0.001). This study 
included various body fat mass measures which is important as the site of fat 
deposition may influence the relationship between dietary calcium and adiposity. 
However, the investigators failed to account for the effects of dietary vitamin D. This 
is important because calcium and vitamin D intake tend to be highly correlated in 
most diets, hence it is essential to control for the effects of vitamin D in order to tease 
out the independent effects of dietary calcium on adiposity. 
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1.2.2 Dietary Vitamin D and Adiposity 
Presently, epidemiologic evidence on the relationship between dietary vitamin D 
intake and adiposity in young women is limited. Tidwell and Valliant used a cross-
sectional design to assess the correlation between dietary intakes (by 24-hr recalls) 
and total body fat (by DXA) in a cohort of 100 premenopausal women aged 18 to 40 
years (Tidwell and Valliant, 2011). A large proportion (71%) of participants were 
overweight or obese (BMI ≥ 25 Kg/m2) and mean BMI and % BF were 29.8 ± 6.9 
Kg/m
2
 and 36.9 ± 7.3 % respectively. Average dietary vitamin D and calcium intake 
were also below the recommended dietary allowance for adult women (mean intakes 
of 176 ± 40 IU/day for vitamin D and 720 ± 263 mg/day for calcium). Partial 
correlation between % BF and vitamin D intakes (adjusted for fat, carbohydrate and 
protein intakes) showed that women with lower intakes of dietary vitamin D (≤ 152 ± 
36 IU/day) were more likely to have excessive body fat (% BF > 37.9%) compared to 
women with higher intakes of dietary vitamin D (> 200 ± 32 IU/day) (r = -0.46, P < 
0.01). This study did not adjust for calcium intake which could potentially confound 
any observed relationship between dietary vitamin D and body fat. Controlling for 
calcium is important because most food sources of calcium also provide some 
amounts of dietary vitamin D; hence food calcium and food vitamin D are likely to be 
highly correlated in any diet. Adjustment for dietary calcium in this instance is 
necessary in order to assess the independent effects of food vitamin D.  
Although there is wealth of information supporting the role of dietary calcium 
and dairy products in fat/weight loss, research on the association between dietary 
vitamin D intake and adiposity in non-obese young women remains scarce. Since 
health risks tend to increase with increasing adiposity, it is important to determine 
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modifiable dietary factors that may significantly impact body weight. Previous studies 
examining the role of dietary calcium and vitamin D intake in body weight have relied 
on BMI, waist circumference, and measures of abdominal fat (e.g., use of abdominal 
skin fold thickness) to assess adiposity; however, these proxy measures are not always 
precise in estimating body fat composition. Dual energy x-ray absorptiometry (DXA) 
is considered a more accurate method of estimating percent body fat, (Haarbo et al., 
1991; Bolanowski and Nilsson, 2001), and its use among young women has been 
previously validated (Bolanowski and Nilsson, 2001). The first study of this 
dissertation examined the associations between dietary intakes of calcium and vitamin 
D, and adiposity in young women. We also determined whether the observed 
association differs for body fat measured with dual x-ray absorptiometry (DXA) 
compared with BMI or WC. Since food calcium and food vitamin D are likely to be 
highly correlated in any diet, we included these covariates together in one same 
adjustment to assess the independent effects of each nutrient on adiposity.  
 
1.3 Relationship between Adiposity and Serum 25-OHD Concentration  
Low serum 25-hydroxyvitamin D (25-OHD < 75 nmol/L) is associated with increased 
risk of metabolic syndrome (Ford  et al., 2005; Beydoun et al., 2010), type-II-diabetes 
(Scragg et al., 2004; Pittas et al.,2006), hypertension (Scragg et al., 2007), coronary 
heart disease (Giovannucci et al., 2008; Poole et al., 2006; Cigolini et al., 2006; 
Martins et al., 2007), and cancer (Banerjee and Chatterjee, 2003). Reports from 
NHANES  2001 - 2006 show that about one-fourth of the US population (aged ≥ 1 
year) is at risk of vitamin D inadequacy [serum 25-OHD of 30 – 49 nmol/L], while 
8% were at risk of vitamin D deficiency [serum 25-OHD < 30 nmol/L] (Looker et al., 
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2008). The risk of vitamin D deficiency also differs by age and gender (Fig 4), and by 
race and ethnicity (Fig 5).  
 
Figure 4. Prevalence at Risk for Vitamin D Deficiency by Age and Sex in the United 
States, 2001 – 2006 
 
Source: CDC NCHS. NHANES data for ages 1 - 70 years from 2001 - 2006. 
*P < 0.05 compared with preceding age group within sex. At risk of deficiency is 
defined as serum 25-OHD < 30 nmol/L. Serum 25-OHD values have been adjusted 
for season of blood draw.  
 
 
Figure 5. Age and Season-Adjusted Prevalence at Risk of Deficiency and Inadequacy 
among Persons aged 1 year and over in the United States, 2001-2006 
 
Source: CDC NCHS. National Health and Nutrition Examination Survey (NHANES) 
data for ages 1 - 70 years from 2001 - 2006. P < 0.05 compared with males. P < 0.05 
compared with non-Hispanic white persons. P < 0.05 compared with pregnant or 
lactating women. 
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In the U.S, the prevalence of vitamin D deficiency is highest in non-Hispanic 
blacks (31%) followed by Mexican-Americans (12%) and non-Hispanic White 
(3.2%). Since natural food sources of vitamin D are limited, addition of vitamin D 
fortified foods (e.g., dairy foods) to the diet is important in preventing vitamin D 
insufficiency. Unfortunately, most adults (65 %) in the U.S. do not consume adequate 
amounts of milk and milk products (Forrest and Stuhldreher, 2011). Concern about 
sun exposure and skin cancer risk also prevents people from staying out in the sun for 
long periods, which increases the risk of vitamin D insufficiency (Linos et al., 2012; 
Holick, 2001).  
Accumulating epidemiologic evidence suggests an inverse relationship 
between serum 25-OHD levels and body fat (Zemel et al., 2000; Davies et al., 2000; 
Lovejoy et al., 2001; Vilarrasa et al., 2007; Kremer et al., 2009; Beydoun et al., 2010) 
or BMI (Bell et al., 1985; Liel et al., 1988; Worstman et al., 2000; Rodriguez-
Rodriguez et al., 2009). Among older adults (32 – 62 years), Konradsen et al.,  
observed that subjects with BMI > 39.9 kg/m
2
 had 24% lower serum 25-OHD levels 
and 18% lower 1,25(OH)2D levels than those with BMI < 25 kg/m
2
 (Konradsen et al., 
2008). Studies in elderly women (69 - 87 years) also showed that total body fat is a 
negative predictor of serum 25-OHD levels (β = -0.247, P = 0.016), even after 
adjusting for age, lifestyle, and serum intact parathyroid hormone (Jungert et al., 
2012). Among healthy Caucasians and African-American adults (25 – 48 years), 
Parikh et al., observed that serum 25-OHD concentration was negatively correlated 
with BMI (r = -0.40; P < 0.001) and percentage body fat (r = -0.41; P < 0.001), 
measured by dual energy x-ray absorptiometry (Parikh et al., 2004). Arunabh et al., 
also reported that after adjusting for race, age, season, and dietary vitamin D intake in 
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20 - 80 year old women (mean BMI 23.9 ± 2.9 kg/m
2
) ,serum 25-OHD level was 
inversely correlated with percentage body fat (r = -0.13, P = 0.013), measured using 
dual energy x-ray absorptiometry (Arunabh et al., 2003).  
Among Caucasian and African-American adults (25 – 48 years), serum 25-
OHD concentration was significantly lower (58.7 ± 30.5 vs. 77.4 ± 35.9 nmol/liter; P 
< 0.0001) in obese subjects (mean BMI 37.3 ± 5.8 kg/m
2
) compared with non-obese 
subjects (mean BMI 25.6 ± 2.9 kg/m
2
),(Parikh et al., 2004). A recent study in 66 
Spanish women aged 20 – 35 years also examined the relationship between vitamin D 
status and anthropometric indices in overweight/obese young women (Rodriguez –
Rodriguez et al., 2009). A questionnaire was used to collect demographic and health 
information, and a 3-day food record was used to assess dietary intake. Women were 
divided into two groups depending on their serum vitamin D concentrations: low-D 
(25-OHD < 90 nmol/L) and high-D (25-OHD ≥ 90 nmol/L). The results showed that 
mean serum 25-OHD concentration in the High-D group was almost three times 
higher compared with the Low-D group (130.2 ± 52.3 vs.47.9 ± 18.4 nmol/L, P < 
0.001). While intakes of vitamin D, calcium, and supplements did not differ 
significantly between groups, BMI and waist circumference were significantly lower 
than in the Low-D subjects (26.0 ± 1.3 kg/m
2
 and 79.4 ± 3.4 cm compared to 
28.6 ± 3.2 kg/m
2
 and 86.2 ± 9.3 cm, respectively; P < 0.05) in the high-D subjects. 
Most of the afore-mentioned studies included obese adult women and does not 
provide data on how low-25-OHD is associated with adiposity in non-obese young 
women.  
Cross-sectional studies in menopausal-aged women have reported that 
elevated dietary vitamin D intake and serum 25-OHD values maybe be related to 
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lower visceral adiposity and omental adipocyte size. Caron-Jobin et al., measured 
adipocyte size in 43 menopausal women using adipocyte suspensions from 
collagenase-digested fat tissues (Caron-Jobin et al., 2011). Total and visceral 
adiposity were assesses by DXA and computed tomography, respectively, while 
serum 25-OHD concentration was measured using radio-immunoassay. They found 
that dietary vitamin D intake was inversely associated with visceral adipose tissue 
area (r = -0.34, P ≤ 0.05). Serum 25-OHD concentration was also negatively 
correlated with visceral adipose tissue area (r = -0.32), total adipose tissue area (r = -
0.44), subcutaneous adipose tissue area (r = -0.36), BMI (r = -0.43) and total body fat 
mass (r = -0.41, P ≤ 0.05). This study effectively assessed the role of both dietary 
vitamin D and serum 25-OHD on total and visceral adiposity, but the results are in 
menopausal women and cannot be generalized to pre-menopausal aged women. 
The low levels of serum 25-OHD observed in obesity have been attributed to 
multiple factors including decreased exposure to sunlight because of limited mobility, 
negative feedback from elevated 1, 25-hydroxyvitamin D and PTH levels on hepatic 
synthesis of 25-OHD (Bell et al., 1985), and excessive storage of vitamin D in the 
adipose tissue (Liel et al., 1988; Shi et al., 2001). Lumb et al., were among the first 
researchers to hypothesize that after absorption in the small intestine, vitamin D is 
sequestered and stored in adipose tissue and muscle and then slowly released into 
circulation (Lumb et al., in 1971). The same group went on to demonstrate this 
hypothesis using animal models and human studies. Vitamin D in all body tissues was 
radioactively-labeled by supplementing weanling rats (previously made completely 
vitamin D-deficient) with oral vitamin D3-4-
14
C for two weeks. Measurement of 
radioactivity and vitamin D content in a several organs and tissues showed that the 
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largest amount of radioactivity was located in adipose tissue (Rosenstreich et al., 
1971). Similarly, when 60 individuals were injected with radioactively labeled 
vitamin D3, the highest concentration of biological activity and radioactivity was 
observed in fat tissue (Mawer et al., 1972).  
Cross-sectional studies in morbidly obese subjects have suggested that the 
decline in serum 25-OHD concentration in obesity may be secondary to alteration in 
tissue distribution resulting from increase in adipose mass (Liel et al., 1988). More 
recently, it has been confirmed that obesity-related vitamin D insufficiency is most 
likely a result of decreased bioavailability of vitamin D3 from cutaneous and dietary 
sources due to its deposition in adipose tissue (Worstman et al., 2000; Shi et al., 
2001). Shi et al., have shown that elevated concentrations of 1, 25(OH)2D stimulate 
lipogenesis and inhibit lipolysis in cultured human adipocytes, leading to 
accumulation of fat in adipocytes (Shi et al., 2001). Additionally, 1,25-(OH)2D can 
inhibit the expression of adipocyte uncoupling protein-2 (UCP2), which causes a 
decrease in the metabolic efficiency  of adipocytes (Shi et al., 2002).  
The second study of this dissertation evaluated the extent to which serum 25-
OHD levels is associated with measures of adiposity, and the influence of lifestyle 
factors (e.g., oral contraceptive use, smoking status, and alcohol intake) on this 
association in young women. We also examined whether the relationship between 
vitamin D status and adiposity differs with the site of fat deposition (i.e. android, 
gynoid, arm and leg fat). Android fat is located primarily around organs within the 
abdominal cavity while gynoid fat is found around the hips, thighs, and buttocks. 
Since vitamin D can be sequestered in fat stores (adipocytes), our analysis of the 
association between regional fat distribution and serum 25-OHD levels can provide 
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insight on the relationship between vitamin D status and different forms of obesity, 
and inform directions for future epidemiologic research in this field. 
 
1.4 Cytokines and Immune Function 
The human immune system comprises two major sides: the innate or non-specific 
immune system, and the adaptive or specific immune system (Fig 6). The innate 
immune system is the body’s first line of defense against microorganisms such as 
bacteria that penetrate the epithelial surface (Kaisho, 2007). Innate immunity consists 
of epithelial barriers, circulating phagocytes (primarily neutrophils and macrophages), 
and other cytotoxic cells (e.g., natural killer (NK) cells), as well as constitutive and 
inflammation-induced serum proteins (e.g., complement proteins and positive acute-
phase reactant proteins) (Kaisho, 2007). Activated macrophages secrete small soluble 
hormone-like proteins (cytokines) that allow for communication between cells and the 
external environment (Janeway et al., 2005). T Activated macrophages also release 
proteins known as chemokoines that attract cells with specific chemokine receptors 
such as neutrophils and monocytes from the blood stream (Janeway et al., 2005).  
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Figure 6. Mechanisms of Innate and Adaptive Immunity 
 
Source: Kaisho T. Elucidating the mechanism behind immunity using dendritic cells. 
Riken Research. 2007;2(8). Available at 
http://www.rikenresearch.riken.jp/eng/frontline/5028. 
 
The term cytokines broadly encompasses a large family of proteins, including 
interleukins, colony-stimulating factors, interferons, tumor necrosis factor, and 
chemokines (Leonard, 1999). Cytokines are secreted by white blood cells as well as a 
variety of other cells (fibroblasts, endothelial cells, epithelial cells, etc.) and they work 
in tandem with specific soluble cytokine receptors and cytokine inhibitors to mediate 
and regulate the human immune response.  
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Cytokines can regulate cellular activity in a coordinated interactive way due to the 
following attributes (Leonard, 1999; Stipanuk, 2006): 
i). Pleiotrophy – one cytokine has many different functions. 
ii). Redundancy – several different cytokines can mediate the same or similar 
functions. 
iii). Synergism – occurs when the combined effect of two cytokines on cellular 
activity is greater than the additive effects of individual cytokines. 
iv). Antagonism- the effects of one cytokine inhibits the effects of another. 
 
Although cytokines are produced by many cell types, the majority are 
produced by helper T-cells (Th) and macrophages (Leonard, 1999). The innate 
immune system is regulated by pro-inflammatory cytokines e.g., IL-1 and TNF-α, as 
well as anti-inflammatory cytokines e.g., IL-4 and IL-10, which down-regulate 
inflammation after pathogens have been eliminated (Packard et al., 2009; Damania 
and Blackbourn, 2012). The macrophages and neutrophils of the innate immune 
system cannot always eliminate infectious microorganisms, which is why the 
lymphocytes of the adaptive immune system have evolved to provide a more versatile 
means of defense. The adaptive immune system consists of antibody responses and 
cell-mediated responses, which are carried out by specific cytokines produced by 
different lymphocyte cells, B cells and T cells, respectively (Siffrin et al., 2007; 
Fatourou and Koskinas, 2009; Andersson et al., 2010). 
Pro-inflammatory cytokines function primarily to induce inflammation as a 
result of infection, trauma, ischemia, toxins etc.  Interleukin-1 (IL-1) and tumor 
necrosis factor (TNF-α) typically initiate the cascade of inflammatory mediators by 
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targeting the endothelium. TNF-α is produced by macrophages and monocytes and is 
involved in phagocytic cell activation (in macrophages) and tumor cell cytotoxicity. It 
is the primary cytokine that mediates acute inflammation, activates platelets, and 
initiates cachexia (Bazzoni and Beutler, 1996; O'Dell, 1999). IL-1 and IL-8 are 
primarily synthesized by macrophages, but, IL-1 can also be made by B-cells and 
dendritic cells. The IL-1 family gene encodes three different peptides; IL-1α, IL-1β, 
and IL-1 receptor antagonist (IL-1ra) (Mao et al., 2000). In normal homeostasis, the 
actions of IL-1 are maintained in balance by IL-1ra and other IL-1 inhibitors.  Like 
TNF-α, IL-1 production is induced in response to inflammatory stimuli from target 
cells like NK-cells, T-cells, and B-cells, while IL-8 production is induced in response 
to inflammatory stimuli from neutrophils (Tayal and Kalra, 2008). IL-1 functions in 
cell proliferation and differentiation and production of fever (Tayal and Kalra, 2008), 
while IL-8 is a neutrophil chemoattractant that triggers neutrophil degranulation and 
release of cytotoxic (Dinarello, 2000). Both IL-1β and TNF-α stimulate expression of 
adhesion molecules, including vascular cell adhesion molecule-1, which causes 
endothelial dysfunction (Jialal et al., 2004; Elkind et al., 2002). IL-1 and TNF-α have 
also been strongly implicated in the pathogenesis of inflammatory conditions like 
rheumatoid arthritis (Badolato and Oppenheim, 1996; Feldman et al., 1996) and 
Crohn’s disease (Van Dullemen et al., 1995) 
Anti-inflammatory cytokines block the inflammatory cascade initiated by pro-
inflammatory cytokines in the host. They work together with specific cytokine 
inhibitors and soluble cytokine receptors to regulate the human immune response. 
Some of the most studied anti-inflammatory cytokines include interleukin (IL)-1 
receptor antagonist, IL-4, IL-6, IL-10, IL-11, and IL-13 (Opal and DePalo, 2000). IL-
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4 is a highly pleiotropic (it can act on many different types of cells) cytokine produced 
by mature Th-2 cells, mast cells and basophils. It drives Th-2 responses, mediates the 
recruitment and activation of mast cells, and stimulates the production of antibodies 
via the differentiation of B-cells into IgE-secreting cells (Wang et al., 1995; Brown 
and Hural, 1997). IL-4 also kills parasites in the body and suppresses macrophage-
derived nitric oxide production (Vannier et al., 1992). IL-4 is able to affect a variety 
of structural cells. For instance, it can enhance proliferation of vascular endothelium 
and skin fibroblasts, or decrease the proliferation of vascular smooth muscle cells (Toi 
et al., 1991; Brown and Hural, 1997). It can also induce a potent cytotoxic response 
against tumor cell formation (Tepper et al., 1992; Toi et al., 1992).  
IL-10 is synthesized by Th-2 lymphocyte cells, CD4+ cells, monocytes, and 
B-cells. It can inhibit cytokine production by neutrophils and natural killer cells. IL-
13 is secreted by activated T lymphocytes and has profound effects on the expression 
of surface molecules on both monocytes and macrophages (de Waal Malefyt et al., 
1993). IL-4, IL-10 and IL-13 have marked inhibitory effects on the expression and 
release of monocyte-derived pro-inflammatory cytokines e.g., TNF-α, IL-1, IL-6 and 
IL-8, (te Velde et al., 1990; Paul, 1991; Gerard et al., 1992; de Waal Malefyt et al., 
1993; Marchant et al., 1994; Zurawski and de Vries, 1994; Brandtzaeg et al., 1996; 
Clarke et al., 1998). They down-regulate the pro-inflammatory cytokines by 
promoting the degradation of their messenger RNA (Opal et al., 1998). IL-6 is often 
used as a marker for systemic activation of pro-inflammatory cytokines (Barton, 
1997). IL-6 production is induced by lipopolysaccharide stimulation, along with TNF-
α and IL-1 (Opal and DePalo, 2000).  Although IL-6 is generally considered to be a 
pro-inflammatory cytokine, it also possesses anti-inflammatory properties. IL-6 is a 
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potent inducer of the acute-phase protein response (Barton et al., 1996). It also 
inhibits the production of pro-inflammatory cytokines such as GM-CSF and IFN-γ 
(Barton, 1997). 
 
1.4.1 C-Reactive Protein and Inflammation  
When macrophages encounter microbes such as bacteria in tissues, they release 
cytokines that increase the permeability blood vessels, allowing fluids and proteins to 
pass into the tissues. The macrophages also release proteins called chemokines, which 
direct the migration of neutrophils to the site of infection. Cytokines and complement 
fragments have important effects on the adhesive properties of the endothelium, 
causing leukocytes to stick to the endothelial cells of the blood vessel wall. The 
dilation and increased permeability of the blood vessels leads to increased blood flow 
and leakage of fluid which accumulates at the site of infection (Janeway et al., 2005). 
This process is generally described as inflammation and is defined by four Latin 
words, calor, dolor, rubor, and tumor: meaning heat, pain, redness, and swelling, all 
of which reflect the effects of cytokines and other inflammatory mediators. Figure 7 
below depicts how infection triggers an inflammatory response in tissues. 
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Figure 7. Activation of Inflammatory Response in Tissues 
 
Source: Janeway et al., 2005. Immunology biology, the immune system in health and 
disease.  
 
C-reactive protein (CRP) is an acute-phase reactant protein synthesized by 
the liver in response to a variety of inflammatory cytokines produced by macrophages 
(Pepys and Hirschfield, 2003) and adipocytes (Lau et al., 2005). CRP is a 224-residue 
protein located on chromosome 1q21-q23. It has a molecular mass of 25106Da and is 
a member of the pentaxin family of proteins (Du Clos, 2003). CRP binds to Fc-
receptors and phosphocholine residues (Fig 8) on the surface of microbes, damaged 
tissue, nuclear antigens, in order to activate the humoural, adaptive immune system 
(via phagocytosis by macrophages) (Marnel et al., 2005).  
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Figure 8. CRP Ligand and Receptor Binding in Cells 
 
Source: Marnel et al. Clin Immunol 2005; 117: 104-11. 
 
Interaction of CRP with Fc-receptors leads to the generation of pro-
inflammatory cytokines (e.g., TNF-α, IL-1, and IL-6), that enhance the inflammatory 
response (Fig 9). Consequently, the level of CRP in plasma increase rapidly in 
response to infection, trauma, tissue injury or necrosis, infection, or other 
inflammatory stimuli (e.g., autoimmune disorders).  
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Figure 9. Possible Mechanism of CRP Modulating Inflammation 
  
Source: Marnel et al. Clin Immunol 2005; 117: 104-11. 
 
CRP is also important in innate immunity, where it acts as an early defense 
system against infections. During acute phase response, levels of CRP rapidly 
increase within the first two hours of infection, reaching a peak within forty-eight 
hours. Since its half-life is constant (18 hours), the level of CRP in blood is a direct 
reflection of the severity of inflammation or infection. Even though measurement of 
CRP concentration is not specific enough to diagnose any particular disease, it does 
serve as a general marker for infection and inflammation, which is important in the 
early detection and treatment of chronic diseases such as diabetes mellitus (Pradhan et 
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al., 2001; Dehdhan et al., 2007), hypertension (Kong et al., 2012; Cheung et al., 
2012), and cardiovascular disease (Danesh et al., 2004; Swardfager et al., 2012). 
 
1.5 Vitamin D and Inflammation 
Few studies have examined the regulatory influence of vitamin D on cytokines in 
humans. Research in elderly populations suggests that changes in serum 25-OHD 
levels may not be associated with alterations in pro- or anti-inflammatory cytokines 
(Barnes et al., 2011). However, during pathophysiological conditions (e.g., severe 
obesity and end-stage renal disease), some pro-inflammatory cytokines such as (TNF-
α) were elevated while anti-inflammatory cytokines like IL-10 were reduced in 
subjects with low-serum 25-OHD concentrations (Bellia et al., 2011; Kelly et al., 
2011).  
Animal studies and population based studies have proposed that 1,25-
(OH)2D  may help to suppress inflammation  by meditating the release of specific 
cytokines and expression of cytokine receptors (Canning et al., 2001; Zhu et al., 2005; 
Shab-Bidar et al., 2012). Figure 10, shows a proposed mechanism by which calcitriol 
could influence gene transcription of specific cytokines. After 1,25(OH)2D  is 
produced in the kidney, it travels from the blood (bound to vitamin D binding protein) 
into the nucleus of cells, where it binds to the vitamin D receptor (VDR). The 
ligand/receptor complex then binds to vitamin D response element (VDRE) located in 
the promoter region of target genes. The DNA-bound complex subsequently interacts 
with nuclear co-regulators, such as SKIIP (MacDonald et al., 2004), and alters the rate 
of gene transcription of certain cytokines, including IL-10 and IL-8 (Bosse et al., 
2009). 
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Figure 10. Genes Involved in the Vitamin D Pathway 
 
Source: Bosse et al. Respir Res 2009; 10: 98. 
 
1.6 Relationship between Serum 25-OHD, Adiposity and Inflammation 
Visceral obesity is associated with a chronic, low-grade inflammation of white 
adipose tissue, characterized by increased production of pro-inflammatory cytokines 
(e.g., IL-1, IL-6, and tumor necrosis factor- α) and acute phase reactant proteins (e.g,. 
C - reactive protein) (Hotamisligil  et al., 1993; Vozarova et al., 2001; Xu et al., 2003; 
Moriseset et al., 2008), some of which are   actually secreted by adipose tissue itself 
(Mohamed-Ali et al., 1997; Fried et al., 1998; Yudkin et al., 2000; Galic et al., 2010). 
These cytokines may have local physiological effects on white adipose tissue 
physiology as well as systemic effects on other organs (Bastard et al., 2006).  
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The distribution of body fat in obesity is also of importance because an excess 
of abdominal fat is associated with high amounts of visceral fat which is thought to be 
metabolically active and can cause dysmetabolism of fatty acids, thus increasing the 
influx of free fatty acids into the splanchnic circulation (Bergman et al., 2007; Nielsen 
et al., 2004). High amounts of unbound free fatty acids in the blood can lead to 
hyperlipidemia and hypertriglyceridemia, both of which can promote the onset of 
cardiac complications. Varghese et al. conducted a case control study in patients with 
coronary artery disease (mean age cases: 43 ± 11.4 and controls 40.8 ± 9.3 years) to 
access the importance of fat distribution in heart disease (Varghese et al., 2012). 
Controls were age-and sex matched to subjects and computer tomography scans were 
used to measure subcutaneous and visceral fat area. Result showed that visceral fat 
area was highly correlated with CRP (r = 0.45, P = 0.001) as well as a significant 
predictor of cardiovascular risk (P = 0.009). Among healthy older Korean adults 
(mean age 41.3 ± 13 years), visceral fat was found to be the most important predictor 
of hs-CRP concentration, explaining 19.6% of the variance in high sensitive CRP (β = 
0.009 mg/dL, P < 0.001) (Kim et al., 2008). Another cross-sectional  study of 100 
Korean adults (ages 20-60 years) showed that in both obese and non-obese  adults, 
serum concentrations of  CRP, TNF-α, and IL-6 were significantly positively 
correlated with body weight , BMI, waist circumference, and waist to hip-ratio (Park 
et al., 2005). Regression analysis further showed a significant association between 
BMI and CRP (β = 0.158 mg/dL, P = 0.028), and a positive association between 
visceral adiposity and elevated cytokine levels (IL-6) in obese subjects (β = 0.012 
pg/mL, P = 0.042). Even though the above studies reported of an inverse association 
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between measures of adiposity and inflammation (hs-CRP, TNF-α, and IL-6), all 
these studies were conducted in older adults or critically ill patients. 
Some cross-sectional studies in obese and healthy U.S. adults have shown an 
inverse association between serum 25-OHD levels and plasma CRP concentrations 
(Bellia et al., 2011; Beydoun et al., 2010). Elevated CRP concentration is a public 
health concern because it is an independent risk factor for several chronic diseases, 
including cardiovascular disease (Pradhan et al., 2001; Singh et al., 2005; Dehghan et 
al., 2007; Lopez-Garcia et al., 2005; Pickup and Mattock, 2003; Ridker, 2001; Ridker 
et al., 2000; Rost et al., 2001), and type II diabetes (Schmidt et al., 1999; Pradhan et 
al., 2001; Freeman et al., 2002). Studies in post-menopausal women (Ridker et al., 
1998) have also shown that women with high baseline CRP levels (> 7.3 mg/L) were 
almost 5-times more likely to experience any vascular event (Relative Risk 4.8; 95% 
CI, 2.3 - 10.1) compared to women with low baseline CRP concentrations (< 1.5 
mg/L). This association remained significant even after adjusting for body mass 
index, diabetes, hypertension, hypercholesterolemia, physical activity, and family 
history of cardiovascular disease (Ridker et al., 1998).  
Nationally representative data from the National Health and Nutrition 
Examination Surveys (NHANES) 2001 to 2006 showed that after controlling for the 
effects of age, gender, and race, there was an inverse association between 25-OHD 
and CRP concentrations (ß = -0.30 mg/dL, P < 0.001) in asymptomatic adults with 
low vitamin D levels (below the population median, i.e. 25-OHD < 52.5 nmol/L), 
(Amer and Quayyum, 2012). However, this association became non-significant once 
the serum 25-OHD increased above the population median (≥ 52.5 nmol/L), (ß = -
0.05 mg/dl, P = 0.08). Garcia-Bailo et al. recently reported of a cross-sectional study 
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(n = 1403) among adult men and women (20-29 years) that showed positive 
associations between plasma concentrations of 25-OHD and hs-CRP levels (ß = 0.011 
± 0.002 mg/L, P < 0.0001) after controlling for factors such as age, gender, waist 
circumference, physical activity, ethnicity and season in the overall population 
(García-Bailo et al., 2013). They also observed that among individuals with 25-OHD 
> 51.9 nmol/L, the positive association between 25-OHD and hs-CRP was no longer 
significant (ß = 0.003 ± 0.004 mg/L, P = 0.29), after adjustment for hormonal 
contraceptive (HC) use. HC use was therefore a confounder of the association 
between 25-OHD and hs-CRP in this population.  
Supplementation with vitamin D has been effective in down-regulating the 
expression of pro-inflammatory cytokines in some populations (Zittermann et al., 
2009; Schleithoff et al., 2006; Shab-Bidar et al., 2010), but not others (Jorde et al., 
2010; Beilfuss et al., 2012). A clinical trial by Zittermann et al. supplemented 200 
healthy-but-overweight subjects participating in a weight-reduction program with 
either 83 mcg (3320 IU) of vitamin D daily or placebo for 12 months. All subjects all 
had low 25-OHD concentrations (< 30 nmol/L) at the time of treatment 
randomization. They found that even though  weight loss was not significantly 
affected by vitamin D supplementation,  mean 25-OHD and 1,25(OH)2 D 
concentrations increased by 55.5 nmol/L and 40.0 pmol/L, respectively, in the 
treatment group compared to 11.8 nmol/L and 9.3 nmol/L, respectively, in the placebo 
group (P < 0.001). Subjects receiving vitamin D supplements also had significantly 
lower concentrations of TNF-α compared with the placebo supplemented group (7.04 
± 2.25 pg/mL vs. 7.90 ± 2.80, P = 0.049).  
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Another study in older men with congestive heart failure also showed that a 
daily regimen of 50 μg vitamin D3 plus 500 mg calcium for 9 months was beneficial 
in suppressing TNF-α while increasing the levels of anti-inflammatory cytokines like 
IL-10 (Schleithoff et al., 2006). In a randomized controlled trial among 100 patients 
with type II diabetes mellitus, subjects were assigned either a plain yogurt drink (PD; 
containing 170 mg calcium and no detectable vitamin D/250 mL) or a vitamin D3-
fortified yogurt drink (FD; containing 170 mg calcium and 500 IU/250 mL) twice a 
day (Shab-Bidar et al., 2010). Following treatment, patients who received the vitamin 
D fortified drink had a significant increase in serum 25-OHD concentration (before 
38.5 ± 20.2 vs. after 72.0 ± 23.5 nmol/L; P < 0.001) compared with patients who got 
the plain drink (before 38.0 ± 22.8 vs. after 33.4 ± 22.8 nmol/L, P = 0.28). Intake of 
FD was also associated with a significant decrease in hs-CRP concentration (before 
2.04 ± 2.69 vs. after 1.60 ± 1.04 mg/L; P < 0.001). 
Beilfuss et al. investigated the relationship between vitamin D status (and such 
pro-inflammatory cytokines as tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-
6) and high sensitive C-reactive protein (hs-CRP) in overweigh/obesity patients. A 
total of 332 subjects (21-70 years), with BMI between 28.0 and 47.0 kg/m
2 
were 
included in this 12 month randomized control trial. Hs-CRP and cytokines were 
measured using high sensitivity ELISAand serum levels of 25-OHD were measured 
by radioimmunoassay. Participants received either 40,000 IU vitamin D 
(cholecalciferol) per week (DD), or 20,000 IU vitamin D per week (DP), or placebo. 
No associations between IL-6, TNF-α and 25-OHD were found at baseline. After the 
one year intervention, IL-6 levels were significantly reduced in DD and DP subjects 
(delta -0.14; 95% CI (4.98 - 27.85), compared to placebo group (delta 0.02; 95% CI (-
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8.08 - 7.72). Hs-CRP levels were however significantly increased in DD and DP 
subjects (delta 0.11; 95% CI (-9.91 - 59.28), compared to placebo group (delta -0.08; 
95% CI (-18.89 - 37.04). 
Information on the relationship between erum 25-OHD status and 
inflammation remains largely conflicted, with the majorities of studies being carried 
out in post-menopausal, obese, or chronically ill populations. Studies examining 
relationships between vitamin D status and inflammation in young women remain 
scare. Few studies have controlled for the potential confounding effects of factors 
such as oral contraceptive use, alcohol intake, or smoking status, especially in young 
women. Our third study examined the association between vitamin D status (serum 
25-OHD levels), adiposity, and inflammatory factors in apparently healthy 
premenopausal aged women. 
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CHAPTER 2 
SPECIFIC AIMS AND HYPOTHESES 
2.1 Calcium, Vitamin D Intakes and Adiposity in Young Women 
2.1.1 Specific Aims 
1. To evaluate the extent to which dietary calcium and vitamin D intakes are 
associated with adiposity in young women enrolled in the UMass Amherst Vitamin D 
Status Study.  
2. To determine whether the above association varies with different types of adiposity, 
e.g., total body fat percentage (TBF %) measured with dual xray absorptiometry 
(DXA), compared to body mass index (BMI) or waist circumference (WC)  
 Primary Exposure - Dietary Intakes:  Vitamin D, Calcium, and Dairy.  
 Outcome – Obesity Markers:  Total body fat percentage (% TBF), Waist 
Circumference (WC), and body mass index (BMI). 
 
2.1.2 Hypotheses 
1. Dietary calcium, vitamin D, and dairy intakes will be inversely associated with 
measures of adiposity (% TBF, BMI, WC) in this population of apparently healthy 
young .women (i.e. women with higher food calcium, dairy,  or vitamin D intakes will 
be more likely to have lower adiposity measures, evidenced by low BMI, WC, or % 
TBF (TBF ≤ 32%, BMI < 25 Kg/m2, or waist circumference ≤ 80 cm] compared to 
women with lower intakes of calcium, dairy, or vitamin D). 
2. The hypothesized inverse association between calcium-vitamin D- intakes and body 
composition will be stronger with total body fat percentage (%TBF) measured by 
DXA as compared to BMI. 
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2.2 Serum 25-OHD Concentration and Adiposity in Young Women 
2.2.1 Specific Aims 
1. To determine the extent to which the relationship between vitamin D status and 
adiposity is influenced by lifestyle factors (e.g., oral contraceptive use, smoking 
status, alcohol intake and physical activity level) in young women.  
2. To determine whether the relationship between vitamin D status and adiposity 
varies with the site of fat deposition (i.e. android, gynoid, arms, legs, and trunk fat). 
3. To estimate the prevalence of vitamin D insufficiency in a population of 
premenopausal aged women using two different sets of cut-off values for serum 25-
OHD concentration (i.e. Traditional (FNB/ IOM, 2010) cut-off values: serum 25-
OHD < 25.0 nmol/L = Deficient, 25.0 – 49.9 nmol/L = Insufficient , and ≥ 50.0 
nmol/L = Adequate. Current evidenced based (Bischoff-Ferrari et al., 2006; Holick et 
al., 2011) proposed cut-offs, serum 25-OHD < 50.0 nmol/L = Deficient, 50.0 – 74.9 
nmol/L = Insufficient, and ≥ 75.0 nmol/L = Adequate).  
4. To evaluate the correlation between dietary vitamin D intake and serum 25-OHD 
concentration in this population.  
 Primary Exposure – Adiposity:  Total body fat percentage (% TBF), 
Android Fat (ANF), Gynoid Fat (GYF), Android to Gynoid Fat Ratio 
(AGFR), Arm Fat (AF), Leg Fat (LF), Trunk Fat (TF), Body Mass Index 
(BMI), Waist Circumference (WC). 
 Outcome - Vitamin D Status: Serum 25-OHD Concentration in nmol/L. 
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2.2.2 Hypotheses 
1. Women with higher adiposity (TBF > 32%, BMI ≥ 25 Kg/m2, or waist 
circumference > 80 cm) will be more likely to have lower serum 25-OHD 
concentrations, compared to women with lower adiposity measures (TBF ≤ 32%, BMI 
< 25 Kg/m
2
, or waist circumference < 80 cm). Oral contraceptive use, smoking status 
and alcohol intake may confound the association between adiposity and 25-OHD in 
young women.  
2. The hypothesized inverse association between adiposity and serum 25-OHD levels 
will be stronger with AN, GY, and %TBF than AF, LF, or TF. 
3. The prevalence of vitamin D deficiency (25-OHD < 75 nmol/L) will be low (< 15 
%) in this population of young women as a result of seasonal variation in 25-OHD 
levels and vitamin D supplement intake. 
4. Dietary vitamin D intake will be correlated with serum 25-OHD concentration, but 
may not be necessarily be a significant predictor of serum 25-OHD concentrations. 
 
2.3 Serum 25-OHD, Adiposity and Inflammation in Young Women 
2.3.1 Specific Aims  
1. To determine the extent to which serum 25-OHD level is associated with 
inflammatory biomarkers (including highly sensitive C-reactive protein (hs-CRP), 
interleukin (IL)-1β, 2, 4, 5, 6, 7, 8, 10, 12p70, 13, granulocyte-macrophage-colony-
stimulating factor (GM-CSF), interferon-gamma (IFN-γ)  and tumor necrosis factor-
alpha (TNF-α) in apparently healthy young women. 
2. To determine whether adiposity is associated with inflammation in young women. 
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3. To determine whether adiposity modifies the relationship between 25-OHD status 
and inflammation in young women. 
 Primary Exposure: Vitamin D Status- Serum 25-OHD concentration 
 
 Outcome – Inflammation: High sensitive C-reactive protein (hs-CRP), 
interleukin (IL)-1β, 2, 4, 5, 6, 7, 8, 10, 12p70, 13, granulocyte-
macrophage-colony-stimulating factor (GM-CSF), interferon-gamma 
(IFN-γ), and tumor necrosis factor-alpha (TNF-α). 
 Other Covariates: Adiposity - Total body fat percentage (% TBF), Android 
Fat (AN), Gynoid Fat (GY), Arm Fat (AF), Leg Fat (LF), Trunk Fat (TF), 
Body Mass Index (BMI), Waist Circumference (WC), Waist-to-Height-
Ratio (WHtR). 
 
2.3.2 Hypotheses 
1. Serum 25-OHD levels will be inversely associated with the inflammatory 
biomarker (hs-CRP) in young women.  
2. High adiposity (TBF > 32%, BMI ≥ 25 Kg/m2, or waist circumference > 80 cm) 
will confound/modify the relationship between serum 25-OHD and inflammation in 
this population. 
3. Regional fat mass (AN, GY, AF, LF, TF) will be positively correlated with pro-
inflammatory biomarkers (e.g., TNF-α, IL-1β, IL-6, IL-12p70) in young women. 
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2.4 Additional Covariates  
Previous studies have suggested that cigarette smoking and high levels of alcohol use 
is linked to impaired intestinal calcium absorption (Berg, 2008; Sampson, 2002; 
Saggese et al., 1995). We used the Harvard FFQ described earlier to collect 
information on alcohol use (i.e. beer, red and white wine, and liquor) in our 
population. We also collected information on self-reported history of smoking with 
our study questionnaire.   
Physical activity, specifically vigorous activities and high-intensity exercise 
have been linked with lower amounts of subcutaneous skinfold thicknesses and fat 
distribution (Obarzanek et al., 1994). Higher amounts of leisure time physical activity 
has also been positively associated with the low/ normal BMI and lower body fat 
range in women (Ball et al., 2001). In our study, women were asked to report their 
average weekly physical activity using a modified assessment based on that used by 
the Nurses’ Health Study II. Activities listed on the questionnaire included walking, 
jogging, running, bicycling, aerobics/dance/rowing machine, tennis/racket sports, 
swimming, yoga/pilates, and resistance exercises. All responses ranged from zero to 
eleven or more hours per week. We assigned metabolic equivalent (MET) scores 
using procedures described in literature (Ainsworth et al., 1993). The validity of these 
physical activity questions have been previously assessed in a representative sample 
of the Nurses’ Health Study II Cohort (n = 147), with a correlation of 0.62 reported 
for the questions listed above collected over four weeks using activity diaries and a 
correlation of 0.79 reported for the questions of physical activity recalled in the past 
week (Wolf, 1994).  
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Current smoking status and increasing BMI have been independently 
associated with a higher risk of serum 25-OHD deficiency (Odds Ratio 1.59; 95% CI 
1.35 - 1.87 for smoking status and Odds Ratio 1.04; 95% CI 1.02 - 1.06) (Melamed et 
al., 2008). Cutaneous synthesis of vitamin D also decreases with increasing age 
(Holick et al., 1989); and people with darker skin color require almost ten times more 
sunlight exposure in order to make the same amount of vitamin D as light skinned 
people because of melanin in the skin which blocks the absorption of UVB radiation 
(Clemens et al., 1982; Holick and Chen, 2008).  Vitamin D insufficiency is also more 
common at the end of winter than at the end of summer (Millen and Bodnar, 2008). 
Among free-living healthy young adults in Boston, Massachusetts, the prevalence of 
vitamin D insufficiency (25-OHD ≤ 20 ng/mL) was more common at the end of 
winter than at the end of summer (30 % vs. 11% respectively) (Tangricha et al., 
2002). There was also a significant seasonal variation in the 25-OHD concentrations 
between the winter and summer (35 ± 10 ng/mL at the end of summer, compared to 
30 ± 10 ng/mL at the end of winter; P <0.01). Seasonal variation in 25-OHD levels 
was highest in subjects aged 18 to 29 years (28 ± 10 ng/mL at the end of winter, vs. 
36 ± 10 ng/mL at the end of summer) and people who took multivitamin / vitamin D 
supplement were also more likely to have high serum 25-OHD concentrations than 
those who did not. Subjects who took a daily multivitamin supplement increased their 
serum 25-OHD levels by 30% compared to those who did not (37 ng/mL vs. 29 
ng/mL, P < 0.01) and this association was true in both summer and winter seasons 
(Tangricha et al., 2002). We included all the above covariates in our analyses to 
assess for potential interaction/confounding effects. 
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2.5 Human Subjects Protection  
Ethical clearance for this dissertation will was not done separately because this 
dissertation was conducted as part of the UMass Amherst Vitamin D Status Study, 
which had already obtained ethical clearance from the Human Subjects Committee of 
the University of Massachusetts at Amherst. Potential participants were provided with 
information describing the study and were made aware that participation was entirely 
voluntary. Each participant read and signed an informed consent document prior to 
her participation. One potential risk of participation was breach of privacy by study 
personnel. To minimize this risk, subjects were assigned a unique code to be used on 
forms instead of their names. Only project investigators had access to records linking 
subjects’ name and codes and all identifying information was kept separate from 
analysis databases. All study staff were educated on the need for confidentiality and 
all records were kept in a locked filing cabinet. Sensitive digital information was kept 
in password-protected computer files.   
 
2.6 Permission to Access Data 
Prior to accessing the data to be used for this dissertation analyses, written permission 
was obtained from the principal investigators of the UMass Amherst Vitamin D Status 
Study; Dr. Alayne Ronnenberg and Dr. Elizabeth Bertone-Johnson (Appendix A). 
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CHAPTER 3 
ASSOCIATIONS BETWEEN CALCIUM, VITAMIN D INTAKES AND 
OBESITY MARKERS IN YOUNG WOMEN (18 – 30 YEARS) 
A. A. Addo-Lartey 
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01003, USA  
Abstract: Calcium and vitamin D intakes have been linked with reduced body mass 
index (BMI ≥ 30 kg/m2) and body fat percentage in older adults and in obese women. 
However, very little is known about the extent of these associations in healthy non-
obese young women. We evaluated these relationships among 270 women aged 18-30 
years (Mean BMI: 22.9 ± 3.3 kg/m
2
) in a cross-sectional analysis within the UMass 
Amherst Vitamin D Status Study (2006-2011). Dietary information and total body fat 
percentage (%TBF) were obtained using a validated food frequency questionnaire and 
dual energy x-ray absorptiometry, respectively. After adjustment for total energy 
intake, physical activity level and smoking status, women reporting adequate intakes 
of calcium (≥ 1000 mg/day) but low intakes of vitamin D (< 600 IU/day) were over 
two-fold more likely to have high TBF (≥ 32%); [Odds Ratio, OR, 95% Confidence 
Interval, CI: 2.27; 1.02 - 5.04], compared to those with adequate intakes of both 
calcium (≥ 1000 mg/day) and vitamin D (≥ 600 IU/day). Low intake of calcium from 
dietary supplements (225 to 500 mg/day) was associated with risk of increased WC (≥ 
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80 cm) [OR, 95% CI: 2.27, 1.17 - 4.39]. Furthermore, the risk of being 
overweight/obese (BMI ≥ 25 kg/m2) increased in a linear manner across tertiles of 
decreasing supplemental calcium intake (Ptrend = 0.02). Our findings suggest that 
addition of calcium supplements to inadequate diets could reduce adiposity risk in 
young women. Adequate dietary intakes of both calcium and vitamin D may also be 
necessary to reduce body fat percentage, even among non-obese young women. 
Further studies are needed to examine these associations and also investigate whether 
dietary intakes of calcium and/or vitamin D modify adiposity levels in young women.  
Keywords: Calcium, Vitamin D, Adiposity, Percentage body fat, Body mass index, 
Waist circumference, Young women 
 
3.1 Introduction 
In addition to their well-established roles in bone metabolism [1-3], intakes of calcium 
and vitamin D have been inversely associated with adiposity in some populations [4-
6]. In the U.S., about 50% of dietary calcium is derived from dairy products [7, 8], 
although other foods, including broccoli, kale, almonds, and soybeans, can provide 
substantial amounts of calcium, particularly for vegetarians [9]. While most 
circulating vitamin D is derived from endogenous cutaneous synthesis following 
exposure to ultraviolet rays [10-12], fortified foods can provide considerable amounts 
of vitamin D. Milk, for instance, is usually fortified with about 400 IU (10 µg) of 
vitamin D per quart, providing 100 IU per eight ounce glass, while most cereals are 
fortified with about 40 - 140 IU (1 to 3.5 µg) of vitamin D per serving [13]. Fatty fish 
(especially wild salmon, mackerel, and catfish), fish oils, oysters, and certain 
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mushroom species also provide substantial amounts of dietary vitamin D [11-14]. 
Data from the National Health and Nutrition Examination Survey (NHAHES) 2003 – 
2006 [15] show that despite the variety of both plant and animal dietary sources of 
calcium, mean daily calcium intake from food sources for young women (19 to 30 
years) remains inadequate (838 ± 25 mg/day) and below the current recommended 
dietary allowance (RDA) of 1000 mg/day for adults females (20 - 39 years) [16]. 
Similarly, among premenopausal aged women (19 - 50 years), mean daily intake of 
vitamin D from food sources was around 160 ± 12 IU/day, [15] which is much lower 
than the newly established RDA of 600 IU/day for young women [16].  
While many epidemiologic studies have described an inverse relationship 
between calcium-vitamin D intake and adiposity, particularly in older or obese 
women [17-25], the exact mechanism explaining this association is yet to be fully 
elucidated. Zemel and colleagues have hypothesized that the association could be 
mediated through plasma concentrations of 1, 25 dihydroxyvitamin D3 (calcitriol), the 
metabolically active form of vitamin D [17-20]. This hypothesis suggests that low 
dietary calcium intake increases production of calcitriol, which, in turn, stimulates 
intracellular calcium (Ca
2+
) influx. The increased intracellular Ca
2+
 concentration then 
enhances expression of lipogenic genes while inhibiting lipolysis, leading to increased 
fat cell mass (adiposity). Additional studies by the same group indicate that the 
inverse association between dietary calcium and adiposity appears stronger for 
calcium consumed from dairy products than from other calcium sources [17-20, 26], 
and in the United States, dairy products are typically the primary source of both 
calcium and vitamin D [7, 8].  
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Most of the studies assessing the relationship between dietary intakes of 
calcium, vitamin D and adiposity have relied on proxy measures of adiposity such as 
body mass index (BMI), waist circumference, and skinfold measures of abdominal 
fat. However, the use of these proxy measures may underestimate true body fat 
percentage [27-29]. In contrast, dual energy x-ray absorptiometry (DXA) is 
considered a more accurate method of estimating percentage body fat [30, 31] and its 
use among young women has been previously validated [31]. Given that health risks 
increase dramatically with increasing adiposity, identifying modifiable dietary factors 
in early adulthood may significantly impact risk of obesity and related conditions later 
in life. For the present analyses, we examined the association between dietary intakes 
of calcium, vitamin D or dairy products and three measures of adiposity (DXA 
estimates of percentage body fat, BMI and waist circumference) among young women 
enrolled in the UMass Amherst Vitamin D Status Study. 
 
3.2 Materials and Methods  
3.2.1 Study Design and Population 
The University of Massachusetts Amherst Vitamin D Status Study is a cross-sectional 
study intended to assess vitamin D status in young women and to identify its dietary, 
environmental, and lifestyle determinants, as well as its association with other health 
measurements. Between March 2006 and September 2011, 288 healthy women aged 
18 to 30 years from the Amherst, Massachusetts, area were enrolled in the study. 
Women were recruited into the study using advertisement and fliers posted around 
college. Women were eligible to participate if they were not currently pregnant; not 
experiencing untreated depression; did not have a history of high blood pressure or 
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elevated cholesterol, kidney or liver disease, bone disease  (e.g., osteomalacia), 
digestive disorders, multiple sclerosis, rheumatoid arthritis, thyroid 
disease, hyperparathyroidism, cancer, Type 1 or Type 2 diabetes mellitus, 
or polycystic ovaries; and were not  taking corticosteroids, anabolic steroids, 
anticonvulsants,  propranolol, or cimetidine. The present analyses include 270 women 
who met eligibility criteria and had dual energy x-ray absorptiometry (DXA) 
measurements. This study was approved by the Institutional Review Board at the 
University of Massachusetts, Amherst. Written informed consent was obtained from 
all participants. 
 
3.2.2 Anthropometry and Lifestyle Factors 
All study measurements were completed in a single clinic visit scheduled for the late 
luteal phase of each participant's menstrual cycle. Information on lifestyle and 
demographic factors was collected by self-reported questionnaire. During the study 
visit, women’s weight was measured using a calibrated scale with subjects wearing 
light clothing and no shoes. Height and waist circumference were measured to the 
nearest 0.1 cm using a wall mounted stadiometer and a flexible tape measure, 
respectively. Body mass index (BMI) was calculated as weight in kilograms divided 
by the square of height in meters. Percentage of total body fat (%TBF) was measured 
by dual energy x-ray absorptiometry (Fig 11) using the total body scan mode on a 
narrow angle fan GE Lunar Prodigy scanner (GE Lunar Corp., Madison, WI).  The 
DXA scan was performed with the participant lying in a supine position with her arms 
and legs placed according to the manufacturer’s specifications. Measurements were 
completed by the same technician, and the machine was calibrated daily using the 
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standard calibration method provided by the manufacturer.  The coefficient of 
variation for repeated scans of the manufacturer’s phantom is less than 1%.  
 
Figure 11. A DXA Scan in Progress 
 
Source: http://www.bodycompositioncenter.com/ 
 
To estimate level of physical activity, we asked participants to report the time 
they spent each week engaged in specific activities including walking, jogging, 
running, bicycling, aerobics/dancing, tennis/racket sports, swimming, yoga/pilates and 
weight training. These questions were based on those used in the Nurses’ Health 
Study II and have been previously validated in that population [32].  We then 
calculated total metabolic equivalents (MET), which were recorded in hours of 
activity per week. The MET per week score measures the intensity of a physical 
activity, with 1 MET being defined as the amount of energy expended when a person 
is at rest [33]. We also used self-reported questionnaires to collect information on 
race, anthropometric and lifestyle factors, including smoking status, alcohol intake 
and use of oral contraceptives. 
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3.2.3 Dietary Assessment 
Dietary intake of food and supplements in the previous two months was assessed 
using a modified version of the Harvard Food Frequency Questionnaire (FFQ), which 
has been extensively validated for use in U.S. women [34, 35]. Calcium and vitamin 
D-rich food items on the modified questionnaire included regular and fortified dairy 
foods and fortified orange juice and breakfast cereals, dark meat fish, shellfish, leafy 
green vegetables and multivitamins or other supplements containing calcium or 
vitamin D. FFQs were analyzed at Harvard University, where nutrient intakes were 
calculated by multiplying the frequency of intake of a specified portion size of each 
food by its nutrient content and then summing across all food items. Adequacy of 
dietary intakes of calcium and vitamin D were determined by comparing reported 
intakes with the Recommended Dietary Allowance (RDA) for women in this age 
range [16]. Intake of dairy foods was assessed using self-reported intake of selected 
dairy foods (skim, low fat or whole milk, sherbet or ice milk, ice cream, yogurt, 
cottage cheese and other cheeses). Average number of servings per day was estimated 
by dividing the frequency of intake of each food by the number of days. For instance, 
if a participant reported eating yogurt once a week, the number of servings per day 
was estimated as 1/7 days = 0.14 servings per day.  
 
3.2.4 Statistical Analysis 
All analyses were completed using STATA version 12.0 (Stata Corporation., College 
Station, TX.). The distribution of participant characteristics were assessed using 
descriptive statistics (means, variances, percentiles) and graphs (histograms and 
scatter plots (Appendix B).  We compared participant characteristics by adequacy of 
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calcium and vitamin D intakes [16] using student t-tests and chi-squared tests. Only 
one subject reported an implausible total energy intake (> 5000 kcal/day); however, 
this participant was not excluded from our analyses as her physical activity level was 
high (>100 metabolic equivalents [METs]/week).  
Total body fat percentage was categorized as “low” (TBF < 32%) or “high” 
(TBF ≥ 32%) based on gender- and age-specific cut-offs [36] and also on the current 
American Council on Exercise recommendation for maximum body fat percentage in 
women who are non-athletes [37].  BMI was classified as “low” (BMI < 25 kg/m2) or 
“high” (BMI ≥ 25 kg/m2) based on current recommendations by the World Health 
Organization [38] and National Heart, Lung and Blood Institute and the North 
American Association for the Study of Obesity [39]. The waist circumference (WC) 
cut-off point for high central obesity was defined as WC ≥ 80 cm, based on guidelines 
proposed by the International Diabetes Federation [40].  
We assessed the nature and strength of associations among covariates, dietary 
intakes, and adiposity variables using normal throery multiple linear regression. 
Linear and restricted cubic spline model fit were also obtained to assess departure 
from linearity (Appendix C).  Model adequacy was assessed using residual versus 
predicted values, and Cook’s distance plots were used to identify influential data 
points. Crude and adjusted associations between dietary calcium, vitamin D intakes 
and adiposity were estimated from unadjusted and multivariable adjusted linear 
regression. The dependent variable in these analyses was adiposity defined as total 
body fat percentage (TBF), body mass index (BMI) and waist circumference (WC). 
Total energy and physical activity level were considered a priori to be likely 
confounders of adiposity-calcium-vitamin D relationships. Selected covariates were 
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considered for inclusion in our final multivariable models based on evidence in the 
literature suggesting their potential role as confounders or effect modifiers. We 
conducted model assessment with and without each of these covariates, and included 
in the final regression model any variable with P < 0.20 or led to at least a 10% 
change in the beta coefficient for each adiposity measure. Our final model was further 
evaluated for multicollinearity between covariates. This was necessary to ensure that 
the effect of one variable in our model does not depend on the level of another 
variable in that same model.  
Logistic regression was used to estimate odds ratios and 95% confidence 
intervals for the association between intakes of dietary calcium, vitamin D, dairy 
products, and event of high adiposity, defined as TBF ≥ 32%, BMI ≥ 30 kg/m2, and 
WC ≥ 80 cm. Calcium and vitamin D were each evaluated as follows:  total intake, 
intake from food sources only, and intake from supplements only. Covariates were 
included in the final regression model based on likelihood ratio tests and the changes 
they effected in the betas for the primary predictors. Selected important variables, 
including total energy intake and physical activity level, were included a priori. The 
Hosmer-Lemeshow goodness of fit test for our main effects model had a P-value of 
0.25, indicating adequate goodness of fit. To evaluate linear trends, we used a Mantel 
extension test, modeling the medians of each tertile of dietary intake as a continuous 
variable. All P-values were two-sided and considered statistically significant if P < 
0.05.  
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3.3 Results  
The characteristics of the study participants are presented in Table 7. The majority of 
participants were Caucasian (86.2%). About one-half (51.5%) of women had high 
adiposity (%TBF ≥ 32) while one-third (33.3%) had a WC measurement ≥ 80 cm. 
About 21.1% were overweight or obese (BMI ≥ 25 kg/m2). Mean calcium and vitamin 
D intakes were 1220 ± 616 mg/day and 375 ± 298 IU/day, respectively (Table 8). A 
large proportion of women (83.3%) had total vitamin D intakes less than the current 
RDA of 600 IU/day (FNB/IOM, 2010), and about 40% of women had inadequate total 
calcium intakes (< RDA of 1000 mg/day). 
Overall, 37.4% of women had low intakes of both vitamin D and calcium. 
Women reporting adequate calcium or vitamin D intakes reported higher intakes of 
total energy, protein and fat (P < 0.01). From Table 9a, women with adequate calcium 
intakes were more likely to be non-smokers (P = 0.01) and exercised more than those 
with low total calcium intakes (P < 0.01). Compared to women with adequate vitamin 
D intake, women with low vitamin D intakes were more likely to have high total body 
fat percentage (P = 0.04) or use oral contraceptive (P = 0.01), (Table 9b). Participants 
with low TBF (< 32 %) reported higher intakes of food vitamin D compared to 
women with TBF ≥ 32 % (257 ± 19 vs. 205 ± 12, P = 0.02), (Table 10b). Some of the 
major dietary contributors to vitamin D intake in our cohort were milk (28.0%), skim 
milk (12.1%), cream (16.1%), yogurt (10.9%), eggs (4.3%) and cold breakfast cereals 
(1.5%). Dairy products thus accounted for over two-thirds of dietary vitamin D intake 
(data not shown). 
Study participants who were smokers had low BMI (< 25kg/m
2
), (Table 11a). 
Correlation analyses (Table 13) indicated that adiposity measures were highly 
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correlated with each other; %TBF and BMI (r = 0.76; P < 0.01), %TBF and WC (r = 
0.72; P < 0.01) and BMI and WC (r = 0.84; P < 0.01). Physical activity level was 
inversely correlated with %TBF (r = -0.14; P = 0.02), but not BMI (r = 0.01, P = 
0.92) or WC (r = 0.01, P = 0.86). Physical activity level was also an independent 
predictor of total body fat (ß: -0.03 ± 0.1%, P = 0.02), (Table 14).  
Energy adjusted and multivariable adjusted linear regression showed no 
significant associations between adiposity (TBF and BMI) and intakes of calcium or 
vitamin D (Table 15). Among all women, supplemental calcium intake (adjusted for 
total energy intake) was inversely associated with waist circumference (ß: -0.004 ± 
0.002 cm, P = 0.045). However, the strength of this association became marginal after 
adjustment for physical activity level, smoking status and vitamin D intake (ß: -0.005 
± 0.003 cm, P = 0.07). In the subset of calcium supplement users, indicated that for 
every 100 mg increase in calcium supplement intake, waist circumference was 
reduced by 0.8 ± 0.4 cm (P = 0.04).  
Logistic regression analyses of the event of high adiposity (TBF ≥ 32 % , BMI 
≥  30kg/m2 , and WC ≥ 80 cm) (Tables 16 & 17), indicated that among all 
participants, there was a slight inverse (beneficial) trend in relative odds of high 
adiposity with increasing calcium or vitamin D intake; however, these associations 
were not statistically significant (P > 0.05). Intakes of calcium and vitamin D were 
significantly correlated (Table 13): total calcium and total vitamin D (r = 0.51, P < 
0.01); food calcium and food vitamin D (r = 0.75, P < 0.01); calcium supplement and 
vitamin D supplement (r = 0.46, P < 0.01). We therefore adjusted vitamin D and 
calcium for each other as appropriate to assess the independent effects of each 
nutrient. Compared to women in the highest tertile of calcium supplement intake 
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(Table 17), women with lower calcium intake from supplements were more likely to 
have waist circumference ≥ 80 cm (OR = 2.04; 95% CI: 1.04 – 3.99). We also found 
evidence of a linear dose-relationship across tertiles of decreasing supplemental 
calcium intake and risk of high BMI (Ptrend = 0.02). From Table 18, both energy 
adjusted and multivariable logistic regression models showed that the risk of having a 
high body fat percentage (%TBF ≥ 32) was greater among women reporting a 
combination of high calcium intake (≥ 1000 mg/day) but low intake of vitamin D (< 
600 IU/day), compared to women with high intakes of both calcium (≥ 1000 mg/day) 
and vitamin D (≥ 600 IU/day) [OR = 2.37; 95% CI: 1.09 - 5.12 and OR = 2.27; 95% 
CI:1.02 – 5.04, respectively) 
 
3.4 Discussion  
In this cross-sectional study among college-aged women, linear regression analyses 
showed that low intake of calcium supplements was significantly associated with 
events of waist circumference ≥ 80 cm. Among young women 18-30 years old, a 
waist circumference greater than 80 cm indicates central obesity (i.e., an excess of 
abdominal fat) and suggests increased visceral adiposity. Visceral fat is more 
metabolically active than subcutaneous fat [41, 42], and large deposits can disrupt 
fatty acid metabolism, increasing the influx of free fatty acids entering splanchnic 
circulation [43, 44]. Excessive amounts of unbound fatty acids in the blood contribute 
to hyperlipidemia and hypertriglyceridemia, both of which can promote or exacerbate 
obesity-related chronic conditions [45-47]. Our findings suggest that increased intake 
of supplemental calcium may help reduce the risk of central obesity (high waist 
circumference) among pre-menopausal Caucasian women. However, the cross-
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sectional design of our study precludes causal inferences (i.e., it is impossible to 
determine whether high waist circumference influenced calcium supplement intake or 
whether the reverse was true). Additional prospective and intervention studies 
utilizing larger cohorts are needed to further evaluate these associations and to 
examine the mechanism(s) by which calcium intake, especially calcium from dietary 
supplements, may modulate adiposity in normal- and over- weight young women.  
In our samples, women in the second tertile of total calcium intake (median 
intake of 1143 mg/day) had significantly higher risk of increased waist circumference 
measurement (OR = 2.27; 95% CI: 1.17 - 4.39), compared to women in the highest 
tertile of total calcium intake (median intake of 1658 mg/day). Similarly, total calcium 
intake was marginally associated with increased risk of high total body fat percentage 
(OR = 1.82; 95% CI: 0.99 - 3.37) among women in the second tertile of total calcium 
intake, but this association was not present with respect to BMI. This observation 
possibly lends support to the notion that BMI is a poor proxy for estimating adiposity, 
especially in a cohort of relatively active young adult women, where high BMI (≥ 25 
kg/m
2
) may lead to misclassification of heavily muscled women as overweight or 
obese [27-29]. In our cohort, waist circumference was strongly correlated with total 
body fat percentage (r = 0.72; P < 0.01). Since WC is less expensive and invasive as 
compared to dual energy x-ray absorptiometry (DXA), its use as a proxy for fat mass 
in youg women warantly further investigation. 
Our logistic regression analyses showed that calcium intake (total calcium, 
calcium from food sources only and calcium supplements) was inversely correlated 
with %TBF, BMI, and WC, although these associations were not statistically 
significant. This finding may have been due to the fact that the ranges of BMI, WC, 
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and %TBF were relatively narrow in our study compared to those in other studies of 
older individuals. Mean intake of total calcium in our study (1220 ± 616 mg/day) was 
also above the RDA (1000 mg/day) for women 19 - 50 years, which contrasts with 
several reports from similar cohorts [15, 17, 18, 23, and 24]. In one example, Lin et 
al. conducted a prospective analysis of the effect of calcium intake on changes in 
body composition during a two-year exercise intervention among 54 sedentary but 
normal weight Caucasian US women (18 - 31 years) [22]. Dietary intake was assessed 
with 3-day diet records at baseline and every 6 months, and DXA was used to 
estimate body fat percentage and lean mass. They reported that total calcium intake, 
adjusted for total energy intake, was negatively correlated with changes in body 
weight (r = -0.35, P < 0.05) and body fat percentage (r = -0.34, P < 0.05). Mean 
calcium intake was also estimated as 781 ± 212 mg/day, which is lower than the 
current RDA for adult women.  
In the Quebec Family Study (n = 235 women, ages 20 - 65 years), Jacqmain et 
al. observedthat percentage body fat, BMI and WC were lower in women consuming 
600 mg or more of calcium per day (BF: 31.3 ± 0.9 % vs. 37.3 ± 1.6 %, P < 0.05; 
BMI: 27.0 ± 0.7 vs. 31.8 ± 1.2 kg/m
2
, P < 0.05; and WC: 82.0 ± 1.6 vs. 93.6 ± 2.6 cm, 
P < 0.05) as compared to women with lower intakes [24]. In our sample, conversely, 
when we used the current RDA of 1000 mg/day to assess adequacy of calcium intake 
in the present study, we found no significant differences in adiposity measures 
(%TBF, BMI or WC) for women consuming ≥ 1000 mg/day of calcium compared to 
those consuming less calcium (%TBF: 32.0 ± 7.8 vs. 32.2 ± 8.7 %, P = 0.81; BMI: 
22.7 ± 2.9 vs. 23.1 ± 3.7 kg/m
2
,
 
P = 0.38; and WC: 76.9 ± 8.3 vs. 78.2 ± 9.9 cm, P = 
0.26). After adjusting for age, energy intake, percentage dietary fat, dietary protein 
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intake and markers of socioeconomic status, Jacqmain et al. reported that dietary 
calcium intake (assessed with 3-day food records) was negatively correlated with 
computed tomography estimates of percentage body fat (r = -0.17, P < 0.05) [24]. We 
did not observe an association in our sample (r = -0.04, P = 0.47). 
In our cohort, women reporting adequate intakes of calcium (≥ 1000 mg/day) 
but low intakes of vitamin D (< 600 IU/day) were twice as likely to have high body 
fat (%TBF ≥ 32), compared to those with adequate intakes of both calcium (≥ 1000 
mg/day) and vitamin D (≥ 600 IU/day). In independent studies of agouti-mice as well 
as overweight/obese adult women, Zemel et al. have hypothesized that suppression of 
1,25-dihydroxyvitamin D activation with high-calcium diets would reduce adipocyte 
intracellular Ca
2+
 concentration, inhibit fatty acid synthase activity and activate 
lipolysis, thus exerting an anti-obesity effect [17-20]. In our sample, we were unable 
to assess the relationship between vitamin D intake from food sources and serum 
concentrations of 25-hydroxyvitamin D3. However, previous findings from a sub-
sample of our cohort (n = 186) suggested a statistically significant modest correlation 
between dietary vitamin D intake and serum 25-dihydroxy vitamin D3 levels (r = 
0.18, P = 0.01)[49].  
Women in our study were similar to each other with respect to some 
characteristics known to be associated with adiposity, including smoking, alcohol 
use, physical activity levels and intakes of total calcium and energy [50-54], but we 
still adjusted for these covariates as they could potentially confound any observed 
associations.  However, it is still possible that there may be residual confounding by 
other unknown factors.  
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Few studies have examined the association between dietary vitamin D intake 
and adiposity. Our findings did not corroborate the observations of Tidwell and 
Valliant, who recently reported an inverse correlation between dietary vitamin D 
intake and percentage body fat (measured using DXA) in African American women 
[25]. Using cross-sectional data from 100 pre-menopausal women (18 - 40 years), 
they estimated partial correlations between vitamin D intake and body fat, controlling 
for fat, carbohydrate and protein intakes. In their study, women with lower intakes of 
dietary vitamin D (152 ± 36 IU/day) were statistically significantly more likely to 
have excessive body fat (%BF > 37.9 %) than were women with higher intakes of 
dietary vitamin D (200 ± 32 IU/day) (r = -0.46, P < 0.01). Our results may have 
differed from that of Tidwell & Valliant because of differences in sample 
characteristics, which could have precluded the discovery of associations between 
nutrient intake and adiposity. We also controlled for dietary calcium intake (which 
was highly correlated with vitamin D from food sources) in order to assess the 
independent effects of dietary vitamin D intake on adiposity. Tidwell and Valliant’s 
cohort included primarily overweight and obese African-American women (mean 
BMI: 29.8 ± 6.9 kg/m
2
 and % BF: 36.9 ± 7.3 %). In contrast, women in our study 
were predominately Caucasian with relatively low BMI (22.9 ± 3.2 kg/m
2
) and TBF 
(31.9 ± 7.8 %). This dissimilarity in women’s body composition may be central in 
defining how dietary calcium and vitamin D intake is related to adiposity in young 
women. Use of a comprehensive FFQ compared to a one-time 24-hr dietary recall 
[25] also enabled us to assess usual dietary intake over a longer period, which may be 
more predictive of adiposity than recent intake.  
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In contrast to what has been reported in other studies [6, 17-20], we did not 
find any significant associations between intake of dairy foods and measures of 
adiposity (percentage body fat, BMI and waist circumference) in our cohort.  
Some of the strengths of our study include a comprehensive assessment of 
nutrient intake using a validated food frequency questionnaire. Overall, we expected 
some degree of misclassification of dietary intake because it is challenging to 
accurately estimate dietary intake over time without error. Although it is especially 
difficult to estimate and recall past portion size accurately, research has shown that it 
is much easier for people to recall the frequency of intake, which is well correlated 
with portion size [55]. It is also unlikely that any misclassification of dietary intake in 
our study would be related to adiposity (total body fat percentage) in a systematic 
way, as participants were unaware of their body fat statistics prior to having the DXA 
scan.  
We assessed adiposity using DXA scans, which have been previously 
validated and found to accurately differentiate between women with 
acceptable/normal body fat and those with high or excess adiposity [30, 31]. DXA 
scans estimate body composition by measuring the amount of energy absorbed from 
two x-ray beams through the body. These two beams have different energy levels, 
such that the differential absorption of the beans allows for distinction of bone mineral 
mass from soft tissue mass [56]. The accuracy of body composition measurement is 
therefore dependent in part on the accuracy of soft tissue measurements.  
DXA assessment of body composition is largely accurate in non-obese 
persons; however, some studies have indicated that DXA measurements may be less 
accurate in obese individuals [57-58]. Although DXA is widely accepted as a 
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benchmark method for the measurement of body composition [59], there is some 
potential for non-differential misclassification of body composition. This is because 
all methods that assess body composition in vivo only provide indirect estimates of 
body composition. Only chemical analysis and cadaver dissection can offer accurate 
direct measures of body composition [60-61]. In our analyses, we included all 
participants with DXA scan information because body fat percentage was one of our 
outcomes of interest hence we cannot justifiably exclude any subject based on their 
body fat percentage. This study design therefore suggests that if DXA- estimated 
percentage body fat values are less accurately detected in obese persons (BMI > 30 
kg/m
2
) then our findings related to percentage of body fat in this population of young 
women may be underestimated. 
Some limitations of our study include the homogeneity of our population. Our 
population was comprised of mostly non-obese and few obese individuals and all 
participants were between 18 to 30 years.  Subjects were also predominately were 
Caucasian. Our findings are therefore limited to mostly non-obese young Caucasian 
women and may not be generalizable to women in other age groups, BMI categories, 
or ethnicities. In addition, because all exposures and outcome variables were assessed 
at one time-point, causal relationships cannot be inferred from our study. Prospective 
studies are needed to better undertand the role of dietary calcium and vitamin D intake 
in obesity development. 
 
3.5 Conclusions and Significance 
Calcium and vitamin D intakes have been linked with reduced adiposity in older 
adults and in obese women (body mass index, BMI,  ≥ 30 kg/m2), but few studies 
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have examined these associations in healthy young women. Obesity is a precursor of a 
host of chronic conditions, including cardiovascular disease, type II diabetes mellitus, 
and several cancers. Understanding and identifying modifiable dietary factors 
associated with obesity (increased adiposity) is therefore important in formulating 
nutrition interventions targeted at obesity reduction/prevention. The results of this 
study suggest that even though obesity is generally associated with sedentary lifestyle 
and energy imbalance, micronutrient status may also influence obesity risk. Our 
findings indicate that a dietary high intake of both calcium and vitamin D may protect 
against high body fat percentage, even among non-obese young women.  Women with 
lower intakes of total and supplemental calcium were also showed increased risk of 
high waist circumference, an indicator of central obesity, compared to women with 
higher calcium intakes. Globally, obesity is a growing public health concern; and the 
possibility that adiposity risk in young women may be influenced by a high intake of 
calcium, especially calcium obtained from supplements, warrants further study.  
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Table 7. Characteristics of Participants: UMass Amherst Vitamin D Status Study, 
2006 – 2011 
 
Covariate Mean ± Standard Deviation Min - Max 
Age, years  21.4 ± 2.8 18.0 - 30.9 
BMI, kg/m
2
  22.9 ±  3.3 16.7 - 37.7 
Waist Circumference, cm 77.4 ±  9.0 58.4 - 114.3 
Waist : Height, ratio 0.5 ±  0.1 0.4 - 0.7 
Total Body Fat, %  32.1 ±  8.2 14.8 - 56.6 
Arm Fat, % 30.6 ± 9.3 8.2 - 52.5 
Leg Fat, % 35.4 ± 7.5 8.7 - 54.2 
Trunk Fat, % 31.9 ± 9.6 11.7 - 60.7 
Android Fat, % 34.5 ± 10.7 12.5 - 62.9 
Gynoid Fat, % 40.5 ± 6.7 16.1 - 59.9 
Android : Gynoid Fat, ratio  0.8 ± 0.2 0.4 - 1.8 
Physical Activity, MET-hrs/week
╔
  49.6 ± 43.4 0 - 206.9 
Systolic Blood Pressure, mm Hg 108.1 ± 10.8 77 - 160 
Diastolic Blood Pressure, mm Hg 69.9 ± 7.7 50 - 105 
Fasting Blood Glucose, mg/dL
ϖ
 81.8 ± 10.0 42 - 134 
Serum 25-OHD, nmol/L
‡
 79.2 ±  32.3 21.7 - 174.3 
╔ 
MET, metabolic equivalent hours of activity per week, n = 261 for physical activity. 
50 MET-hrs / week is approximately equivalent to about 25-30 minutes of moderate 
intensity exercise per day, e.g., walking outdoors or on a treadmill. 
ϖ 
n = 257 for fasting blood glucose.                
‡ 
n = 174 for serum 25-OHD.           
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Table 7. Continued  
 
Covariate n (%) 
Race
┴
 
Caucasian 
Other 
 
232 (86.2) 
37 (13.8) 
Education  
Some College 
College Graduate 
 
224 (83.0) 
46 (17.0) 
Currently Drink Alcohol  
No 
Yes 
 
70 (25.9) 
200 (74.1) 
Currently Smoke
┴ 
   
No 
Yes 
 
254 (94.4) 
15 (5.6) 
Currently Use Oral Contraceptive 
No 
Yes 
 
155 (57.4) 
115 (42.6) 
BMI, kg/m
2
  
 < 25 
 
 ≥ 25  
 
213 (78.9) 
57 (21.1) 
Waist Circumference, cm 
 < 80  
      ≥ 80  
 
180 (66.7) 
90 (33.3) 
Total Body Fat, %  
 < 32  
      ≥ 32  
 
131 (48.5) 
139 (51.5) 
Android: Gynoid Fat, ratio 
 < 1 
      ≥ 1 
 
202 (74.8) 
68 (25.2) 
Serum 25-OHD, nmol/L
‡
  
      < 50  
      50 - 75  
      ≥ 75  
 
28 (16.1) 
65 (37.4) 
81 (46.5) 
‡ 
n = 174 for serum 25-OHD.              
┴ 
n = 269 for race and smoking status. 
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Table 8. Unadjusted Dietary Intakes of Participants 
 
 
Dietary Intake 
Mean ±  
Standard Error 
Min - Max 
Energy, kcal/day 2192 ± 54 474 - 6765 
Total Protein, g/day  98 ± 3 22 - 315 
Total Fat, g/day  72 ± 2 15 - 236 
Total Calcium Intake, mg/day  
Food calcium 
Supplemental
 
calcium (n = 93 users) 
1220 ± 37 
1091 ± 35 
377 ± 30 
224 - 4601 
180 - 4601 
11 - 1334 
Vitamin A, IU/day 16120 ± 651 791 - 79213 
Thiamin, mg/day 1.9 ± 0.1 0.1 - 6.1 
Riboflavin, mg/day 2.6 ± 0.1 0.4 - 9.8 
Niacin, mg/day 27.5 ± 0.9 1.3 - 101.7 
Pantothenic acid, mg/day 6.7 ± 0.2 0.5 - 34.9 
Vitamin B6, mg/day 2.5 ± 0.1 0.1 - 10.4 
Folate, µg/day 661 ± 23 28 - 2338 
Vitamin B12, µg/day 6.3 ± 0.3 0.1 - 34.3 
Vitamin C, mg/day 153 ± 6 1 - 1054 
Total Vitamin D Intake, IU/day  
Food vitamin D 
Supplemental
 
vitamin D (n = 110 users) 
375 ± 18 
230 ± 11 
357 ± 26 
3 - 1806 
3 - 1006 
29 - 1400 
Vitamin E, mg/day 152 ± 143 1 - 38535 
Iron, mg/day 17.9 ± 0.6 1.3 - 73.0 
Zinc, mg/day 13.6 ± 0.4 2.9 - 54.2 
Linoleic acid, g/day 24.2 ± 0.8 4.6 - 102.2 
Linolenic acid, g/day 12.7 ± 0.4 1.7 - 70.8 
Dairy Intake, total servings/day
₸
 1.9 ± 0.1 0 - 7.2 
§ 
IU, International Units: 1 IU = 0.025 µg. 
 
₸
 n = 169 for dairy intake responders. 1 serving dairy = 8 fluid oz. (1 cup) of milk or 
yogurt; 1.5 oz of natural cheese; 2 oz of processed cheese, 2 cups of cottage cheese. 
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Table 9a. Variations in Characteristics of Participants by Adequacy of Total Calcium 
Intake
 Ϫ
,
 
Defined by Recommended Dietary Allowance (RDA) 
 Total Calcium Intake (mg/day) 
 
Covariate 
Low (< 1000) 
(n = 108) 
Adequate (≥ 1000) 
(n = 162) 
P 
ⱶ
 
 Mean ± Standard Deviation  
Age, y  21.4 ± 2.8 21.4 ± 2.8 0.97 
Waist Circumference, cm 
< 80 (n = 180)
 
≥ 80 (n = 90) 
78.2 ±  9.9 
72.4 ±  4.1 
88.8 ±  8.4 
76.9 ±  8.3 
72.3 ±  5.0 
86.5 ±  5.1 
0.26 
0.95 
0.12 
BMI, kg/m
2
  
< 25 (n = 213)
 
≥ 25 (n = 57) 
23.1 ±  3.7 
21.5 ±  2.1 
28.4 ±  2.9 
22.7 ±  2.9 
21.6 ±  1.8 
27.2 ±  2.4 
0.38 
0.59 
0.08 
Total Body Fat, %  
< 32 (n = 131)
 
≥ 32 (n = 139) 
32.2 ±  8.7 
25.1 ±  4.3 
38.9 ±  6.0 
32.0 ±  7.8 
25.4 ±  4.2 
38.2 ±  4.9 
0.81 
0.66 
0.49 
Physical Activity, MET-hrs/week
╧ 
 39.5 ± 35.0 56.6 ± 47.3 < 0.01 
Energy, kcal/day 1714 ± 621 2511 ± 885 < 0.01 
Total Protein, g/day  
Animal Protein 
Plant Protein 
77 ± 42 
46 ± 38 
31 ± 19 
111 ± 43 
63 ± 36 
48 ± 28 
< 0.01 
< 0.01 
< 0.01 
Total Fat, g/day  
Animal Fat 
Non-animal Fat 
58 ± 25 
26 ± 16 
32 ± 16 
82 ± 35 
36 ± 21 
46 ± 28 
< 0.01 
< 0.01 
< 0.01 
Ϫ
 RDA for women ages 19 – 50 years is 1000 mg/day. This is the average daily level 
of intake sufficient to meet the nutrient requirements of nearly all (97% - 98%) 
healthy individuals. 
ⱶ
 P-values for any difference across categories estimated using student t-test.  
╧ 
50 MET-hrs / week is equivalent to about 25-30 minutes of moderate intensity 
exercise per day, e.g., walking outdoors or on a treadmill. 
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Table 9a. Continued  
 Total Calcium Intake (mg/day) 
 
Covariate 
Low (< 1000) 
(n = 108) 
Adequate (≥ 1000) 
(n = 162) 
P
 ⱶ
 
 n (%)  
Race
┴ 
 
Caucasian 
Other 
 
92 (85.2) 
16 (14.8) 
 
140 (87.0) 
21 (13.0) 
0.68 
 
Education  
Some College 
College Graduate 
 
91 (82.1) 
17 (17.9) 
 
186 (82.7) 
39 (17.3) 
0.64 
Currently Drink Alcohol  
No 
Yes 
 
24 (22.2) 
84 (77.8) 
 
46 (28.4) 
116 (71.6) 
0.26 
Currently Smoke 
┴ 
  
No 
Yes 
 
96 (89.7) 
11 (10.3) 
 
158 (97.5) 
4 (2.5) 
0.01 
Currently Use Oral 
Contraceptive 
No 
Yes  
 
 
65 (60.2) 
43 (39.8) 
 
 
90 (55.6) 
72 (44.4) 
 
0.45 
BMI, kg/m
2
  
 < 25 
 
 ≥ 25  
 
83 (76.9) 
25 (23.1) 
 
130 (80.2) 
32 (19.8) 
0.50 
Waist Circumference, cm 
 < 80  
      ≥ 80  
 
70 (64.8) 
38 (35.2) 
 
110 (67.9) 
52 (32.1) 
0.60 
Total Body Fat, %  
 < 32  
      ≥ 32  
 
52 (48.1) 
56 (51.9) 
 
79 (48.8) 
83 (51.2) 
0.92 
Android: Gynoid Ratio 
 < 1 
      ≥ 1 
 
81 (75.0) 
27 (25.0) 
 
121 (74.7) 
41 (25.3) 
0.95 
Serum 25-OHD, nmol/L
‡,§
 
      < 75  
      ≥ 75  
 
40 (54.0) 
34 (46.0) 
 
47 (51.7) 
44 (48.4) 
0.89 
ⱶ
 P-values for any difference across categories estimated using chi-square test for 
proportions.  
┴ 
N = 269 for smoking status. 
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Table 9b. Variations in Characteristics of Participants by Adequacy of Total Vitamin 
D Intake
 Ϫ
,
 
Defined by Recommended Dietary Allowance (RDA) 
 Total Vitamin D Intake (IU/day)
 §
 
 
Covariate 
Low (< 600) 
(n = 225) 
Adequate (≥ 600) 
(n = 45) 
P 
ⱶ
 
 Mean ± Standard Deviation  
Age, y  21.3 ± 2.7 21.7 ± 3.5 0.41 
Waist Circumference, cm 
< 80 (n = 180)
 
≥ 80 (n = 90) 
77.7 ±  9.0 
72.5 ±  4.4 
87.4 ±  7.1 
75.8 ±  8.8 
71.8 ±  5.5 
88.2 ±  3.9 
0.19 
0.42 
0.70 
BMI, kg/m
2
  
< 25 (n = 213)
 
≥ 25 (n = 57) 
22.9 ±  3.3 
21.6 ±  1.9 
27.7 ±  2.7 
22.6 ±  3.2 
21.5 ±  1.9 
27.9 ±  2.3 
0.54 
0.71 
0.89 
Total Body Fat, %  
< 32 (n = 131)
 
≥ 32 (n = 139) 
32.3 ±  8.1 
25.3 ±  4.4 
38.3 ±  5.2 
30.8 ±  8.6 
25.2 ±  3.8 
39.9 ±  5.9 
0.24 
0.91 
0.24 
Physical Activity, MET-hrs/week
₸ 
 47.7 ± 41.2 59.4 ± 52.8 0.11 
Energy, kcal/day 2094 ± 769 2684 ± 1197 < 0.01 
Total Protein, g/day  
Animal Protein 
Plant Protein 
93 ± 40 
53 ± 34 
40 ± 26 
123 ± 63 
73 ± 50 
50 ± 24 
< 0.01 
< 0.01 
0.01 
Total Fat, g/day  
Animal Fat 
Non-animal Fat 
70 ± 32 
31 ± 18 
39 ± 25 
84 ± 40 
38 ± 26 
45 ± 24 
0.02 
0.02 
0.13 
Ϫ
 RDA for women ages 19 – 50 years is 600 IU/day. This is the average daily level 
of intake sufficient to meet the nutrient requirements of nearly all (97% - 98%) 
healthy individuals. 
ⱶ
 P-values for any difference across categories estimated using student t-test.  
§ 
IU (International Units): 1 IU = 0.025 µg. 
₸ 
50 MET-hrs / week is approximately equivalent to about 25-30 minutes of 
moderate intensity exercise per day, e.g., walking outdoors or on a treadmill. 
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Table 9b.Continued 
 Total Vitamin D Intake (IU/day)
 §
 
 
Covariate 
Low (< 600) 
(n = 225) 
Adequate (≥ 600) 
(n = 45) 
P 
ⱶ
 
 n (%)  
Race
┴ 
 
Caucasian 
Other 
 
194 (86.6) 
30 (13.4) 
 
38 (84.4) 
7 (15.6) 
0.70 
 
Education  
Some College 
College Graduate 
 
186 (82.7) 
39 (17.3) 
 
38 (84.4) 
7 (15.6) 
0.77 
Currently Drink Alcohol  
No 
Yes 
 
60 (26.7) 
165 (73.3) 
 
10 (22.2) 
35 (77.8) 
0.56 
Currently Smoke 
┴ 
  
No 
Yes 
 
213 (95.1) 
11 (4.9) 
 
41 (91.1) 
4 (8.9) 
0.29 
Currently Use Oral 
Contraceptive 
No 
Yes 
 
 
137 (60.9) 
88 (39.1) 
 
 
18 (40.0) 
27 (60.0) 
 
0.01 
BMI, kg/m
2
  
 < 25 
 
 ≥ 25  
 
176 (78.2) 
49 (21.8) 
 
37 (82.2) 
8 (17.8) 
0.55 
Waist Circumference, cm 
 < 80  
      ≥ 80  
 
146 (64.9) 
79 (35.1) 
 
34 (75.6) 
11 (24.4) 
0.17 
Total Body Fat, %  
 < 32  
      ≥ 32  
 
103 (45.8) 
122 (54.2) 
 
28 (62.2) 
17 (37.8) 
0.04 
Android: Gynoid Ratio 
 < 1 
      ≥ 1 
 
169 (75.1) 
56 (24.9) 
 
33 (73.3) 
12 (26.7) 
0.80 
Serum 25-OHD, nmol/L
‡,§
 
      < 75  
      ≥ 75  
 
77 (53.1) 
68 (44.9) 
 
16 (51.2) 
13 (44.8) 
0.84 
ⱶ
 P-values for any difference across categories estimated using chi-square test for 
proportions.  
§ 
IU (International Units): 1 IU = 0.025 µg. 
┴ 
N = 269 for smoking status. 
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Table 10a. Variations in Characteristics of Participants by Total Body Fat (TBF) 
Percentage  
 
Covariate 
Low TBF < 32 % 
(n = 131) 
High TBF ≥ 32 % 
(n = 139) 
P 
ⱶ
 
 Mean ± Standard Deviation  
Age, y  21.5 ± 3.0 21.3 ±  2.7 0.60 
BMI, kg/m
2
  21.0 ±  2.0 24.6 ±  3.2 < 0.01 
Waist Circumference, cm 72.2 ±  5.8 82.3 ±  8.7 < 0.01 
Waist to Height, ratio 0.44 ±  0.03 0.50 ±  0.05 < 0.01 
Total Body Fat, %  25.3 ±  4.2 38.5 ±  6.8 < 0.01 
Arm Fat, % 23.4 ± 5.9 37.3 ± 6.3 < 0.01 
Leg Fat, % 29.5 ± 4.8 41.0 ± 4.8 < 0.01 
Trunk Fat, % 24.1 ± 5.0 39.2 ± 6.9 < 0.01 
Android Fat, % 26.1 ± 6.1 42.5 ± 7.4 < 0.01 
Gynoid Fat, % 35.4 ± 4.6 45.4 ± 4.4 < 0.01 
Android : Gynoid Fat, ratio  0.74 ± 0.16 0.94 ± 0.12 < 0.01 
Physical Activity, MET-hrs/week
╔
  57.4 ± 46.9 42.8 ± 39.1 < 0.01 
Systolic Blood Pressure, mm Hg 105.9 ± 10.0 110.1 ± 11.2 < 0.01 
Diastolic Blood Pressure, mm Hg 68.3 ± 7.9 71.4 ± 7.1 < 0.01 
Fasting Blood Glucose, mg/dL
 ϖ
 80.1 ± 10.1 83.4 ± 9.7 0.01 
Serum 25-OHD, nmol/L
‡,§
 78.0 ± 31.9 80.4 ± 32.8    0.63 
ⱶ
 P-values for test of Null: Equal means, estimated with student t-test. 
╔ 
MET, metabolic equivalent of activity hours per week, n = 261 for physical activity. 
ϖ 
n = 257 for fasting blood glucose.  
‡ 
n = 174 for serum 25-OHD, 
§ 
2.496 nmol/L = 1 ng/mL. 
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Table 10a. Continued  
 
Covariate 
Low TBF < 32 % 
(n = 131) 
High TBF ≥ 32 % 
(n = 139) 
P 
ⱶ
 
 n (%)  
Race
┴
 
Caucasian 
Other 
 
111 (85.4) 
19 (14.6) 
 
121 (87.0) 
18 (13.0) 
0.69 
Education  
Some College 
College Graduate 
 
108 (82.4) 
23 (17.6) 
 
116 (83.5) 
23 (16.5) 
0.83 
Currently Drink Alcohol  
No 
Yes 
 
34 (26.0) 
97 (74.0) 
 
36 (25.9) 
103 (74.1) 
0.99 
Currently Smoke
┴
 
No 
Yes 
 
120 (92.3) 
10 (7.7) 
 
134 (96.4) 
5 (3.6) 
0.14 
Currently Use Oral 
Contraceptive 
No 
Yes 
 
 
79 (60.3) 
52 (39.7) 
 
 
76 (54.7) 
63 (45.3) 
 
0.35 
BMI, kg/m
2
  
 < 25 
 
 ≥ 25  
 
125 (95.4) 
6 (4.6) 
 
88 (63.3) 
51 (36.7) 
< 0.01 
Waist Circumference, cm  
< 80   
     ≥ 80  
 
119 (90.8) 
12 (9.2) 
 
61 (43.9) 
78 (56.1) 
< 0.01 
Android: Gynoid Ratio 
 < 1 
      ≥ 1 
 
126 (96.2) 
5 (3.8) 
 
76 (54.7) 
63 (45.3) 
< 0.01 
Serum 25-OHD, nmol/L
‡,§
 
      < 75  
      ≥ 75  
 
46 (55.4) 
37 (44.6) 
 
47 (51.7) 
44 (48.4) 
0.62 
ⱶ
 P-values for chi-squared tests. 
┴ 
n = 269 for race and smoking status. 
‡ 
n = 174 for serum 25-OHD, 
§ 
2.496 nmol/L = 1 ng/mL. 
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Table 10b. Variations in Dietary Intakes of Participants by TBF Percentage 
 
 
Covariate 
Low TBF  
< 32 % 
(n = 131) 
High TBF  
≥ 32 % 
(n = 139) 
P 
ⱶ
 
 Mean ± Standard Error  
Energy, kcal/day 2152 ± 84 2136 ± 68 0.28 
Total Protein, g/day  102 ± 4 93 ± 4 0.13 
Total Fat, g/day  75 ± 3 70 ± 3 0.30 
Total Calcium Intake, mg/day  
Food calcium 
Supplemental
 
calcium (n = 93 users) 
1281 ± 63 
1157 ± 59 
370 ± 46 
1163 ± 42 
1028 ± 40 
383 ± 40 
0.12 
0.07 
0.82 
Vitamin A, IU/day 17758 ± 1072 14731 ± 744 0.02 
Thiamin, mg/day 2.0 ± 0.1 1.7 ± 0.1 0.01 
Riboflavin, mg/day 2.8 ± 0.1 2.4 ± 0.1 0.01 
Niacin, mg/day 29 ± 1 26 ± 1 0.04 
Pantothenic acid, mg/day 7.3 ± 0.4 6.1 ± 0.2 0.01 
Vitamin B6, mg/day 2.7 ± 0.1 2.4 ± 0.1 0.06 
Folate, µg/day 724 ± 38 601 ± 25 0.01 
Vitamin B12, µg/day 6.9 ± 0.5 5.8 ± 0.3 0.04 
Vitamin C, mg/day 163 ± 11 143 ± 7 0.12 
Total Vitamin D Intake, IU/day
§
  
Food vitamin D 
Supplemental
 
vitamin D (n = 110 users) 
409 ± 29 
257 ± 19 
363 ± 39 
344 ± 22 
205 ± 12 
350 ± 35 
0.07 
0.02 
0.81 
Iron, mg/day 19 ± 1 17 ± 1 0.01 
Zinc, mg/day 15 ± 0.7 13 ± 0.4 0.02 
Linoleic acid, g/day 25 ± 1 24 ± 1 0.37 
Linolenic acid, g/day 14 ± 1 12 ± 1 0.09 
Dairy Intake, total servings/day
₸
 1.9 ± 0.2 1.9 ± 0.1 0.87 
ⱶ
 P-values for test of Null: Equal means, estimated with student t-tests.
 
§ 
IU, International Units: 1 IU = 0.025 µg.  
₸
 n = 169 for dairy intake responders. 1 serving dairy = 8 fluid oz. (1 cup) of milk or 
yogurt; 1.5 oz of natural cheese; 2 oz of processed cheese, 2 cups of cottage cheese. 
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Table 11a. Variations in Characteristics of Participants by Body Mass Index (BMI) 
 
Covariate 
Low BMI < 25 kg/m
2
 
(n = 213) 
High BMI ≥ 25 kg/m2 
(n = 57) 
P 
ⱶ
 
 Mean ± Standard Deviation  
Age, y  21.4 ± 2.8 21.5 ±  2.9    0.85 
BMI, kg/m
2
  21.6 ±  1.9 27.7 ±  2.7 < 0.01 
Waist Circumference, cm 74.3 ±  6.2 89.1 ±  8.0 < 0.01 
Waist to Height, ratio 0.45 ±  0.04 0.54 ±  0.05 < 0.01 
Total Body Fat, %  29.7 ±  6.7 40.9 ±  7.2 < 0.01 
Arm Fat, % 28.4 ± 8.4 38.6 ± 8.0 < 0.01 
Leg Fat, % 33.7 ± 6.4 41.9 ± 7.6 < 0.01 
Trunk Fat, % 28.9 ± 7.7 42.9 ± 8.0 < 0.01 
Android Fat, % 31.4 ± 8.9 46.4 ± 8.1 < 0.01 
Gynoid Fat, % 39.1 ± 5.8 46.1 ± 7.0 < 0.01 
Android : Gynoid Fat, ratio  0.8 ± 0.1 1.0 ± 0.1 < 0.01 
Physical Activity, MET-hrs/week
╔
  48.9 ± 41.5 52.2 ± 50.3    0.61 
Systolic Blood Pressure, mm Hg 107.1 ± 10.7 111.8 ± 10.7 < 0.01 
Diastolic Blood Pressure, mm Hg 69.2 ± 7.6 72.6 ± 7.3 < 0.01 
Fasting Blood Glucose, mg/dL
 ϖ  
80.6 ± 10.3 86.2 ± 7.4 < 0.01 
Serum 25-OHD, nmol/L
‡,§
 77.6 ±  31.1 84.5 ±  35.8    0.23 
ⱶ
 P-values for test of Null: Equal means, estimated with student t-tests. 
╔ 
MET, metabolic equivalent of activity hours per week, n = 261 for physical activity. 
ϖ 
n = 257 for fasting blood glucose.  
‡ 
n = 174 for serum 25-OHD, 
§ 
2.496 nmol/L = 1 ng/mL. 
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Table 11a. Continued  
Covariate Low BMI < 25 
kg/m
2
 
(n = 213) 
High BMI ≥ 25 
kg/m
2
 
(n = 57) 
P 
ⱶ
 
 n (%)  
Race
┴ 
 
Caucasian 
Other 
 
184 (86.8) 
28 (13.2) 
 
48 (84.2) 
9 (15.8) 
0.62 
Education  
Some College 
College Graduate 
 
177 (83.1) 
36 (16.9) 
 
47 (82.5) 
10 (17.5) 
0.91 
Currently Drink Alcohol  
No 
Yes 
 
56 (26.3) 
157 (73.7) 
 
14 (24.6) 
43 (75.4) 
0.79 
Currently Smoke 
┴ 
  
No 
Yes 
 
197 (92.9) 
15 (7.1) 
 
57 (100.0) 
0 (0.0) 
0.04 
Currently Use Oral 
Contraceptive 
No 
Yes 
 
 
120 (56.3) 
93 (43.7) 
 
 
35 (61.4) 
22 (38.6) 
 
0.49 
Waist Circumference, cm 
 < 80  
      ≥ 80  
 
176 (82.6) 
37 (17.4) 
 
4 (7.0) 
53 (93.0) 
< 0.01 
Total Body Fat, %  
 < 32  
      ≥ 32  
 
125 (58.7) 
88 (41.3) 
 
6 (10.5) 
51 (89.5) 
< 0.01 
Android: Gynoid Ratio 
 < 1 
      ≥ 1 
 
183 (85.9) 
30 (14.1) 
 
19 (33.3) 
38 (66.7) 
< 0.01 
Serum 25-OHD, nmol/L
‡,§
 
      < 75  
      ≥ 75  
 
72 (54.6) 
60 (45.4) 
 
21 (50.0) 
21 (50.0) 
0.61 
ⱶ
 P-values estimated with chi-squared tests. 
╔ 
MET, metabolic equivalent of activity hours per week, n = 261 for physical 
activity. 
ϖ 
n = 257 for fasting blood glucose.  
┴ 
n = 269 for race and smoking status. 
‡ 
n = 174 for serum 25-OHD, 
§ 
2.496 nmol/L = 1 ng/mL. 
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Table 11b. Variations in Dietary Intakes of Participants by BMI 
 
 
Dietary Intake 
Low BMI 
< 25 kg/m
2
 
(n = 213) 
High BMI 
≥ 25 kg/m2 
(n = 57) 
P 
ⱶ
 
 Mean ± Standard Error  
Energy, kcal/day 2215 ± 61 2106 ± 113 0.41 
Total Protein, g/day  98 ± 3 97 ± 6 0.89 
Total Fat, g/day  73 ± 2 69 ± 4 0.43 
Total Calcium Intake, mg/day  
Food calcium 
Supplemental
 
calcium (n = 93 users) 
1243 ± 43 
1102 ± 40 
407 ± 35 
1135 ± 75 
1048 ± 75 
261 ± 43 
0.24 
0.54 
0.05
* 
Vitamin A, IU/day 16663 ± 762 14469 ± 1169 0.17 
Thiamin, mg/day 1.9 ± 0.1 1.8 ± 0.1 0.29 
Riboflavin, mg/day 2.6 ± 0.1 2.5 ± 0.2 0.43 
Niacin, mg/day 27.7 ± 1.0 26.6 ± 2.1 0.60 
Pantothenic acid, mg/day 6.8 ± 0.3 6.2 ± 0.4 0.29 
Vitamin B6, mg/day 2.5 ± 0.1 2.5 ± 0.2 0.91 
Folate, µg/day 672 ± 26 619 ± 45 0.34 
Vitamin B12, µg/day 6.3 ± 0.3 6.4 ± 0.6 0.83 
Vitamin C, mg/day 155 ± 7 144 ± 13 0.53 
Total Vitamin D Intake, IU/day
§ 
 
Food vitamin D 
Supplemental
 
vitamin D (n = 110 users) 
383 ± 21 
231 ± 12 
362 ± 31 
350 ± 34 
228 ± 25 
333 ± 45 
0.48 
0.92 
0.66 
Iron, mg/day 18.3 ± 0.6 16.9 ± 1.4 0.32 
Zinc, mg/day 13.7 ± 0.5 13.1± 0.8 0.51 
Linoleic acid, g/day 24.5 ± 0.9 23.3 ± 1.5 0.52 
Linolenic acid, g/day 13.0 ± 0.5 11.6 ± 0.9 0.21 
Dairy Intake, total servings/day
₸
 1.8 ± 0.1 2.2 ± 0.3 0.09 
ⱶ
 P-values for test of Null: Equal means, estimated with student t-tests.
 
*  
Estimated P-value is borderline significant (P = 0.048). 
§ 
IU, International Units: 1 IU = 0.025 µg.  
₸
 n = 169 for dairy intake responders. 1 serving dairy = 8 fluid oz. (1 cup) of milk or 
yogurt; 1.5 oz of natural cheese; 2 oz of processed cheese, 2 cups of cottage cheese. 
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Table 12a. Variations in Characteristics of Participants by Waist Circumference 
(WC) Measurement 
 
 
Covariate 
Low WC < 80 cm 
(n = 180) 
High WC ≥ 80 cm 
(n = 90) 
P 
ⱶ
 
 Mean ± Standard Deviation  
Age, y  21.4 ± 2.8 21.5 ±  3.0 0.75 
BMI, kg/m
2
  21.3 ±  1.9 26.0 ±  3.2 < 0.01 
Waist Circumference, cm 72.4 ±  4.6 87.5 ±  6.8 < 0.01 
Waist to Height, ratio 0.44 ±  0.03 0.52 ±  0.05 < 0.01 
Total Body Fat, %  28.6 ±  6.4 39.0 ±  6.8 < 0.01 
Arm Fat, % 27.3 ± 8.3 37.0 ± 7.7 < 0.01 
Leg Fat, % 32.7 ± 6.2 40.8 ± 6.9 < 0.01 
Trunk Fat, % 27.5 ± 7.2 40.5 ± 8.0 < 0.01 
Android Fat, % 38.3 ± 5.8 45.0 ± 6.2 < 0.01 
Gynoid Fat, % 40.5 ± 7.3 41.1 ± 6.4 < 0.01 
Android : Gynoid Fat, ratio  0.77 ± 0.14 0.98 ± 0.13 < 0.01 
Physical Activity, METs/week
╔
  49.3 ± 41.3 50.4 ± 47.4 0.84 
Systolic Blood Pressure, mm Hg 107.7 ± 11.0 108.9 ± 10.6 0.38 
Diastolic Blood Pressure, mm Hg 69.3 ± 7.8 71.2 ± 7.6 0.06 
Fasting Blood Glucose, mg/dL
 ϖ
 80.4 ± 10.4 84.6 ± 8.4 < 0.01 
Serum 25-OHD, nmol/L
‡,§
 78.3 ± 31.6 80.5 ± 33.3    0.67 
ⱶ
 P-values for test of Null: Equal means, estimated with student t-test. 
╔ 
MET, metabolic equivalent of activity hours per week, n = 261 for physical activity. 
ϖ 
n = 257 for fasting blood glucose.  
‡ 
n = 174 for serum 25-OHD, 
§ 
2.496 nmol/L = 1 ng/mL. 
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Table 12a. Continued 
 
Covariate 
Low WC < 80 cm 
(n = 180) 
High WC ≥ 80 cm 
(n = 90) 
P 
ⱶ
 
 n (%)  
Race
┴
 
Caucasian 
Other 
 
157 (87.7) 
22 (12.3) 
 
75 (83.3) 
15 (16.7) 
0.33 
Education  
Some College 
College Graduate 
 
150 (83.3) 
30 (16.7) 
 
74 (82.2) 
16 (17.8) 
0.82 
Currently Drink Alcohol  
No 
Yes 
 
42 (23.3) 
138 (76.7) 
 
28 (31.1) 
62 (68.9) 
0.17 
Currently Smoke
┴
 
No 
Yes 
 
166 (92.7) 
13 (7.3) 
 
88 (97.8) 
2 (2.2) 
0.09 
Currently Use Oral Contraceptive 
No 
Yes 
 
99 (55.0) 
81 (45.0) 
 
56 (62.2) 
34 (37.8) 
0.26 
BMI, kg/m
2
  
 < 25 
 
 ≥ 25  
 
176 (97.8) 
4 (2.2) 
 
37 (41.1) 
53 (58.9) 
< 0.01 
Total Body Fat, %  
 < 32  
      ≥ 32  
 
119 (66.1) 
61 (33.9) 
 
12 (13.3) 
78 (86.7) 
< 0.01 
Android: Gynoid Ratio 
 < 1 
      ≥ 1 
 
166 (92.2) 
14 (7.8) 
 
36 (40.0) 
54 (60.0) 
< 0.01 
Serum 25-OHD, nmol/L
‡,§
  
      < 75  
      ≥ 75  
 
54 (54.6) 
45 (45.4) 
 
39 (52.0) 
36 (48.0) 
0.74 
ⱶ
 P-values estimated with chi-squared tests. 
┴ 
n = 269 for race and smoking status. 
‡ 
n = 174 for serum 25-OHD, 
§ 
2.496 nmol/L = 1 ng/mL. 
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Table 12b. Variations in Dietary Intakes of Participants by WC Measurement 
 
 
 
Covariate 
Low WC  
< 80 cm 
(n = 180) 
High WC  
≥ 80 cm 
(n = 90) 
P 
ⱶ
 
 Mean ± Standard Error  
Energy, kcal/day 2162 ± 65 2253 ± 96 0.42 
Total Protein, g/day  93 ± 3 106 ± 6 0.03 
Total Fat, g/day  72 ± 2 74 ± 4 0.61 
Total Calcium Intake, mg/day  
Food calcium 
Supplemental
 
calcium (n = 93 users) 
1249 ± 48 
1093 ± 44 
420 ± 38 
1162 ± 57 
1085 ± 59 
266 ± 35 
0.27 
0.92 
0.02 
Vitamin A, IU/day 16677 ± 851 15245 ± 956 0.30 
Thiamin, mg/day 1.9 ± 0.1 1.9 ± 0.1 0.99 
Riboflavin, mg/day 2.6 ± 0.1 2.7 ± 0.2 0.64 
Niacin, mg/day 27 ± 1 29 ± 2 0.31 
Pantothenic acid, mg/day 6.5 ± 0.2 7.0 ± 0.5 0.31 
Vitamin B6, mg/day 2.5 ± 0.1 2.6 ± 0.2 0.32 
Folate, µg/day 659 ± 30 664 ± 41 0.91 
Vitamin B12, µg/day 6.2 ± 0.3 6.4 ± 0.5 0.72 
Vitamin C, mg/day 154 ± 8 150 ± 10 0.76 
Total Vitamin D Intake, IU/day
§
  
Food vitamin D 
Supplemental
 
vitamin D (n = 110 users) 
394 ± 24 
229 ± 13 
372 ± 33 
338 ± 25 
233 ± 20 
315 ± 39 
0.14 
0.86 
0.33 
Iron, mg/day 18 ± 1 18 ± 1 0.57 
Zinc, mg/day 13 ± 1 14 ± 1 0.38 
Linoleic acid, g/day 24 ± 1 24 ± 1 0.92 
Linolenic acid, g/day 13 ± 1 12 ± 1 0.59 
Dairy Intake, total servings/day
₸
 1.7 ± 0.1 2.1 ± 0.2 0.08 
ⱶ
 P-values for test of Null: Equal means, estimated with student t-tests.
 
§ 
IU, International Units: 1 IU = 0.025 µg.  
₸
 n = 169 for dairy intake responders. 1 serving dairy = 8 fluid oz. (1 cup) of milk or 
yogurt; 1.5 oz of natural cheese; 2 oz of processed cheese, 2 cups of cottage cheese. 
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Table 13. Correlations between Participant Characteristics and Adiposity Measures  
 
Correlation Coefficients
 
(r) 
₸
 
Covariate 
Total Body Fat (%)      BMI (kg/m
2
)      Waist Circumference (cm) 
     r                P
                      
r              P
                         
r                    P
 
 
Physical activity, METs/week  - 0.14 0.02   0.01 0.92   0.01 0.86 
Total body fat, % ---- ----   0.76 < 0.01   0.72 < 0.01 
Waist circumference, cm   0.72 < 0.01   0.84 < 0.01 ---- ---- 
BMI, kg/m
2
   0.76 < 0.01 ---- ----   0.84 < 0.01 
Energy, kcal - 0.05 0.43 - 0.06 0.37   0.02 0.78 
Total Calcium, mg/day  
  Food 
  Supplement
 
- 0.05 
- 0.04 
- 0.02 
0.41 
0.47 
0.72 
- 0.08 
- 0.04 
- 0.10 
0.18 
0.47 
0.10 
- 0.06 
- 0.01 
- 0.12 
0.31 
0.82 
0.04 
Total Vitamin D, IU/day  
  Food 
  Supplement
 
- 0.09 
- 0.09 
- 0.05 
0.13 
0.14 
0.46 
- 0.06 
- 0.01 
- 0.07 
0.34 
0.91 
0.29 
- 0.08 
- 0.004
 
- 0.10 
0.18 
0.95 
0.11 
Dairy Products, total servings/day    0.04 0.64   0.09 0.24   0.12 0.11 
₸
 r (Correlation Coefficient) and P-value for significance estimated using Pearson’s Product.  
Additional Pearson Product Correlation Estimates: 
Total calcium and total vitamin D (r = 0.51, P < 0.01) 
Food calcium and food vitamin D (r = 0.75, P < 0.001) 
Calcium supplement and vitamin D supplement (r = 0.46, P < 0.01). 
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Table 14. Associations
 
(ß ± SE)
 ϖ
 of Adiposity (Total Body Fat Percentage,  
Body Mass Index and Waist Circumference) and Other Parameters
ϖ
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Total Body Fat %  
 
Independent Predictor 
Unadjusted 
ß ± SE 
 
P-value 
Age,  years
 
-0.23 ± 0.18 0.19 
College graduate
 
- 2.1 ± 1.32 0.11 
Currently smoke 
 
-3.01 ± 2.17 0.17 
Currently drink alcohol
 
1.39 ± 1.13 0.22 
Currently use oral contraceptives
 
0.03 ± 1.01 0.98 
Physical activity level, MET-hrs/week
 
-0.03 ± 0.01 0.02 
 Body Mass Index,  kg/m
2
 
Age,  years
 
0.04 ± 0.07 0.57 
College graduate
 
- 0.34 ± 0.53 0.52 
Currently smoke 
 
-1.16 ± 0.87 0.18 
Currently drink alcohol
 
0.60 ± 0.45 0.19 
Currently use oral contraceptives
 
-0.26 ± 0.40 0.52 
Physical activity level, MET-hrs/week
 
0.001 ± 0.01 0.92 
 Waist Circumference, cm 
Age,  years
 
0.04 ± 0.07 0.57 
College graduate
 
- 0.34 ± 0.53 0.52 
Currently smoke 
 
-1.16 ± 0.87 0.18 
Currently drink alcohol
 
0.60 ± 0.45 0.19 
Currently use oral contraceptives
 
-0.26 ± 0.40 0.52 
Physical activity level, MET-hrs/week
 
0.001 ± 0.01 0.92 
ϖ 
Regression coefficients (ß) ± standard errors (SE).  
All analyses were estimated using simple linear regressions.
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Table 15. Crude and Adjusted Indepenent Associtaions with Adiposity (ß ± SE)
 ϖ
 in  
Young Women  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Dietary Intake 
Total Body Fat (%) 
β Std. Err P 
 Energy Adjusted
§
 
Total Calcium, mg/day
 
-0.0004 0.001 0.68 
Food Calcium, mg/day
 
-0.0003 0.001 0.83 
Supplemental
 
Calcium, mg/day
 
-0.001 0.002 0.66 
*
Supplemental
 
Calcium, mg/day
 
-0.003 0.003 0.44 
Total Vitamin D, IU/day
  
-0.002 0.002 0.18 
Food Vitamin D, IU/day
 
-0.004 0.003 0.21 
Supplemental
 
Vitamin D, IU/day
 
-0.002 0.002 0.44 
*
Supplemental
 
Vitamin D, IU/day
 
-0.002 0.003 0.45 
 Multivariable Adjusted 
Ж
 
Total Calcium, mg/day
 
0.001 0.001 0.66 
Food Calcium, mg/day
 
0.002 0.002 0.27 
Supplemental
 
Calcium, mg/day
 
-0.002 0.002 0.76 
*
Supplemental
 
Calcium, mg/day
 
-0.004 0.003 0.20 
Total Vitamin D, IU/day
  
-0.003 0.002 0.22 
Food Vitamin D, IU/day
 
-0.006 0.004 0.14 
Supplemental
 
Vitamin D, IU/day
 
-0.001 0.002 0.64 
*
Supplemental Vitamin D, IU/day
 
0.003 0.004 0.44 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using 
simple or multiple linear regressions.
   
§
 Energy adjusted by including total energy intake in the regression model. 
Ж 
Multivariable adjusted for total energy intake, physical activity level, smoking status 
and calcium or vitamin D intake as appropriate. 
* 
Among supplement users only. 
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Table 15. Continued 
 
 
  
 
Dietary Intake 
Body Mass Index (kg/m
2
) 
β Std. Err       P  
 Energy Adjusted
§
 
Total Calcium, mg/day
 
-0.0004 0.0004 0.32 
Food Calcium, mg/day
 
-0.0001 0.001 0.93 
Supplemental
 
Calcium, mg/day
 
-0.001 0.001 0.08 
*
Supplemental
 
Calcium, mg/day
 
-0.002 0.001 0.17 
Total Vitamin D, IU/day
  
-0.001 0.001 0.46 
Food Vitamin D, IU/day
 
 0.0004 0.001 0.72 
Supplemental Vitamin D, IU/day
 
-0.001 0.001 0.27 
*
Supplemental Vitamin D, IU/day
 
-0.001 0.001 0.60 
 Multivariable Adjusted 
Ж
 
Total Calcium, mg/day
 
-0.0004 0.001 0.39 
Food Calcium, mg/day
 
-0.0003 0.001 0.72 
Supplemental
 
Calcium, mg/day
 
-0.002 0.001 0.11 
*
Supplemental
 
Calcium, mg/day
 
-0.002 0.001 0.12 
Total Vitamin D, IU/day
  
 -0.0001 0.001 0.90 
Food Vitamin D, IU/day
 
 0.001 0.002 0.64 
Supplemental Vitamin D, IU/day
 
 -0.0001 0.001 0.94 
*
Supplemental Vitamin D, IU/day
 
 0.002 0.002 0.35 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using 
simple or multiple linear regressions.
   
§
 Energy adjusted by including total energy intake in the regression model. 
Ж 
Multivariable adjusted for total energy intake, physical activity level, smoking status 
and calcium or vitamin D intake as appropriate. 
* 
Among supplement users only. 
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Table 15. Continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Dietary Intake 
Waist Circumference (cm) 
β Std. Err P 
 Energy Adjusted
§
 
Total Calcium, mg/day
 
-0.002 .001 0.11 
Food Calcium, mg/day
 
-0.001 .001 0.53 
Supplemental
 
Calcium, mg/day
 
-0.004 .002  0.05
* 
Supplemental
¥ 
Calcium, mg/day
 
-0.006 .003 0.05 
Total Vitamin D, IU/day
  
-0.003 .002 0.14 
Food Vitamin D, IU/day
 
-0.001 .003 0.82 
Supplemental Vitamin D, IU/day
 
-0.003 .002 0.11 
Supplemental
¥
 Vitamin D, IU/day
 
-0.003 .003 0.31 
 Multivariable Adjusted 
Ж
 
Total Calcium, mg/day
 
-0.002 .001 0.24 
Food Calcium, mg/day
 
-0.001 .002 0.61 
Supplemental
 
Calcium, mg/day
 
-0.005 .003 0.07 
Supplemental
¥ 
Calcium, mg/day
 
-0.008 .004 0.04 
Total Vitamin D, IU/day
  
-0.001 .002 0.66 
Food Vitamin D, IU/day
 
0.001 .010 0.80 
Supplemental Vitamin D, IU/day
 
-0.001 .003 0.79 
Supplemental
¥
 Vitamin D, IU/day
 
0.003 .004 0.75 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using 
simple or multiple linear regressions. 
* 
Esitmated
 
P-value is borderline significant (P = 0.045). 
§
 Energy adjusted by including total energy intake in regression model. 
Ж 
Multivariable adjusted for total energy intake, physical activity level, smoking status 
and calcium or vitamin D intake as appropriate. 
¥ 
Among supplement users only. 
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Table 16. Prevalence Odds Ratio for the Association
 
of Calcium and Vitamin D Adequacy  
with Events of Adiposity  
   
 
 
  
Odds Ratio 
(95% Confidence Interval) 
 
Adequacy of  
Dietary Intake 
 
Control / Cases 
Energy 
Adjusted 
§
 
Multivariable 
Adjusted 
¤
 
  Total Body Fat (≥ 32%) 
Total Calcium, mg/day    
< 1000  52 / 56 1.13 (0.65 - 1.94) 1.23 (0.69 - 2.20) 
≥ 1000  79/ 83 1.0 1.0 
Total Vitamin D, IU/day    
< 600 103 / 122 0.54 (0.27 - 1.06) 0.55 (0.27 - 1.10) 
≥ 600 28/ 17 1.0 1.0 
  Body Mass Index (≥  25 kg/m2) 
Total Calcium, mg/day    
< 1000  83 / 25 0.90 (0.46 - 1.74) 0.80 (0.41 - 1.59) 
≥ 1000  130 / 32 1.0 1.0 
Total Vitamin D, IU/day    
< 600 176 / 49 0.83 (0.36 - 1.95) 0.90 (0.37 - 2.16) 
≥ 600 37 / 8 1.0 1.0 
        Waist circumference (≥  80 cm) 
Total Calcium, mg/day    
< 1000  70 / 38 0.75 (0.42 - 1.33) 0.75 (0.41 - 1.36) 
≥ 1000  110 / 52 1.0 1.0 
Total Vitamin D, IU/day    
< 600 146 / 79 0.53 (0.25 - 1.14) 0.57 (0.26 - 1.24) 
≥ 600 34 / 11 1.0 1.0 
 
All models were constructed using logistic regression. Outcome variable coding was 
as follows: percentage total body fat, (Control = 0 is < 32%, Case = 1 is ≥ 32%); 
body mass index, (Control = 0 is < 25 kg/m
2, Case = 1 is ≥ 25 kg/m2); waist 
circumference, (Control = 0 is < 80 cm, Case = 1 is ≥ 80 cm). 
§
 Energy adjusted by including total energy intake in the regression model. 
¤
 Multivariable adjusted for total energy intake, physical activity level, smoking 
status and calcium or vitamin D intake as appropriate. 
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Table 17. Association
 
of Calcium and Vitamin D Intakes with Event of High Adiposity  
 
 
               Total Body Fat (≥ 32%) 
  Odds Ratio  (95% Confidence Interval) 
Exposure Controls / Cases Energy Adjusted 
§
             Multivariable 
Adjusted 
¤
   
Total Calcium, (tertile medians in mg/day) 
T1 (692) 46 / 44 1.02 (0.52 - 2.00)     0.80 (0.37 - 1.74) 
T2 (1143) 35 / 55 1.82 (0.99 - 3.37)     1.56 (0.80 - 3.02) 
T3 (1658) 50 / 40 1.0                      1.0 
P trend  
 
 0.86                    0.64 
Food Calcium, (tertile medians in mg/day) 
T1 (597) 45 / 45 1.08 (0.52 - 2.27)     0.72 (0.30 - 1.71) 
T2 (980) 36 / 54 1.72 (0.90 - 3.30)     1.28 (0.61 - 2.67) 
T3 (1498) 50 / 40 1.0                      1.0 
P trend  0.72                    0.48 
Supplemental Calcium, (tertile medians in mg/day) 
T1 (93) 46 / 44 1.02 (0.52 - 2.00)     0.96 (0.46 - 1.99) 
T2 (450) 35 / 55 1.82 (0.99 - 3.37)     1.74 (0.92 - 3.31) 
T3 (623) 50 / 40 1.0                      1.0 
*
P trend  0.50                  0.81 
Total Vitamin D, (tertile medians in IU/day) 
T1 (109) 40 / 50 1.29 (0.71 - 2.35)     1.16 (0.57 - 2.38) 
T2 (299) 44 / 46 1.10 (0.61 - 1.99)     1.05 (0.55 - 2.00) 
T3 (600) 47/ 43 1.0                      1.0 
P trend  
 
 0.42                  0.70 
Food Vitamin D, (tertile medians in IU/day) 
T1 (71) 39 / 51 1.62 (0.87 - 3.04)     1.50 (0.71 - 3.17) 
T2 (188) 41 / 49 1.51 (0.83 - 2.77)     1.34 (0.68 - 2.71) 
T3 (369) 51 / 39 1.0                      1.0 
P trend  0.11                    0.28 
Supplemental Vitamin D, (tertile medians in IU/day) 
T1 (85) 40 / 50 1.29 (0.71 - 2.35)     1.40 (0.70 - 2.79) 
T2 (400) 44 / 46 1.10 (0.61 - 1.99)     1.18 (0.61 - 2.28) 
T3 (800) 47 / 43 1.0                      1.0 
*
P trend  0.86                   0.45 
All models were constructed using logistic regression. Outcome variable coding (Percentage 
total body fat, Control = 0 is < 32%, Case = 1 is ≥ 32%). 
§
 Energy adjusted by including total energy intake in the regression model. 
¤
 Multivariable adjusted for total energy intake, physical activity level, smoking status and 
calcium or vitamin D intake as appropriate. 
* 
Among supplement users only. 
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Table 17. Continued 
 
 
 
                        Body Mass Index (≥ 25 kg/m2) 
  Odds Ratio  (95% Confidence Interval) 
Exposure Controls / Cases Energy Adjusted 
§ 
           Multivariable Adjusted 
¤
   
Total Calcium, (tertile medians in mg/day) 
T1 (692) 71 / 19 1.31 (0.55 - 3.12)     1.48 (0.56 - 3.87) 
T2 (1143) 66 / 24 1.88 (0.88 - 4.03)     1.84 (0.83 - 4.10) 
T3 (1658) 76 / 14 1.0                      1.0 
P trend  
 
 0.52                   0.41 
Food Calcium, (tertile medians in mg/day) 
T1 (597) 71 / 19 1.19 (0.47 - 3.05)     1.53 (0.53 - 4.37) 
T2 (980) 67 / 23 1.60 (0.72 - 3.57)     1.86 (0.77 - 4.54) 
T3 (1498) 75 / 15 1.0                      1.0 
P trend  0.67                   0.41 
Supplemental Calcium, (tertile medians in mg/day) 
T1 (93) 71 / 19 1.31 (0.55 - 3.12)     1.38 (0.56 - 3.42) 
T2 (450) 66 / 24 1.88 (0.88 - 4.03)     1.80 (0.84 - 3.89) 
T3 (623) 76 / 14 1.0                      1.0 
*
P trend  0.046                    0.02 
Total Vitamin D, (tertile medians in IU/day) 
T1 (109) 68 / 22 1.06 (0.52 - 2.15)     0.81 (0.35 - 1.88) 
T2 (299) 75 / 15 0.67 (0.32 - 1.42)     0.59 (0.27 - 1.30) 
T3 (600) 70 / 20 1.0                      1.0 
P trend  
 
 0.99                    0.52 
Food Vitamin D, (tertile medians in IU/day) 
T1 (71) 67 / 23 1.08 (0.52 - 2.26)     1.01 (0.43 - 2.38) 
T2 (188) 76 / 14 0.60 (0.28 - 1.31)     0.53 (0.23 - 1.25) 
T3 (369) 70 / 20 1.0                      1.0 
P trend  0.95                   0.99 
Supplemental Vitamin D, (tertile medians in IU/day) 
T1 (85) 68 / 22 1.06 (0.52 - 2.15)     0.70 (0.31 - 1.57) 
T2 (400) 75 / 15 0.67 (0.32 - 1.42)     0.49 (0.22 - 1.11) 
T3 (800) 70 / 20 1.0                      1.0 
*
P trend  0.82                    0.27 
All models were constructed using logistic regression. Outcome variable coding (body mass 
index, Control = 0 is < 25 kg/m
2, Case = 1 is ≥ 25 kg/m2). 
§
 Energy adjusted by including total energy intake in the regression model. 
¤
 Multivariable adjusted for total energy intake, physical activity level, smoking status and 
calcium or vitamin D intake as appropriate. 
* 
Among supplement users only. 
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Table 17. Continued 
 
 
 
 
                         Waist Circumference (≥ 80 cm) 
  Odds Ratio (95% Confidence Interval) 
Exposure Controls / Cases Energy Adjusted  
§ 
          Multivariable 
Adjusted 
¤
   
Total Calcium, (tertile medians in mg/day) 
T1 (692) 44 / 31 1.58 (0.75 - 3.34)     1.36 (0.59 - 3.10) 
T2 (1143) 40 / 32 2.27 (1.17 - 4.39)     1.92 (0.96 - 3.84) 
T3 (1658) 51 /22 1.0                      1.0 
P trend  
 
 0.20                  0.44 
Food Calcium, (tertile medians in mg/day) 
T1 (597) 47 / 26 1.22 (0.55 - 2.70)     1.26 (0.52 - 3.05) 
T2 (980) 38 / 36 1.64 (0.83 - 3.25)     1.61 (0.76 - 3.40) 
T3 (1498) 50 / 23 1.0                      1.0 
P trend  0.55                   0.58 
Supplemental Calcium, (tertile medians in mg/day) 
T1 (93) 50 / 26 1.58 (0.75 - 3.34)     1.39 (0.63 - 3.05) 
T2 (450) 38 / 33 2.27 (1.17 - 4.39)     2.04 (1.04 - 3.99) 
T3 (623) 47 / 26 1.0                      1.0 
*
P trend  0.09                   0.01 
Total Vitamin D, (tertile medians in IU/day) 
T1 (109) 45 / 32 1.31 (0.69 - 2.47)     0.84 (0.39 - 1.77) 
T2 (299) 46 / 26 1.16 (0.62 - 2.19)     0.93 (0.47 - 1.83) 
T3 (600) 44 / 27 1.0                      1.0 
P trend  
 
 0.41                    0.65 
Food Vitamin D, (tertile medians in IU/day) 
T1 (71) 47 / 29 1.16 (0.66 - 2.24)     0.92 (0.43 - 1.96) 
T2 (188) 44 / 31 0.87 (0.67 - 1.66)     0.68 (0.33 - 1.39) 
T3 (369) 44 / 25 1.0                      1.0 
P trend  0.72                    0.80 
Supplemental Vitamin D, (tertile medians in IU/day) 
T1 (85) 47 / 29 1.31 (0.69 - 2.47)     0.82 (0.40 - 1.68) 
T2 (400) 39 / 34 1.16 (0.62 - 2.19)     0.83 (0.42 - 1.66) 
T3 (800) 49 / 22 1.0                      1.0 
*
P trend  0.55                  0.47 
All models were constructed using logistic regression. Outcome variable coding (waist 
circumference, Control = 0 is < 80 cm, Case = 1 is ≥ 80 cm). 
§
 Energy adjusted by including total energy intake in the regression model. 
¤
 Multivariable adjusted for total energy intake, physical activity level, smoking status and 
calcium or vitamin D intake as appropriate. 
* 
Among supplement users only. 
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Table 18. Association
 of Women’s Combined Total Calcium and Vitamin D Intakes  
with Events of High Adiposity 
   
  
Odds Ratio 
(95% Confidence Interval) 
 
Combined Total Intakes 
 
Controls / Cases 
Energy 
Adjusted 
§
 
Multivariable 
Adjusted 
¤
 
  Total Body Fat (≥ 32%) 
Low Calcium
₸
 &  Low 
Vitamin D
┬
 
49 / 52 1.80 (0.76 - 4.21) 1.69 (0.70 - 4.09) 
Low Calcium
₸
  &   High 
Vitamin D
┴
 
3 / 4 2.22 (0.41 - 12.03) 2.13 (0.37 - 12.16) 
High Calcium
╧
 &  Low 
Vitamin D
┬
 
54 / 70 2.37 (1.09 - 5.12) 2.27 (1.02 - 5.04) 
High Calcium
╧
 & High 
Vitamin D
┴
 
25 / 13 1.0 1.0 
  Body Mass Index (≥ 25 kg/m2) 
Low Calcium
₸
 &  Low 
Vitamin D
┬
 
77 / 24 1.21 (0.43 - 3.40) 1.33 (0.46 - 3.81) 
Low Calcium
₸
  &  High 
Vitamin D
┴
 
6 / 1 0.64 (0.06 - 6.49) 0.89 (0.08 - 9.84) 
High Calcium
╧
 &  Low 
Vitamin D
┬
 99 / 25 
1.06 (0.41 - 2.73) 1.05 (0.40 - 2.73) 
High Calcium
╧
 & High 
Vitamin D
┴
 
31 / 7 1.0 1.0 
        Waist circumference (≥ 80 cm) 
Low Calcium
₸
 &  Low 
Vitamin D
┬
 
65 / 34 2.42 (0.93 - 6.31) 2.51 (0.95 - 6.66) 
Low Calcium
₸
  &   High 
Vitamin D
┴
 
5 / 2 1.80 (0.28 - 11.62) 2.17 (0.32 - 14.88) 
High Calcium
╧
 &  Low 
Vitamin D
┬
 81 / 43 
1.96 (0.83 - 4.65) 1.94 (0.81 - 4.67) 
High Calcium
╧
 & High 
Vitamin D
┴
 
29 / 9 1.0 1.0 
All models were constructed using logistic regression. Outcome variable coding was as 
follows: percentage total body fat, (Control = 0 is < 32%, Case = 1 is ≥ 32%); body mass 
index, (Control = 0 is < 25 kg/m
2, Case = 1 is ≥ 25 kg/m2); waist circumference, (Control = 0 is 
< 80 cm, Case = 1 is ≥ 80 cm). 
§
 Energy adjusted by including total energy intake in the regression model. 
¤
 Multivariable adjusted for total energy intake, physical activity level and smoking status. 
╧ High Calcium = Total Calcium intake ≥ 1000 mg/day. 
₸ 
Low Calcium = Total Calcium intake < 1000 mg/day.  
┴ 
High Vitamin D = Total Vitamin D intake ≥ 600 IU/day.  
┬ 
Low Vitamin D = Total Vitamin D intake < 600 IU/day. 
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CHAPTER 4 
ASSOCIATIONS BETWEEN SERUM 25-HYDROXYVITAMIN D 
CONCENTRATION AND ADIPOSITY MEASURES IN YOUNG WOMEN  
(18 – 30 YEARS) 
A. A. Addo-Lartey 
§
, E. R. Bertone-Johnson
 ‡
, C. Bigelow 
‡
, R. J. Wood 
§
, S. E. Zagarins
‡
, 
S. H. Gehlbach
 ‡
, A. G. Ronnenberg 
§ 
§
 Department of Nutrition, School of Public Health and Health Sciences, University of 
Massachusetts Amherst, MA, 01003, USA 
‡ 
Division of Epidemiology and Biostatistics, Department of Public Health, School of 
Public Health and Health Sciences, University of Massachusetts Amherst, MA, 01003, 
USA  
Abstract: Some cross-sectional studies have suggested that serum 25-hydroxyvitamin D 
levels [25-OHD] are consistently lower in overweight/obese women (body mass index, 
BMI, ≥ 25 kg/m2) compared to women with low BMI (< 25 kg/m2). Our objective was to 
determine the extent of association between serum 25-OHD concentrations and adiposity 
measures in apparently healthy young women. This was a cross-sectional analysis among 
174 pre-menopausal aged women (18-31 years) enrolled the UMass Amherst Vitamin D 
Status Study (2006 - 2011). Serum 25-hydroxyvitamin D levels [25-OHD] were assessed 
using radioimmunoassay. Total and regional body fat percentages were measured by dual 
energy x-ray absorptiometry. Our results showed that vitamin D insufficiency (25-OHD < 
75 nmol/L) was common (53.4%). Overal, total, food, and supplemental vitamin D intakes 
were not associated with serum 25-OHD concentrations (P > 0.05). However, among 
supplement users only (44.3% of women), intake of vitamin D supplements was positively 
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associated with 25-OHD levels (ß = 0.03 ± 0.01, P = 0.05). We found no significant 
correlations of 25-OHD levels with adiposity measures (P > 0.05). After adjusting for 
season, physical activity level and smoking status, adiposity was not associated with risk of 
low 25-OHD (< 75 nmol/L). Prospective studies are needed to determine if adiposity plays a 
causal role in modifying 25-OHD levels in young women. 
Keywords: Vitamin D, Serum 25-hydroxyvitamin D, Adiposity, Body fat percentage, 
Young women 
 
4.1 Introduction 
Vitamin D is naturally synthesized in the skin, but can also be found in some foods, 
especially wild salmon, mackerel, beef or veal liver, and fish oils [1-3]. Vitamin D obtained 
from sun exposure, food, and supplements is biologically inert and must undergo undergo 
two hydroxylations for activation. The first hydroxylation occurs in the liver, where the 
enzyme 25-hydoxylase (CYP27A) converts the vit D to 25-OHD (calcidiol). The second 
hydroxylation is carried out by the enzyme 1-α-hydroxylase (CYP27B) in the kidney and 
forms the biologically active 1, 25D (calcitriol).  
Sub-optimal concentrations of serum/plasma 25-OHD (< 75 nmol/L) has been 
associated with increased risk of metabolic syndrome [4-5], and chronic diseases such as 
type-II-diabetes [6-7], hypertension [8], coronary heart disease [9-12], and cancer [13]. 
Reports from NHANES (2001 – 2006) show that about one-fourth of the US population 
(aged ≥ 1 year) is at risk of vitamin D inadequacy (25-OHD of 30 – 49 nmol/L), while 8% 
of the population are at risk of vitamin D deficiency [25-OHD < 30 nmol/L] [14]. Among 
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young adult women (19 - 30 years), the percentage at risk for vitamin D deficiency (25-
OHD < 30 nmol/L) is estimated to be about 11% [14].  
Accumulating epidemiologic evidence is conflicting on the relationship between 
serum 25-OHD levels and adiposity. Some cross-sectional studies in adult men and women 
indicate that 25-OHD concentrations are lower in obese compared with non-obese subjects 
[15-19], and negatively associated with BMI [15-22] and body fat percentage [15-17, 23-25] 
measured by dual energy x-ray absorptiometry (DXA). Other studies in similar populations 
have however failed to confirm these observations [26, 27]. The low levels of 25-OHD 
observed in obesity have been attributed to multiple factors including, i) decreased exposure 
to sunlight because of limited mobility [28], ii) negative feedback from elevated 1,25-
dihydroxyvitamin D (1,25-(OH)2D) and parathyroid hormone levels on hepatic synthesis of 
25-OHD [28, 29], and iii) decreased bioavailability of vitamin D3 from cutaneous and 
dietary sources due to its deposition in adipose tissue [30, 31]. It is unclear whether the use 
of oral contraceptives and lifestyle choices such as cigarette smoking and alcohol use can 
influence the association between 25-OHD levels and adiposity in reproductive aged 
women. The aim of this cross-sectional study was to evaluate the association between serum 
25-OHD levels and regional adiposity measures and the influence of oral contraceptive use 
or lifestyle factors on this association in young women enrolled in the UMass Amherst 
Vitamin D Status Study.  
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4.2 Materials and Methods   
4.2.1 Study Design and Population 
Between March 2006 and September 20011, 288 healthy women aged 18 to 30 years from 
the Amherst, Massachusetts, area were enrolled in the University of Massachusetts Amherst 
Vitamin D Status Study. Recruitment criteria have been described in detail previously 
(section 3.2.1). Assays for serum 25-hydroxyvitamin D (25-OHD) concentrations were 
available for 174 women providing blood samples. This study was approved by the 
Institutional Review Board at the University of Massachusetts, Amherst. Written informed 
consent was obtained from all participants. 
 
4.2.2 Assessment of Serum 25-OHD Status  
All study measurements were completed in a single clinic visit scheduled for the mid-luteal 
phase of participant's menstrual cycle. Women provided a fasting venous blood sample 
which was immediately processed and stored at −80 °C, usually within two hours of draw. 
Assays for serum 25-hydroxyvitamin D concentrations (25-OHD) were available for 175 
women providing blood samples. Serum 25-OHD levels were determined using a 
commercially available radioimmunoassay kit (25-hydroxyvitamin D 
125
I RIA Kit; DiaSorin 
Inc., Stillwater, MN, USA), [32]. Gamma irradiation of I
125
 (in counts per minute; CPM) 
was quantified using a Beckman Gamma 4000 counter (Beckman Coulter, California, 
USA), and CPM were converted into concentration units using GraphPad Prism version 4.0 
for Windows (GraphPad Software, San Diego, CA). In light of the on-going debate 
regarding use of a higher 25-OHD cut-off, vitamin D status was classified as follows; serum 
  
120 
25-OHD < 50 nmol/L [< 20 ng/mL] = deficient, 25-OHD of 50 - 75 nmol/L [20 - 50 ng/mL] 
= insufficient, and 25-OHD ≥ 75 nmol/L [50 ng/mL] = sufficient [33, 34].  
 
4.2.3 Dietary Assessment 
Dietary intake of food and supplements in the previous two months was assessed using a 
modified version of the Harvard Food Frequency Questionnaire (FFQ). This FFQ has been 
previously validated for use in U.S. women [35, 36]. Vitamin D-rich food items on the 
modified questionnaire included regular and fortified dairy foods and fortified orange juice 
and breakfast cereals, dark meat fish, shellfish, leafy green vegetables and multivitamins or 
other supplements containing vitamin D. Alcohol intake was measured using FFQs which 
were analyzed at Harvard University. Nutrient intakes were calculated by multiplying the 
frequency of intake of a specified portion size of each food by its nutrient content and then 
summing across all food items. Adequacy of dietary vitamin D intake was determined by 
comparing reported intakes with the Estimated Average Requirement (EAR) or 
Recommended Dietary Allowance (RDA) for women in this age range [37].  
 
4.2.4 Assessment of Covariates 
Information on lifestyle and demographic factors was collected by self-reported 
questionnaire. Women’s weight, height, and waist circumference were directly measured 
using a calibrated scale, wall mounted stadiometer, and a flexible tape measure, 
respectively.  
Body mass index (BMI) was calculated as weight in kilograms divided by the square 
of height in meters. Body composition was measured by dual energy x-ray absorptiometry 
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(DXA) using the total body scan mode on a narrow angle fan GE Lunar Prodigy scanner 
(GE Lunar Corp., Madison, WI). DXA scans were performed with the participant lying in a 
supine position with arms and legs placed flat by the side. Measurements were completed by 
the same technician, and the machine was calibrated daily using the standard calibration 
method provided by the manufacturer.  The coefficient of variation for repeated scans of the 
manufacturer’s phantom was less than 1%. DXA scans also provided direct estimates of 
regional adiposity measurements (fat mass and percentage fat mass), including the arms, 
legs, and trunk, android and gynoid regions (Fig 12). Android fat is the fat stored in the 
midsection of the body, predominantly in the abdomen, but also the in the chest and upper 
arms. Gynoid fat is stored primarily around the hips, thighs, and buttocks. Individuals with 
disproportionate amounts of android or gynoid fat are usually referred to as apple-or pear-
shape, respectively (Fig 13). Total body fat percentage (TBF %) was obtained directly from 
DXA scans (estimated using the ratio of whole-body fat mass to whole-body total mass). 
 
Figure 12. A Dual-Energy X-ray Absorptiometry (DXA) Scan Report Showing Different 
Body Composition Measures 
 
Source: http://www.rugkliniek.nu/het-onderzoek/wervelkolom-idxa-scan/ 
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Figure 13. A DXA Scan showing Regional Adiposity Measures 
                          
Dorgan et al. Breast Cancer Research 2012; 14:.R107. 
 
To measure physical activity levels, participants were asked to report the time they spent 
each week engaged in specific activities including walking, jogging, running, bicycling, 
aerobics/dancing, tennis/racket sports, swimming, yoga/pilates and weight training. These 
questions were based on those used in the Nurses’ Health Study II and have been previously 
validated in that population [38]. We then calculated total metabolic equivalents (MET), 
which were recorded in MET-hours of activity per week. The MET-hours per week score 
measures the intensity of a physical activity, with 1 MET being defined as the amount of 
energy expended when a person is at rest [39]. We also collected information on race, use of 
oral contraceptives and smoking status. 
 
4.2.5 Statistical Analysis 
All analyses were completed using STATA version 12.0 (Stata Corporation., College 
Station, TX.). We compared demographic, dietary and life style characteristics of women 
using student t-tests for normally distributed continuous data, and chi-squared tests for 
Apple Shape vs. Pear shape 
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categorical data. BMI was classified as “low” (< 25 kg/m2) or “high” (≥ 25 kg/m2) based on 
current recommendations by the World Health Organization [40] and National Heart, Lung 
and Blood Institute and the North American Association for the Study of Obesity [41]. 
Waist circumference (WC) cut-off point for high central obesity was defined as WC ≥ 80 
cm, using guidelines proposed by the International Diabetes Federation [42]. Total body fat 
percentage was categorized as “low” (< 32%) or “high” (≥ 32%) based on gender- and age-
specific cut-offs [43] and also on the current American Council on Exercise 
recommendation for maximum body fat percentage in women who are non-athletes [44]. 
One way analysis of variance (ANOVA) was used to test between-group differences for 
anthropometric and adiposity measures with Scheffe post-hoc tests for differences in 
adiposity based on categories of 25-OHD concentration.  
Correlation between adiposity measures and serum 25-OHD was assessed using 
Pearson’s Product Correlation test. We assessed the nature and strength of associations 
among covariates, 25-OHD and adiposity variables using normal throery multiple linear 
regression. Linear and restricted cubic spline model fit were also obtained to assess 
departure from linearity (Appendix D).  Model adequacy was assessed using residual versus 
predicted values, and Cook’s distance plots were used to identify influential data points. 
Crude and adjusted associations between 25-OHD and adiposity were estimated from 
unadjusted and multivariable adjusted linear regression. The dependent variable in these 
analyses was vitamin D staus defined as serum 25-OHD < 50 nmol/L, 50-75 nmol/L and ≥ 
75 nmol/L.  
Selected covariates were considered for inclusion in our multivariable linear 
regression models based on evidence in the literature suggesting their potential role as 
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confounders or effect modifiers. Season of blood draw and physical activity level were 
considered a priori to be likely confounders of the association between serum 25-OHD and 
adiposity. Additional covariates including age, smoking status, alcohol intake, and use of 
oral contraceptives were considered for inclusion in our final multivariable models. We 
conducted model assessment with and without each of these covariates, and included in the 
final regression model any variable with P < 0.20 or led to at least a 10% change in the beta 
coefficient for serum 25-OHD concentration. Our final model was further evaluated for 
multicollinearity between covariates. To evaluate linear trends, we used a Mantel extension 
test, modeling the medians of each tertile of adiposity measure as a continuous variable. All 
P-values were two-sided and considered statistically significant if P < 0.05.  
 
4.3 Results  
Demographic characteristics of participants has been reported previously (section 3.3). Body 
mass index (BMI), total body fat percentage (TBF %) and waist circumference (WC) ranged 
from 16.7 – 37.7 kg/m2, 14.8 – 56.6 %, and 58.4 – 114.3 cm, respectively (Table 7). Serum 
vitamin D levels (25-OHD) ranged from 21.7 - 174.3 nmol/L (Table 19) with a mean of 
79.2 ± 32.3 nmol/L. Overall, characteristics of participants, including demographic, lifestyle 
factors, and dietary intakes did not vary by serum 25-OHD status (Table 20 - 21). Mean 
serum 25-OHD levels also did not differ by oral contraceptive use, alcohol intake or 
smoking status (Table 22). 
Figure 14 shows the covariation and Pearson product correlation between vitamin D 
intake and serum 25-OHD levels. Overal, total, food, and supplemental vitamin D intake 
were not associated with serum 25-OHD concentrations (P > 0.05). However, further 
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analysis among women using supplements containing vitamin D (44.3% of women), 
showed that use of vitamin D supplements was positively associated with serum 25-OHD 
levels (ß = 0.03 ± 0.01, P = 0.05). Thus for every 100 IU/day increase in vitamin D 
supplement intake, serum 25-OHD concentrations subsequently improved by 3 nmol/L.  
Figures 15-20 show no significant correlation between serum 25-OHD levels and 
adiposity measures. Mean serum levels of 25-OHD did not differ by total body fat 
percentage, BMI, or waist circumference (Table 23). Crude and adjusted mean measures of 
adiposity did not differ vary by serum 25-OHD status. There was no evidence of a linear 
dose-relationship between adiposity and serum 25-OHD levels (Table 24). Simple and 
multivariable adjusted regression analyses (Table 26), adjusted for season, physical activity 
level and smoking status also showed no significant associations between serum 25-OHD 
levels and adiposity measures.  
 
4.4 Discussion 
To our knowledge, this is the first study to assess the association between serum 25-OHD 
and adiposity in a general population of pre-dominantly non-obese physically active young 
women. After adjusting for physical activity level, smoking status, and season of blood 
draw, we did not find serum 25-OHD concentration to be associated with adiposity 
measures in apparently healthy young women.  
Our results showed that 16.1% of women in our population were at risk for vitamin 
D deficiency (serum 25-OHD < 50 nmol/L). Our estimate is slightly higher than reports 
from NHANES data which indicates that about 11% of young adult women (19 – 30 years) 
in the U.S. are at risk of vitamin D deficiency (25-OHD < 30 nmol/L) [14]. It is not entirely 
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surprising that our estimate of vitamin D deficiency prevalence is larger than reports from 
NHANES. This is because NHANES data is a nationally representative assessment while 
our cohort is from the Northeastern Region of the U.S. Cutaneous synthesis of vitamin D is 
influenced by several factors, including time of day, season of year, and latitude. At 
latitudes above 42
◦
N (In Massachusetts, New York, Connecticut, and Pennsylvania), very 
little pre-vitamin D3 is synthesized in skin (using 7-dehydrocholesterol) from November 
through February (winter months) because the incident angle of sunlight at these latitudes 
during this time of year causes blockage of the UVB photons needed to convert 7-
dehydrocholesterol to pre-vitamin D3 [45]. During spring and summer months, more UVB 
photons are able to penetrate the ozone layer because the sun is directly overhead [45]. We did 
not find serum 25-OHD levels to be associated with season of blood draw. This could be 
because only very few women (1.7 %) provided blood samples for serum 25-OHD assays in 
summer months.   
We also assessed the relationship between vitamin D intake and serum 
concentrations of 25-OHD and the results showed a relatively poor correlation between 
vitamin D intake from foods and serum 25-OHD levels (r = -0.02, P = 0.75), demonstrating 
that food vitamin D intake (natural and fortified) might only be modestly related to vitamin 
D status. Vitamin D from supplement intake also accounted for only 4% of variation in 
serum 25-OHD concentrations. Our observations suggest that other factors apart from 
vitamin D intake might influence serum 25-OHD status in young women. Additional studies 
are needed to investigate these relationships. 
In the present study, we observed no significant correlations between serum 25-OHD 
levels and BMI, TBF%, WC, or regional adiposity measures, including percentage of fat in 
the arms legs, trunk, android, and gynoid regions. Unadjusted and adjusted generalized 
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linear regression analyses also showed no significant associations between serum 25-OHD 
concentrations and BMI, waist circumference (WC), or total body fat percentage (TBF %), 
which does not support the hypothesis that adipose tissue exerts an important effect on 
serum 25-OHD levels [46-49]. Shi et al., have demonstrated that elevated concentrations of 
1,25-(OH)2D stimulates lipogenesis and inhibit lipolysis in cultured human adipocytes, 
leading to accumulation of fat in adipocytes [31]. Also, 1, 25(OH)2D can inhibit the 
expression of adipocyte uncoupling protein-2 (UCP2), which causes a decrease in the 
metabolic efficiency  of adipocytes [48].  
Among healthy Caucasians and African-American adults (25 – 48 years), Parikh et 
al., observed that serum 25-OHD concentration was negatively correlated with body mass 
index (BMI: r = -0.40; P < 0.001) and percentage body fat (BF%: r = -0.41; P < 0.001), 
measured by dual energy x-ray absorptiometry [15]. A cross-sectional study by Rodriguez –
Rodriguez et al. in pre-menopausal overweight/obese women (20 – 35 years ) also found 
that while intakes of vitamin D, calcium, and supplements did not differ significantly 
between groups, BMI and WC measures were significantly lower in women with low 25-
OHD (< 90 nmol/L) compared to women with high 25-OHD concentrations (≥ 90 nmol/L), 
i.e. BMI: 26.0 ± 1.3 kg/m
2
 vs. 28.6 ± 3.2 kg/m
2
 and WC: 79.4 ± 3.4 cm vs. 86.2 ± 9.3 cm, 
respectively; P < 0.05) [18]. One potential explanation for this inconsistency in our findings 
compared to previous studies [15, 18] is that previous studies have focused on 25-OHD 
levels in predominately overweight or obese women; while our population comprised 
largely of non-obese women (75.9% of women had BMI < 25 kg/m
2
). Our range of 
adiposity was therefore very narrow; therefore it is likely that we may have had little power 
to evaluate serum 25-OHD levels across a wide range of adiposity values. Rodriguez-
  
128 
Rodriguez et al. also used a relatively higher cut-off (≥ 90 nmol/L) to assess low 25-OHD, 
compared to our evidence-based cut-off of ≥ 75 nmol/L [33, 34]. This variation in 
categorization of vitamin D insufficiency may have influenced the percentage of women 
identified as cases in our study, and this in turn may have limited our power to detect any 
associations of serum 25-OHD and adiposity.  
A recent cross-sectional study among ninety post-menopausal women (69 - 87 years) 
showed that total body fat is a negative predictor of serum 25-OHD levels (β = -0.247, P = 
0.016), even after adjusting for age, lifestyle, and serum intact parathyroid hormone [50]. 
Moschonis et al. [51] have also reported of a cross-sectional study in post-menopausal 
women (mean age, 60.3 ± 5.0 years; mean BMI, 29.5 ± 4.8 kg/m) showing that after 
controlling for age, serum intact parathyroid hormone, insulin-like growth factor I levels, 
ultraviolet B radiation exposure, and physical activity levels, there was an independent 
inverse association between serum 25-OHD and DXA measurements of total body fat (β = -
0.28, P = 0.012), trunk fat (β = -0.20, P = 0.061),  and leg fat mass (β = -0.30, P = 0.005), 
[50].  
We observed no associations between 25-OHD levels and adiposity measures, which 
contrast previous findings [50, 51]. However, this dissimilarity in findings is totally not 
unexpected, especially since young healthy women are more likely to be physically active, 
regardless of their BMI; whereas the association of physical activity and BMI is higher in 
older women [52, 53]. The median BMI in Jungert et al’s study was in the overweight 
category (26.3 kg/m
2
) compared to the low/normal median BMI of 22.6 kg/m
2
 observed in 
our study. We controlled for potential confounding factors including season of blood draw, 
smoking status, and physical activity level which have been independently associated
 
with 
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serum 25-OHD concentrations in previous studies [54-58], although not in our study. 
Physical activity, specifically vigorous activities and high-intensity exercise, has also been 
linked with lower amounts of subcutaneous skinfold thicknesses and fat distribution [59], 
and previous findings from our cohort indicated significant associations between physical 
activity level and total body fat percentage (r = -0.14, P = 0.02). Eventhough women with 
high serum 25-OHD (≥ 75 nmol/L) also reported higher intakes of supplemental calcium 
(420 ± 55 vs. 275 ± 39 g/day, respectively, P = 0.04) as compared to women with low 25-
OHD (< 75 nmol/L), supplemental calcium intake was not a significant predictor of vitamin 
D status.  
We also considered the effects of oral contraceptive (OC) use in the association 
between adiposity and serum 25-OHD, but OC use did not influence the extent of 
association between serum 25-OHD concentration and adiposity and was excluded from or 
final analyses. Oral contraceptives usually contain progestin and/or synthetic estrogen [60], 
which has been associated with elevated 25-OHD in pre-menopausal women, ages 20-40 
years [61]. While the effects of progesterone based OC on vitamin D metabolism are not 
well understood, experimental in vivo studies suggest that estrogen may up-regulate the 
expression of 1- α -hydroxylase, the enzyme responsible for converting 25-OHD to 
1,25(OH)2D in the kidney, as well as the vitamin D receptor and vitamin D binding protein 
[62-64]. Estrogen may also down-regulate 24-hydroxylase, the main enzyme that degrades 
25-OHD in cells [62]. Together, these effects of estrogen may result in elevated circulating 
25-OHD, although the clinical significance of such an effect remains unknown. Additional 
studies with larger cohorts are needed to further investigate whether oral contraceptive use 
modifies 25-OHD levels in young women.  
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Some of the strengths of our study include assessment of vitamin D status with a 
commonly used biomarker, serum levels of 25-OHD [64]. While both 25-OHD and 1, 25-
dihydroxyvitamin D concentrations can be specifically measured in serum or plasma [65, 
66], the concentration of 25-OHD is considered the best indicator of vitamin D status 
because it represents a summation of total cutaneous production of vitamin D and intake of 
vitamin D from foods [65]. Serum 25-OHD also has a fairly long circulating half-life (~ 15 
days) (Jones, 2008) as compared to 1, 25(OH)2 D, which has a relatively short half-life of 
between 4 to 6 hours [67]. Serum 1, 25(OH)2 D concentrations are also closely regulated by 
parathyroid hormone (PTH), calcium, and phosphate [68]; hence, levels of 1,25(OH)2D do 
not typically decrease until vitamin D deficiency is severe [1, 69].  
Our population comprised of non-obese and obese individuals; and we controlled for 
several factors (including season of blood draw, smoking status and physical activity level), 
that could potentially influence a relation between 25-OHD levels and adiposity.  
Some important limitations of our study include the cross-sectional design, and the 
fact that serum 25-OHD level and adiposity measures were assessesed only once. Causal 
relationships between 25-OHD levels and adiposity can therefore not be inferred from our 
results. A one-time measurement of adiposity and 25-OHD may not also reflect long term 
changes in obesity markers and 25-OHD levels. Future studies that evaluate predictors of 
serum 25-OHD status should employ a prospective design and enroll larger cohorts as this 
will help to better understand if serum 25-OHD status differs among women with relatively 
little adiposity.  
Our population was also fairly homogenous; i.e., most women had low BMI (< 25 
kg/m
2
), and all participants were between 18 to 30 years.  Subjects were also predominately 
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were Caucasian. Our findings are therefore limited to mostly non-obese young Caucasian 
women and may not be generalizable to women in other age groups, BMI categories, or 
ethnicities.  
 
4.5 Conclusions and Significance 
Presently, the evidence is conflicting on the relationship between serum 25-OHD levels and 
adiposity in young women. While some cross-sectional studies suggest that 25-OHD 
concentrations are lower in obese compared with non-obese subjects, other studies in similar 
populations have failed to confirm these observations. Previous studies have also not 
explored whether use of oral contraceptives, alcohol intake, or cigarette smoking can 
influence the association between 25-OHD levels and adiposity risk in reproductive aged 
women. Obesity is an independent risk factor for many chronic conditions, including 
cardiovascular disease, type II diabetes mellitus, and several cancers. Understanding and 
identifying any modifiable lifestyle factors that may be associated with obesity (increased 
adiposity) could help in formulating nutrition interventions targeted at obesity 
reduction/prevention. In the present study, serum 25-OHD levels were not associated with 
adiposity measures in young women ages 18-30 years. Further studies are needed to 
corroborate our fingings. In the meantime, we suggest that young women (18 to 30 years) 
should still seek to maintain optimal levels of serum 25-OHD (via food and supplement 
intake), since vitamin D is important for attaining peak bone mass; which in turn decreases 
the risk of osteoporosis and osteoporotic fractures in later life. 
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Table 19. Distribution of Serum 25-Hydroxyvitamin D (25-OHD) Levels  
 
 
 Mean ± Standard Deviation Range 
Serum 25-OHD, nmol/L 79.2 ± 32.3 21.7 - 174.3 
  
 n (%) 
Serum 25-OHD, nmol/L
‡
  
    (< 50 nmol/L) 
    (50 - 75 nmol/L) 
 
28 (16.1) 
65 (37.4) 
    (≥ 75 nmol/L) 81 (46.5) 
 
‡
 2.496 nmol/L = 1 ng/mL. 
 
  
  
142 
 
Table 20. Variations in Characteristics of Participants by Serum 25-OHD Levels  
 
 
 
  
Covariate Low 25-OHD 
< 75 nmol/L
§
 
(n = 93) 
High 25-OHD 
≥ 75 nmol/L§ 
(n = 81) 
P 
ⱶ
 
 Mean ± Standard Deviation  
Age, y  21.7 ± 3.3 21.5 ±  3.1 0.54 
BMI, kg/m
2
  22.8 ±  3.3 23.1 ±  3.3 0.65 
Waist Circumference, cm 78.2 ±  8.6 79.1 ±  9.2 0.51 
Waist to Height, ratio 0.47 ±  0.05 0.48 ±  0.07 0.53 
Total Body Fat, %  31.6 ±  8.4 32.8 ±  8.2 0.34 
Arm Fat, % 29.3 ± 9.5 30.5 ± 9.0 0.40 
Leg Fat, % 35.7 ± 8.2 36.2 ± 7.2 0.66 
Trunk Fat, % 31.0 ± 9.7 32.8 ± 9.8 0.24 
Android Fat, % 33.8 ± 10.6 35.8 ± 10.6 0.23 
Gynoid Fat, % 40.5 ± 7.3 41.1 ± 6.4 0.60 
Android : Gynoid Ratio  0.82 ± 0.18 0.86 ± 0.16 0.25 
Physical Activity, METs/week
╔
  43.7 ± 36.3 56.5 ± 49.6 0.05 
Systolic Blood Pressure, mm Hg 103.8 ± 7.6 105.9 ± 10.2 0.12 
Diastolic Blood Pressure, mm Hg 68.5 ± 6.8 69.3 ± 8.1 0.44 
Fasting Blood Glucose, mg/dL
 ϖ
 79.5 ± 9.0 79.9 ± 10.8 0.82 
Serum 25-OHD, nmol/L 55.7 ± 13.1 106.3 ± 25.8 < 0.01 
ⱶ
 P-values for test of Null: Equal means, estimated with student t-test. 
╔ 
METs, metabolic equivalents, n = 173 for physical activity. 
ϖ 
n = 163 for fasting blood glucose. 
‡ 
2.496 nmol/L = 1 ng/mL. 
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Table 20. Continued  
 
 
Covariate 
Low 25-OHD 
< 75 nmol/L
§
 
(n = 93) 
High 25-OHD 
≥ 75 nmol/L§ 
(n = 81) 
P 
ⱶ
 
 n (%)  
BMI, kg/m
2
  
 < 25 
 
 ≥ 25  
 
72 (77.4) 
21 (22.6) 
 
60 (74.1) 
21 (25.9) 
0.61 
Waist Circumference, cm 
 < 80  
      ≥ 80  
 
54 (58.1) 
39 (41.9) 
 
45 (55.6) 
36 (44.4) 
0.74 
Total Body Fat, %  
 < 32  
      ≥ 32  
 
46 (49.5) 
47 (50.5) 
 
37 (45.7) 
44 (54.3) 
0.62 
Android: Gynoid Ratio 
 < 1 
      ≥ 1 
 
72 (77.4) 
21 (22.6) 
 
57 (70.4) 
24 (29.6) 
0.29 
Race 
Caucasian 
Other 
 
79 (85.0) 
14 (15.0) 
 
68 (84.0) 
13 (16.0) 
0.86 
Education  
Some College 
College Graduate 
 
74 (79.6) 
19 (20.4) 
 
65 (84.2) 
16 (19.8) 
0.91 
Currently Drink Alcohol  
No 
Yes 
 
34 (36.6) 
59 (63.4) 
 
25 (30.9) 
56 (69.1) 
0.43 
Currently Smoke 
No 
Yes 
 
86 (92.5) 
7 (7.5) 
 
79 (97.5) 
2 (2.5) 
0.13 
Currently Use Oral Contraceptive 
No 
Yes 
 
63 (67.7) 
30 (32.3) 
 
44 (54.3) 
37 (45.7) 
0.07 
ⱶ
 P-values for chi-squared tests. 
‡ 
2.496 nmol/L = 1 ng/mL. 
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Table 21. Dietary Intakes of Participants by Serum 25-OHD Levels  
 
 
Dietary Intake 
Low 25-OHD 
< 75 nmol/L
§
 
(n = 93) 
High 25-OHD 
≥ 75 nmol/L§ 
(n = 81) 
P 
ⱶ
 
 Mean ± Standard Error  
Energy, kcal/day 2205 ± 84 2223 ± 87 0.88 
Total Protein, g/day  104 ± 6 102 ± 4 0.75 
Total Fat, g/day  72 ± 3 73 ± 3 0.69 
Total Calcium Intake, mg/day  
Food calcium 
Supplemental
 
calcium (n = 63 users) 
1130 ± 54 
1042 ± 51 
275 ± 39 
1195 ± 61 
1023 ± 58 
420 ± 55 
0.43 
0.81 
0.04 
Vitamin A, IU/day
 Ϫ
 16701 ± 1069 15532 ± 1121 0.45 
Thiamin, mg/day 1.9 ± 0.1 1.8 ± 0.1 0.52 
Riboflavin, mg/day 2.7 ± 0.1 2.5 ± 0.1 0.48 
Niacin, mg/day 29 ± 2 28 ± 1 0.56 
Pantothenic acid, mg/day 7.1 ± 0.4 6.4 ± 0.3 0.20 
Vitamin B6, mg/day 2.6 ± 0.1 2.5 ± 0.1 0.52 
Folate, µg/day 695 ± 40 647 ± 40 0.39 
Vitamin B12, µg/day 6.1 ± 0.4 6.2 ± 0.5 0.88 
Vitamin C, mg/day 150 ± 10 144 ± 9 0.61 
Total Vitamin D Intake, IU/day
 Ϫ
  
Food vitamin D 
Supplemental
 
vitamin D (n = 77 users) 
355 ± 27 
223 ± 19 
307 ± 37 
403 ± 34 
222 ± 20 
396 ± 40 
0.26 
0.99 
0.10 
Iron, mg/day 19 ± 1 18 ± 1 0.85 
Zinc, mg/day 14 ± 1 14 ± 1 0.78 
Linoleic acid, g/day 23 ± 1 24 ± 1 0.44 
Linolenic acid, g/day 12 ± 1 13 ± 1 0.65 
Dairy Intake, total servings/day
₸
 2.0 ± 0.2 1.8 ± 0.2 0.56 
§ 
2.496 nmol/L = 1 ng/mL.  
ⱶ
 P-values for test of Null: Equal means, estimated with student t-tests.
 
Ϫ 
IU, International Units: 1 IU = 0.025 µg.  
₸
 n = 166 for dairy intake responders. 1 serving dairy = 8 fluid oz. (1 cup) of milk or 
yogurt; 1.5 oz of natural cheese; 2 oz of processed cheese, 2 cups of cottage cheese. 
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Table 22. Mean Serum 25-OHD Levels by Oral Contraceptive Use, Alcohol Intake and 
Smoking Status  
 Oral Contraceptive Use  
 Yes (n = 67 ) No (n = 107)  
 Mean ± Standard Deviation P
 ⱶ
 
Serum 25-OHD, nmol/L
§
 83.0 ±  34.0 76.9 ± 31.1 0.23 
   
   
 Smoking status  
 Yes (n = 9 ) No (n = 165)  
 Mean ± Standard Deviation P
 ⱶ
 
Serum 25-OHD, nmol/L
§
 65.1 ±  21.9 80.0 ± 32.6 0.18 
   
   
 Drink Alcohol   
 Yes (n = 115 ) No (n = 59)  
 Mean ± Standard Deviation P
 ⱶ
 
Serum 25-OHD, nmol/L
§
 83.2 ±  32.3 77.5 ± 32.5 0.61 
    
    
ⱶ
 P-values for test of Null: Equal means, estimated with student t-tests. 
§ 
2.496 nmol/L = 1 ng/mL.  
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Figure 14. Covariation and Pearson Product Correlation of Vitamin D Intake and Serum 25-OHD Concentration  
 
 
  
* Fitted values are simple Linear Regression. 
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Figure 15. Covariation and Pearson Product Correlation of Serum 25-OHD and Body Mass Index 
 
 
All women         Low BMI < 25 kg/m
2
       High BMI >= 25 kg/m
2
 
 
 
* Fitted values are simple Linear Regression. 
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Figure 16. Covariation and Pearson Product Correlation of Serum 25-OHD and Waist Circumference  
 
All women         Low WC < 80 cm        High WC >= 80 cm 
 
  
* Fitted values are simple Linear Regression. 
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Figure 17. Covariation and Pearson Product Correlation of Serum 25-OHD Total Body Fat percentage  
 
All women         Low TBF < 32 %       High TBF >= 32 % 
 
  
* Fitted values are simple Linear Regression. 
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Figure 18. Covariation and Pearson Product Correlation of Serum 25-OHD and Regional Adiposity Measures (Arm and Leg Fat) 
 
 
  
* Fitted values are simple Linear Regression. 
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Figure 19. Covariation and Pearson Product Correlation of Serum 25-OHD and Regional Adiposity Measures (Trunk, Android and Gynoid Fat) 
 
 
 
 
* Fitted values are simple Linear Regression. 
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Figure 20. Covariation and Pearson Product Correlation of Serum 25-OHD and Android to Gynoid Fat ratio (AGF ratio) 
 
All women        Low AGF ratio < 1       High AGF ratio >= 1 
  
 
* Fitted values are simple Linear Regression.  
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Table 23. Mean Serum 25-OHD Levels by Adiposity  
 
 
 
  
 Low BMI < 25 kg/m
2
 
(n = 132) 
High BMI ≥ 25 kg/m2 
(n = 42) 
P-value 
ⱶ
 
 Mean ± Standard Deviation  
Serum 25-OHD, nmol/L
§
 77.6 ± 31.1 84.5 ± 35.8 0.23 
 
 Low WC < 80 cm 
(n = 99) 
High WC ≥ 80 cm 
(n = 75) 
P-value 
ⱶ
 
 Mean ± Standard Deviation  
Serum 25-OHD, nmol/L
§
 78.3 ± 31.6 80.5 ± 33.3 0.67 
 
 Low TBF < 32 % 
(n = 83) 
High TBF ≥ 32% 
(n = 91) 
P-value 
ⱶ
 
 Mean ± Standard Deviation  
Serum 25-OHD, nmol/L
§
 78.0 ± 31.9 80.4 ± 32.8 0.63 
 
§ 
2.496 nmol/L = 1 ng/mL.  
ⱶ
 P-values for test of Null: Equal means, estimated with student t-test. 
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Table 24. Unadjusted and Adjusted Mean Values of Adiposity by Serum 25-OHD Levels  
  
 (X = Serum 25-OHD Concentration) 
 
(Y = Adiposity) 
< 50 nmol/L 
(n = 28 ) 
50-75 nmol/L 
(n = 65 ) 
≥ 75 nmol/L 
(n = 81 ) 
P diff
†
 P trend
‡
 
 Unadjusted Means ± Standard Error   
BMI, kg/m
2
  22.3 ±  0.6
 
23.1 ± 0.4
 
23.1 ±  0.4
 
0.57 0.52 
Waist Circumference, cm 76.8 ±  1.7
 
78.8 ±  1.1
 
79.1 ±  1.0
 
0.50 0.78 
Total Body Fat, %  30.9 ±  1.6
 
31.9 ±  1.0
 
32.8 ±  0.9
 
0.58 0.21 
Arm Fat, % 28.5 ± 1.8
 
29.6 ± 1.2
 
30.5 ± 1.0
 
0.61 0.49 
Leg Fat, % 35.5 ± 1.5
 
35.7 ± 1.0
 
36.2 ± 0.9
 
0.90 0.74 
Trunk Fat, % 29.9 ± 1.8
 
31.5 ± 1.2
 
32.8 ± 1.1
 
0.39 0.19 
Android Fat, % 32.5 ± 2.0
 
34.4 ± 1.3
 
35.8 ± 1.2
 
0.36 0.44 
Gynoid Fat, % 40.5 ± 1.3
 
40.5 ± 0.9
 
41.1 ± 0.8
 
0.87 0.72 
Android : Gynoid Fat, ratio  0.79 ± 0.03
 
0.84 ± 0.02
 
0.86 ±  0.02
 
0.23 0.60 
†
 Analysis of variance (ANOVA) was used to compare group differences. 
‡ 
P-value for trend estimated with simple linear regression using median of tertiles of adiposity.
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Table 24. Continued 
  
 (X = Serum 25-OHD Concentration) 
 
(Y = Adiposity) 
< 50 nmol/L 
(n = 28 ) 
50-75 nmol/L 
(n = 65 ) 
≥ 75 nmol/L 
(n = 81 ) 
P diff
†
 P trend
 ѣ
 
 Adjusted Means ± Standard Error 
¤
   
BMI, kg/m
2
  22.2 ±  0.8
 
23.0 ±  0.7
 
22.7 ±  0.7
 
0.57 0.28 
Waist Circumference, cm 75.6 ±  2.2
 
77.9 ±  1.8
 
77.5 ±  1.8
 
0.52 0.28 
Total Body Fat, %  29.4 ±  2.0
 
30.5 ±  1.7
 
31.3 ±  1.7
 
0.39 0.14 
Arm Fat, % 27.7 ± 2.3
 
28.8 ± 1.9
 
29.6 ± 1.9
 
0.27 0.15 
Leg Fat, % 34.6 ± 1.9
 
34.7 ± 1.6
 
35.3 ± 1.5
 
0.41 0.05 
Trunk Fat, % 27.8 ± 2.4
 
29.5 ± 2.0
 
30.6 ± 1.9
 
0.37 0.19 
Android Fat, % 30.1 ± 2.6
 
32.1 ± 2.1
 
33.2 ± 2.1
 
0.43 0.29 
Gynoid Fat, % 39.1 ±1.7
 
39.0 ± 1.4
 
39.6 ± 1.4
 
0.26 0.10 
Android : Gynoid Fat, ratio  0.76 ± 0.04
 
0.82 ± 0.03
 
0.82 ±  0.03
 
0.39 0.58 
†
 Analysis of variance (ANOVA) was used to compare group differences. 
¤ 
Mean values estimated with ANOVA and adjusted for season, smoking status and physical activity level.
  
ѣ  
P-value for trend estimated with multiple linear regression using median of tertiles of adiposity and adjusted for season, smoking 
status and physical activity level. 
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Table 25. Linear Relationship between
 
Serum 25-OHD Levels and Other Parameters  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Serum 25-OHD   
Independent Predictor ß ± SE P-value 
Age,  y
 
-0.13 ± 0.77 0.86 
Education 
a 
- 0.13 ± 6.12 0.98 
Season of blood draw 
b 
       Winter (n = 36) 
           
Spring (n = 98) 
Summer (n = 3) 
Fall (n = 37) 
-7.27 ± 6.04 
Reference 
-9.70 ± 6.29 
-3.78 ± 19.38 
-1.11 ± 7.55 
0.23 
Reference 
0.13 
0.85 
0.88 
Smoking status 
c 
-14.92 ± 11.03 0.18 
Alcohol intake 
c 
2.68 ± 5.18 0.61 
Oral contraceptive use 
c 
6.06 ± 5.02 0.23 
Physical activity level, MET-hrs/week
 
0.10 ± 0.06 0.08 
Total calcium intake, g/day 
Food calcium intake, g/day 
Supplemental calcium intake, g/day 
-0.002 ± 0.01 
-0.004 ± 0.01 
0.01 ± 0.01 
0.67 
0.43 
0.47 
Total vitamin D intake, IU/day 
Food  vitamin D intake, IU/day 
Supplemental  vitamin D intake, IU/day 
0.002 ± 0.01 
-0.004 ± 0.01 
0.01 ± 0.01 
0.83 
0.75 
0.61 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using simple linear regressions.
  
a 
Dummy variable (0 = some college / 1 = college graduate). 
b 
Dummy variable (0 = winter / 1 = non-winter, i.e. Spring, Summer, Fall). 
c 
Dummy variable (0 = no / 1 = yes). 
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Table 26. Linear Relationship between Serum 25-OHD Levels and Adiposity  
 
 
 
 
 
 
 
 
 
  
 Serum 25-OHD Concentration  
 
 
Exposure 
Unadjusted 
ß ± SE 
 
P-value 
Multivariable 
§
 
Adjusted 
ß ± SE 
 
P-value 
BMI,  kg/m
2 
0.67 ± 0.75 0.37 0.39 ± 0.75 0.60 
Waist Circumference, cm
 
0.16 ± 0.28 0.57 0.06 ± 0.28 0.83 
Total Body Fat, %
 
0.19 ± 0.30 0.53 0.17 ± 0.30 0.56 
Arm Fat, %
  
0.05 ± 0.27 0.85 0.04 ± 0.27 0.89 
Leg Fat, %
 
0.07 ± 0.32 0.83 0.09 ± 0.32 0.77 
Trunk Fat, %
 
0.22 ± 0.25 0.37 0.20 ± 0.25 0.43 
Android Fat, %
 
0.19 ± 0.23 0.40 0.15 ± 0.23 0.51 
Gynoid Fat, % 0.06 ± 0.36 0.86 0.07 ± 0.36 0.86 
Android : Gynoid Fat, ratio 12.6 ± 14.2 0.38 7.84 ± 14.29 0.58 
All analyses were estimated using simple or multiple linear regressions. 
§
Multivariable adjusted for season, smoking status and physical activity level. 
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Abstract: Vitamin D deficiency (serum 25-hydroxyvitamin D, 25-OHD, < 50 nmol/L) 
and increased adiposity have been linked with higher levels of inflammatory biomarkers 
in obese/older adults and chronically ill patients. We used cross-sectional data from 270 
healthy young women (18-30 years) participating in the UMass Amherst Vitamin D 
Status Study to evaluate the extent to which serum 25-OHD levels are associated with 
inflammatory biomarkers. 25-OHD levels and inflammatory factors including highly 
sensitive C-reactive protein (hs-CRP); interleukins (IL)-1β, 2, 4 , 5, 6, 7, 8, 10, 12p70, 
13; granulocyte macrophage colony stimulating factor (GM-CSF); interferon-gamma 
(IFN-γ) and tumor necrosis factor-alpha (TNF-α) were assayed in serum using enzyme 
immunosorbent assays or a multiplex microsphere-bead array. Most inflammatory factors 
were strongly correlated with each other (P < 0.01); however, hs-CRP was not correlated 
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with other inflammatory markers (P > 0.05). Levels of IL-1β, IL-7, GM-CSF, and TNF-α 
were higher in women with waist circumference < 80 cm (P < 0.01). Mean 25-OHD 
levels were also greater among women with high hs-CRP (≥ 5 mg/L), compared to 
women with low hs-CRP (< 5 mg/L), (91.6 ± 35.8 vs. 76.4 ± 31.1 mg/L, P = 0.02). After 
adjustment for season, physical activity level, adiposity, alcohol and multivitamin intake, 
25-OHD (< 75 nmol/L) was negatively associated with IL-2 and GM-CSF concentrations 
(ß = -0.02 ± 0.01 pg/mL, P = 0.04), and marginally associated with IL-6 and IL-7 
concentrations (ß = -0.02 ± 0.01 pg/mL, P = 0.05). These findings suggest that IL-2, GM-
CSF, IL-6, and IL-7 levels may be reduced in young women with 25-OHD < 75 nmol/L. 
Further studies are needed to investigate causal relations between 25-OHD status and 
inflammation in young women. 
Keywords: Vitamin D, Serum 25-hydroxyvitamin D, Adiposity, Inflammation, Young 
women 
 
 
 
5.1 Introduction 
Viseral obesity is commonly associated with a chronic, low-grade inflammation of white 
adipose tissue, characterized by increased production of pro-inflammatory cytokines 
(e.g., interleukin-1, interleukin-6, and tumor necrosis factor- α) and acute phase reactant 
proteins (e.g., C - reactive protein) [1-4]., some of which are   actually secreted by 
adipose tissue itself [5-8]. These cytokines may have local physiological effects on white 
adipose tissue physiology as well as systemic effects on other organs [9]. Among patients 
Definition: CRP and hs-CRP assays measure the same molecule in blood; but, hs-CRP is a 
more sensitive test for the detection of very small amounts of CRP (as low as 0.025 mg/L). 
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with coronary artery disease, Verghese et al. found that visceral fat area is highly 
correlated with CRP levls [10]. Cross-sectional studies in Korean adults showed a 
positive association between visceral adiposity and elevated CRP and/or cytokine levels 
(TNF-α, and IL-6) in obese subjects [11]. Abdominal obesity, assessed by android to 
gynoid fat ratio, was an independent predictor of CRP and IL-6 levels in obese adults 
[11]. Additional studies in similar cohorts have suggested that visceral fat mass may be 
the most important predictor of high sensitive-CRP (hs-CRP) concentration [12]. 
Elevated CRP levels is undesirable because it is an independent risk factor for several 
chronic diseases, including cardiovascular disease [15, 22], and type II diabetes [15, 23], 
Vitamin D modulates immune response; and cross-sectional studies in obese but 
healthy U.S. adults have shown an inverse association between serum 25-OHD 
concentrations and plasma CRP concentrations [13-14]. Some have proposed that 
improving vitamin D status (1-alpha, 25-dihydroxyvitamin D3 concentration, (1, 
25(OH)2D3),  may help to suppress inflammation  by meditating the release of specific 
cytokines and expression of cytokine receptors [24-26]. Although accumulating research 
strongly implicates vitamin D in the modulation of systemic inflammation, most of these 
findings have been reported in post-menopausal, obese, or chronically ill populations. We 
used cross-sectional data from 170 healthy young women participating in the UMass 
Amherst Vitamin D Status Study to evaluate the extent to which serum 25-OHD 
concentrations are associated with inflammatory biomarkers in apparently healthy young 
women.  
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5.2 Materials and Methods  
5.2.1 Study Design and Population 
The UMass Amherst Vitamin D Status Study was a cross-sectional study designed to 
assess vitamin D status in young women and to identify factors (dietary, environmental, 
or lifestyle) with which it is associated. The study protocol has been described in detail 
previously (section 3.2.1). The majority of participants completed all study 
questionnaires and tests during a single clinic visit, scheduled on a morning during the 
late luteal phase of their menstrual cycle. Information on lifestyle and demographic 
factors, including smoking and drinking habits and history of oral contraceptive use, was 
collected using self-reported questionnaire. The present analyses include 265 women 
with inflammation data of which 170 women had serum 25-OHD levels available. The 
study was approved by the Institutional Review Board at the University of 
Massachusetts, Amherst. Written informed consent was obtained from all participants. 
 
5.2.2 Assessment of Serum 25-OHD Status 
All study measurements were completed in a single clinic visit scheduled for the mid-late 
luteal phase of each participant's menstrual cycle. Each participant provided a fasting 
venous blood sample which was immediately processed and stored at −80 °C, usually 
within two hours of draw. Serum 25-OHD concentrations were determined using a 
commercially available radioimmunoassay kit (25-hydroxyvitamin D 
125
I RIA Kit; 
DiaSorin Inc., Stillwater, MN, USA), which has been previously validated [30]. Gamma 
irradiation of I
125
 (in counts per minute; CPM) was quantified using a Beckman Gamma 
4000 counter (Beckman Coulter, California, USA), and CPM were converted into 
 162 
 
concentration units using GraphPad Prism version 4.0 for Windows (GraphPad Software, 
San Diego, CA). Serum vitamin D status was classified as follows: 25-OHD < 50 nmol/L 
(< 20 ng/mL) = deficient, 25-OHD of 50 - 75 nmol/L (20 - 50 ng/mL) = suboptimal, and 
25-OHD ≥ 75 nmol/L (50 ng/mL) = optimal [31, 32].  
 
5.2.3 Assessment of Inflammatory Biomarkers 
Highly sensitive C - reactive protein (hs-CRP) was measured in serum using enzyme 
immunosorbent assay (EIA) kits (BioCheck, Inc., Foster City, CA, USA). Cytokine 
levels in serum were determined with a standard human inflammation panel using a 
multiplex microsphere-bead array (Assay Gate, Ijamsville, MD, USA), and quantified 
using a Bio-Plx 200 Bead Reader System (Bio-Rad, Hercules, CA). Inflammatory factors 
assayed included interleukins (IL) -1β, 2, 4, 5, 6, 7, 8, 10, 12p70, 13, tumor necrosis 
factor-alpha (TNF-α), granulocute macrophage colony stimulating factor (GM-CSF), and 
interferon-gamma (IFN-γ). Laboratory methods for the multiplexed ELISA-based 
approach have been described elsewhere [33, 34]. Samples were run in duplicate with 
internal standards. Coefficients of variation for all cytokines were < 10%.  
 
5.2.4 Assessment of Covariates 
All study measurements were completed in a single clinic visit scheduled for the late 
luteal phase of each participant's menstrual cycle. Dietary intake and multivitamin use 
was assessed using a validated food frequency questionnaire (previously described in 
section 3.2.3). Information on demographic factors, oral contraceptive use and lifestyle 
factors (e.g., smoking status and alcohol intake) was collected by self-reported 
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questionnaire. Body mass index (BMI) was calculated as weight in kilograms divided by 
the square of height in meters. Percentage of total body fat (%TBF) was measured by 
dual energy x-ray absorptiometry (DXA) using the total body scan mode on a narrow 
angle fan GE Lunar Prodigy scanner (GE Lunar Corp., Madison, WI).  DXA scans were 
performed with the participant lying in a supine position with arms and legs placed flat 
by the side. Measurements were completed by the same technician, and the machine was 
calibrated daily using the standard calibration method provided by the manufacturer.  The 
coefficient of variation for repeated scans of the manufacturer’s phantom is less than 1%. 
The DXA scan report also provided estimates of sub-regional adiposity measurements 
(fat mass and percentage fat mass), including the arms, legs, trunk, android and gynoid 
regions. Total body fat percentage was obtained directly from DXA scans (estimated 
using the ratio of whole-body fat mass to whole-body total mass). 
 To estimate physical activity levels, we asked participants to report the time they 
spent each week engaged in specific physical activities, including walking, jogging, 
running, bicycling, aerobics/dancing, tennis/racket sports, swimming, yoga/pilates and 
weight training. These questions were based on those used in the Nurses’ Health Study II 
and have been previously validated in that population [35].  We then estimated total 
metabolic equivalents (MET), which were recorded in hours of activity per week. The 
MET per week score measures the intensity of a physical activity, with 1 MET being 
defined as the amount of energy expended when a person is at rest [36] . 
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5.2.5 Statistical Analysis 
STATA version 12.0 (Stata Corporation., College Station, TX.) was used for all 
statistical analyses. Continuous variables that were not normally distributed (e.g., 
inflammatory factors) were log transformed to reduce skewness and improve normality. 
Inflammation factors were expressed as median (inter-quartile range), and Mann-Whitney 
U tests were used to compare group differences by adiposity, oral contraceptive use, 
smoking status and alcohol intake.  
Total body fat percentage was categorized as “low” (TBF < 32%) or “high” (TBF 
≥ 32%) based on gender-and-age specific cut-offs [37] and also on the current American 
Council on Exercise recommendation for maximum body fat percentage in women who 
are non-athletes [38].  BMI was classified as “low” (BMI < 25 kg/m2) or “high” (BMI ≥ 
25 kg/m
2
) based on current recommendations by the World Health Organization [39] and 
National Heart, Lung and Blood Institute and the North American Association for the 
Study of Obesity [40]. The waist circumference (WC) cut-off point for high central 
obesity was defined as WC ≥ 80 cm, based on guidelines proposed by the International 
Diabetes Federation [41]. While current anthropometric guidelines do not state a specific 
cut-off for waist to height ratio (WHtR), previous research indicated that among 
individuals less than 40 years, WHtR less 0.5 is generally considered healthy [42].  
Pearson’s Product Correlation between serum 25-OHD levels and inflammatory 
factors were determined. The nature and strength of associations among covariates, 
dietary intakes, and adiposity variables were assessed using normal throery multiple 
linear regression. Linear and restricted cubic spline model fit were also obtained to 
assess departure from linearity (Appendix E).  Model adequacy was assessed using 
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residual versus predicted values, and Cook’s distance plots were used to identify 
influential data points. 
We started model building with an unadjusted simple linear regression (Model 1) 
using serum 25-OHD as the predictor variable and inflammatory factors as the outcome 
variables. Selected covariates were considered for inclusion in our final multivariable 
models. Season of blood draw was considered a priori to be likely confounder of a serum 
25-OHD-inflammation relation. We conducted model assessment with and without each 
selected covariate, and included in the final regression model any variable with P < 0.20 
or whose inclusion in the model led to at least a 10% change in the beta coefficient for 
each adiposity measure. This was followed with two different models of multivariable 
linear regressions. Model 2 adjusted for season of blood draw and adiposity (BMI, WC, 
TBF, or WHtR), while Model 3 adjusted for all variables in Model 2 plus physical 
activity level, multivitamin intake, and either smoking status, alcohol intake, or oral 
contraceptive use. To assess effect modification (whether the relationship between hs-
CRP and 25-OHD varies with 25-OHD levels), stratified analyses were conducted to 
compare the above associations among individuals with low 25-OHD (< 75, nmol/L) or 
high 25-OHD (≥ 75 nmol/L). Our final model was evaluated for multicollinearity 
between covariates. All P-values were two-sided and considered statistically significant if 
P < 0.05. 
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5.3 Results  
Characteristics of participants are reported in Table 27. We did not find significant 
variations in median and interquartile distribution of inflammatory biomarkers by serum 
25-OHD status (Table 28). However, women with low waist circumference (WC < 80 
cm) had significantly higher levels of cytokines such as interleukin-1β (IL-1β), 
interleukin-7 (IL-7), granulocyte-macrophage-colony-stimulating factor (GM-CSF) and 
tumor necrosis factor-alpha (TNF-α), compared to women with WC > 80 cm; P < 0.01 
(Table 29). Compared to women with lower adiposity (Table 30), those with high BMI (≥ 
25 kg/m
2
) had a 30.6%  higher  IL-6 levels (P = 0.02) while women with high total body 
fat, TBF, percentage (≥ 32%) exhibited a 19.2% increase in IL-6 levels (P = 0.03), Table 
31.  
Median levels of IL-2 and IL-4 were marginally higher among women consuming 
alcohol compared to non-drinkers (P = 0.07, and P = 0.05, respectively), Table 32. 
Inflammatory factors were strongly correlated with each other (P < 0.01), except for 
correlations of hs-CRP with other inflammatory markers (Table 33), which were not 
significantly correlated.  
Table 34 shows the Pearson product correlation between serum 25-OHD 
concentration and inflammatory factors. Overall, correlations of 25-OHD levels with 
inflammation were non-significant for all inflammatory factors (P > 0.05). Mean 25-
OHD levels were also significantly greater among women with high inflammation (hs-
CRP ≥ 5 mg/L), compared to women with low inflammation (hs-CRP < 5 mg/L), (91.6 ± 
35.8 vs. 76.4 ± 31.1, P = 0.02), Table 35.  
 167 
 
Figures 21-34 show the lowess regression curve and linear fit for the association 
between inflammatory factors and 25-OHD concentration. The gray line shows the linear 
prediction and the shaded band gives the confidence interval for the linear fit. The red 
line shows the lowess regression curve for this same association if a linear fit is not 
assumed. While the lowess regression curve closely approximated the least squares linear 
regression line over most of the observed data, there was a slight suggestion of a mild 
departure from the linear model. Further analysis showed that fitting a spline model did 
not significantly explain perceived associations any better than a linear model fit 
(Appendix E).  
We observed significant relationships between adiposity and several cytokines 
(Table 36). For instance, unadjusted linear regressions indicated that IL-6 levels was 
positively associated with BMI, TBF, and WC (ß = 0.08 ± 0.02, P < 0.01; ß = 0.03 ± 
0.01, P < 0.01; and ß = 0.02 ± 0.01 pg/L, P = 0.02, respectively). IL-1ß and GM-CSF 
were negatively associated with WC (ß = -0.02 ± 0.01, P = 0.03; and ß = -0.02 ± 0.01 
pg/L, P = 0.02, respectively) while IL-10 was positively associated with BMI (ß = 0.05 ± 
0.02 pg/L, P = 0.02). IL-13 was positively associated with both BMI (ß = 0.06 ± 0.03 
pg/L, P = 0.03) and TBF (ß = 0.03 ± 0.01 pg/L, P = 0.02).  Season of blood draw was 
also an important predictor of hs-CRP levels in all women. Non winter seasons (i.e. 
spring, summer and fall) were associated with lower hs-CRP concentraion (ß = -0.67 ± 
0.30 mg/L, P = 0.03).  
Crude and adjusted linear associations between serum 25-OHD and inflammatory 
factors are shown in Table 37. Among all women, results adjusted for season, physical 
activity level, adiposity, multivitamin intake, and lifestyle (alcohol, smoking, or oral 
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contraceptive use), showed no significant associations between with 25-OHD levels  and 
log-transformed inflammatory factors. However, among women with low 25-OHD (< 75 
nmol/L) (Table 31), 25-OHD levels were negatively associated with IL-2 concentrations 
after controlling for season, physical activity level, total body fat percentage, alcohol and 
multivitamin intake (ß = -0.02 ± 0.01pg/mL, P = 0.04). Thus, among women with low 
25-OHD, an increase of 1 nmol/L in serum 25-OHD concentration is associated with a 
2.1% lower change in IL-2 level [(i.e. e
-0.021  – 1) x 100]. Similarly, among women with 
low 25-OHD (< 75 nmol/L), serum 25-OHD levels were negatively associated with GM-
CSF concentrations (Table 33), after adjustment for season, physical activity level, waist 
to height ratio, alcohol intake and multivitamin intake (ß = -0.022 ± 0.011 pg/mL, P = 
0.04). Finally, multivariable adjusted regressions also showed that among women with 
25-OHD < 75 nmol/L, serum 25-OHD levels were associated with both IL-6 and IL-7 (ß 
= -0.020 pg/mL, P = 0.05), (Table 35). 
 
5.4 Discussion 
Vitamin D modulates inflammatory cytokines in isolate immune cells, but it is unclear 
whether serum 25-OHD status impacts circulating cytokine levels in young women. In 
this population of young healthy women (18-30 years), we found that among women with 
evidence of vitamin D insufficiency (25-OHD < 75 nmol/L), serum 25-hydroxyvitamin D 
level was negatively associated with pro-inflammatory cytokines such as interleukin-(IL-
2) and granulocute macrophage colony stimulating factor (GM-CSF) after adjustment for 
factors such as season, physical activity level, adiposity, multivitamin intake, and alcohol 
intake (P = 0.04). Low 25-OHD was also marginally associated with decreases in serum 
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concentrations of the inflammatory cytokines IL-6 and IL-7 (P = 0.05). No significant 
associations were observed for 25-OHD and concentrations of IL-1ß, IL-4, IL-5, IL-8, 
IL-10, IL-12, IL-13, TNF-α and IFN-γ (P > 0.05).  
 
5.4.1 Serum 25-OHD and Cytokine Levels 
The role of vitamin D in modulating cytokines levels is largely supported by research 
indicating that supplemental vitamin D intake increases the levels of anti-inflammatory 
cytokines (especially IL-10), and simultaneously lowers or attenuates the increase of pro-
inflammatory cytokines, notably IL-1β and TNF-α [43-46]. Pro-inflammatory cytokines 
function primarily to induce inflammation as a result of infection or trauma. They 
typically initiate the cascade of inflammatory mediators by targeting endothelial cells 
[47]. Anti-inflammatory cytokines on the other hand block the inflammatory cascade 
initiated by pro-inflammatory cytokines [47, 48]. They work together with specific 
cytokine inhibitors and soluble cytokine receptors to regulate the human immune 
response [47, 48].  
Although the exact mechanism(s) explaining the  role of vitamin D  in immune 
modulation of humans is not fully known, in- vivo studies indicate that 1,25 
dihydroxyvitamin D (1,25(OH)2D), which is the biologically active form of vitamin D in 
blood, could influence gene transcription of specific cytokines [24-26]. 1,25(OH)2D is 
thought to exert its anti-inflammatory effects by binding to the vitamin D receptor 
(VDR), which is present in most immune cells [46, 49]. This ligand/receptor complex 
then binds to vitamin D response element (VDRE) in the promoter region of target tissues 
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to and alters the rate of gene transcription of certain cytokines (e.g., IL-10 and IL-8) and 
cytokine receptors (e.g., IL1-RL1) that are involved in innate immunity [46, 49, 50, 51]. 
Studies examining the association between vitamin D and inflammation have 
produced conflicting reports in overweight and obese adults, post-menopausal women, 
and in young apparently healthy young men and women [52-57]. One reason for this 
inconsistency in findings may be attributed to age-related differences. Differences in ages 
of subjects are important because the expression of the VDR decreases with age which 
can in turn reduce the capacity of vitamin D to mediate its biological activities [58].  
Barker et al. conducted a prospective study over two successive winter seasons 
among 28 non-smoking, physically active men and women (25 - 42 years) to evaluate 
whether circulating cytokines varies with alterations in serum 25-hydroxyvitamin D (25-
OHD) concentrations [59]. Participants provided fasting blood samples and a multiplex 
microsphere-bead array was used to measure circulating inflammatory 
cytokines. Vitamin D insufficiency was set at 25-OHD ≤ 80 nmol/L and sufficiency at 
25-OHD > 80 nmol/L. They found that levels of pro-inflammatory cytokines (interleukin 
(IL)-2, IL-1ß, TNF-α and IFN- γ) were significantly greater in subjects with 25-OHD ≤ 
80 nmol/L. Conversely, concentrations of the anti-inflammatory cytokine (i.e., IL-10) did 
not significantly differ by 25-OHD status. Our results are similar but also contrast the 
reports of Barker et al. We observed that among women with 25-OHD < 75 nmol/L, 25-
OHD was inversely associated with and macrophage colony stimulating factor (GM-
CSF) concentrations, but concentrations of IL-1ß, TNF-α IFN- γ, and Il-10 remained 
unchanged with vitamin D status after adjustment for season, physical activity level, 
adiposity, alcohol and multivitamin intake .  
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In the present study, serum 25-OHD levels were negatively associated with GM-
CSF concentrations among women with 25-OHD < 75 nmol/L, after adjustment for 
season, physical activity level, waist to height ratio, alcohol intake and multivitamin 
intake (ß = -0.022 ± 0.011 pg/mL, P = 0.04). Granulocyte-macrophage colony-
stimulating factor (GM-CSF) is an important immune modulator with profound effects on 
the functional activities of various circulating cytokines. Inflammatory cytokines, such as 
IL-1 and TNF-α serve as potent inducers of GM-CSF, but GM-CSF expression can be 
inhibited by IL-4, IL-10, and IFN- γ [60-63]. Multivariable adjusted regressions also 
showed that serum 25-OHD levels were marginally associated with the inflammatory 
markers IL-6 and IL-7 (ß = -0.020 ± 0.010 pg/mL, P = 0.05) in women with vitamin D 
insufficiency (25-OHD < 75 nmol/L). IL-6 is often used as a marker for systemic 
activation of pro-inflammatory cytokines [64] and its production is induced by 
lipopolysaccharide stimulation, along with presence of TNF-α and IL-1 [48].  Although 
IL-6 is generally considered to be a pro-inflammatory cytokine, it also possesses anti-
inflammatory properties (pleiotrophic). IL-6 is a potent inducer of acute-phase protein 
response [64]. It also inhibits the production of pro-inflammatory cytokines such as GM-
CSF and IFN-γ [65]. 
In our study, inflammatory factors were significantly correlated with one-another 
(P < 0.01), except for correlations of hs-CRP with other inflammatory markers. Levels of 
IL-1 and TNF-α were positively correlated with GM-CSF (r = 0.93 and r = 0.71, P < 0.01 
respectively) as were correlations between GM-CSF and IFN- γ, IL-4, and IL-10 (r = 
0.71, r = 0.53, r = 0.20; P < 0.01 respectively). These strong correlations between 
cytokines make it impossible for us to tease out the effects of  indiviual cytokines. 
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Further more, because our analyses made several  comparisons between 25-OHD status 
and inflammatory factors,  we are cautious in making any definite conclusions on 
associations between 25-OHD levels and inflammatory factors. Simply stated, our 
findings merely suggest that sub-optimal vitamin D levels may impact inflammatory 
response in young women. Prospective studies with larger cohorts are needed to 
determine if there is a causal relationship between low 25-OHD and inflammatory factors 
in young women. 
 
5.4.2 Serum 25-OHD and C-Reactive Protein 
C-reactive protein (CRP) is an acute-phase reactant protein synthesized by the liver in 
response to a variety of inflammatory cytokines [66]. Our results contrast with previous 
research that found positive associations between 25-OHD and hs-CRP concentraions in 
young women [67, 68]. Cross-sectional analyses of nationally representative data 
(National Health and Nutrition Examination Surveys, NHANES, 2001 to 2006) showed 
that after controlling for the effects of age, gender, and race, there was an inverse 
association between 25-OHD and CRP concentrations (ß = -0.30, P < 0.001) in 
asymptomatic adults with low vitamin D levels (below the population median, i.e. 25-
OHD < 52.5 nmol/L), [67]. However, this association became non-significant once the 
serum 25-OHD increased above the population median (≥ 52.5 nmol/L), (ß = -0.05, P = 
0.08). Our results contrast that of Amer and Qayyum, in that hs-CRP levels were not 
associated with 25-OHD concentration, even among women with 25-OHD < 75 nmol/L. 
Further adjustment for season BMI, physical activity level, alcohol intake, and 
multivitamin use did not reveal any significant changes in linear relations. We advise that 
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any comparison of our findings to other studies be done with caution, especially since our 
sample size was relatively small and statistical power may have limited.   
Garcia-Bailo et al. carried out a cross-sectional study among adult men (n = 428) 
and women (n = 975) aged 20-29 years that showed positive associations between plasma 
concentrations of 25-OHD and hs-CRP levels in women (ß = 0.011 ± 0.002, P < 0.0001) 
after controlling for factors such as age, gender, waist circumference, physical activity, 
ethnicity and season in the overall population [68]. Garcia-Bailo et al. also reported that 
women using hormonal contraceptives (HC) had significantly higher circulating 25-OHD 
(78.1 ± 33.9 vs. 51.1 ± 24.2 nmol/L, P < 0.0001) and hs-CRP (2.7 ± 3.3 vs. 0.8 ± 1.9 
mg/L, P < 0.0001) than non-HC users. We found no associations between 25-OHD and 
hs-CRP levels (ß = 0.011 ± 0.002 mg/L, P < 0.0001), and 25-OHD status and hs-CRP 
concentrations did not also differ between oral contraceptive (OC) users and non-users 
(83.0 ± 34.0 vs. 76.9 ± 31.1 nmol/L, P = 0.23; and 0.9 ± 2.8 vs. 0.8 ± 3.4 mg/L, P = 0.91, 
respectively). While the populations of both studies remain fairly similar with regard to 
mean age and BMI, our results contrast that of Garcia-Bailo et al., possibly because of 
differences in ethnicity.  About 49.6% of women in Garcia-Bailo et al’s study were 
Caucasian compared to 84.5% in our study. Future studies should consider examining 
associations between ethnicity and lifestyle factors (e.g., OC use) in young women as this 
may be important confounders of the association between 25-OHD and hs-CRP levels.  
  
5.4.3 Adiposity and Inflammation 
In this population of young women, uadjusted linear regressions showed significant 
relationships between adiposity and several cytokines (P < 0.05). To our knowledge, this 
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is the first study to examine associations of obesity markers (body mass index, BMI, total 
body fat percentage, TBF, waist cirfumference, WC, and waist to heigh ratio, WHtR) 
with inflammatory factors in young women. Marques-Vidal et al., evaluated associations 
between obesity markers (BMI, WC and TBF) and inflammatory markers IL-1β, IL-6, 
TNF-α and  hs-CRP in Caucasian adult ages 35-75 years [69]. After adjusting for age, 
physical activity, and smoking, they observed that obese women (BMI ≥ 30 kg/m2) had 
higher hs-CRP levels than overweight or normal women (mean hs-CRP: 2.24 ± 1.05 vs. 
1.47 ± 1.03 vs. 0.93 ± 1.03 mg/L, respectively; P < 0.001). In addition, BMI was 
negatively associated with IL-1β levels (ß = -0.005 ± 0.007 pg/mL, P < 0.05), and 
women with high TBF (≥ 32) or WC (≥ 80 cm) had higher levels of IL-6 (TBF: ß = 0.010 
± 0.003 pg/mL, P < 0.01; WC: ß = 0.011 ± 0.002 pg/mL, P < 0.001). Finally, positive 
associations also existed between TNF-α levels and BMI, TBF, and WC (BMI: ß = 0.019 
± 0.003 pg/mL, P < 0.001; TBF: ß = 0.006 ± 0.002 pg/mL, P < 0.01; WC: ß = 0.007 ± 
0.001 pg/mL, P < 0.001).  
BMI and TBF are common indicators of obesity, but WC and WHtR are often 
discounted as useful indicators of obesity. Among young adults, 18-30 years old, a waist 
circumference greater than 80 cm indicates central obesity (i.e., an excess of abdominal 
fat) and suggests increased visceral adiposity. Visceral fat is more metabolically active 
than subcutaneous fat [70, 71], and large deposits can disrupt fatty acid metabolism, 
increasing the influx of free fatty acids entering splanchnic circulation [72, 73]. Excessive 
amounts of unbound fatty acids in the blood contribute to hyperlipidemia and 
hypertriglyceridemia, both of which can promote or exacerbate obesity-related chronic 
conditions [74-76].  
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WHtR is a measure of the distribution of body fat [77, 78] and is especially useful 
in the assessment of health status for individuals with a higher percentage of muscle and 
a lower percentage of body fat (e.g., athletes). Among individuals less than 40 years, 
WHtR ≤ 0.5 is generally considered healthy [42]. In addition to BMI, future studies on 
obesity and inflammation should consider including WC and WHtR as proxies for 
obesity since both measures are easy to obtain and less intrusive/expensive than 
measuring dual energy x-ray absorptiometry. 
Some of the strengths of our study include assessment of several inflammatory 
biomarkers e.g., highly sensitive C-reactive protein (hs-CRP), interleukin (IL)-1β, 2, 4, 5, 
6, 7, 8, 10, 12p70, 13, granulocyte-macrophage-colony-stimulating factor (GM-CSF), 
interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) using multiplex 
microsphere-based assays. Radioimmuno assays were used assess serum levels of 25-
OHD, which is considered the best indicator of vitamin D status because it represents a 
summation of total cutaneous production of vitamin D and intake of vitamin D from 
foods [79-81]. Our population was comprised of mostly non-obese and few obese 
individuals; and we determined adiposity levels using DXA scans, which have been 
previously validated and found to accurately differentiate between women with 
acceptable/normal body fat and those with high or excess adiposity [82, 83]. An 
important limitation of our study is its cross-sectional design, which prevents us from 
speculating on cause-effect relationships between 25-OHD status, obesity markers, and 
inflammatory factors. Inflammation factors and 25-OHD status were assessed using a 
single serum sample which may not perfectly capture long-term changes of biomarkers, 
although previous research indicates that inflammation levels remain stable over time 
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[91]. We controlled for several factors including season of blood draw, physical activity 
level, adiposity, multivitamin use, and life style factors ( i.e. alcohol intake,  smoking 
status and oral contraceptive use) as these parameters could confound associations of 25-
OHD with inflammation [84-90]. However, it is still possible that there may be residual 
confounding by other unknown factors. Any comparison or interpretation of results 
should also be done with caution. Prospective studies are needed to better understand the 
role of 25-OHD and adiposity in inflammation. Our population was also fairly 
homogenous; with mostly non-obese and few obese individuals. All participants were 
also between 18 to 30 years, and the majorities were Caucasian. Our findings are 
therefore limited to young, non-obese, Caucasian women and may not be generalizable to 
women in other BMI categories, age groups or ethnicities.  
 
5.5 Conclusions and Significance 
Vitamin D insufficiency and increased adiposity have been linked with higher levels of 
inflammatory biomarkers in obese/older adults, and chronically ill patients. However, 
few studies have examined these associations in healthy young women. In the present 
study, we observed that IL-2, IL-6, IL-7, and GM-CSF concentrations were inversely 
associated with serum 25-OHD levels among women with vitamin D insufficiency (25-
OHD < 75 nmol/L). Significant positive associations were also observed between obesity 
markers and inflammatory factors in young women.  
Increased adiposity, high inflammation, and central obesity all tend to increase an 
individual’s risk for cardiovascular disease (CVD), whether or not the individual exhibits 
traditional CVD risk factors such as elevated lipid profile (triglyceride, cholesterol, and 
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low-density lipoprotein levels), smoking history, and presence of hypertension or 
diabetes. Prospective studies with larger cohorts are needed to establish causality, and to 
establish whether findings from our third study could be useful in informing routine 
screening in clinic settings for the prevention, early detection, and management of 
inflammation, an important cardiovascular disease (CVD) risk factors in young women. 
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Table 27. Median and Inter-Quartile Range Distribution of Inflammatory Biomarkers 
 
Inflammatory Factor (pg/mL) Median (Inter-Quartile Range) Min - Max 
IL-1ß 1.48 (2.14) 0.13 - 948.78 
IL-2 5.51 ( 6.33) 0.09 - 2581.44 
IL-4 0.18 (0.24) 0.13 - 41.29 
IL-5 2.26 (3.03) 0.16 - 324.25 
IL-6 2.00 (3.69) 0.14 - 50.92 
IL-7 1.72 (1.04) 0.14 - 91.73 
IL-8 10.52 (14.71) 0.50 - 1735.52 
IL-10 3.57 (7.47) 0.15 - 7093.24 
IL-12p70 2.28 (3.18) 0.15 - 227.51 
IL-13 7.08 (22.19) 0.12 - 238.37 
GM-CSF 4.66 (5.65) 0.51 - 64.26 
TNF-α 2.36 (3.84) 0.12 - 620.00 
IFN-γ 0.80 (3.30) 0.10 - 42.80 
hs-CRP (mg/L)
 ѣ
 0.71 (2.30) 0.13 - 48.18 
ѣ 
n = 171 for hs-CRP.  
Definition: Interleukin (IL), granulocyte-macrophage-colony-stimulating factor (GM-CSF), tumor 
necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and C-reactive protein (hs-CRP). 
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Table 28. Variations in Median and Inter-Quartile Range Distribution of Inflammatory Biomarkers  
by Serum 25-OHD Status 
 
Inflammatory Factor 
(pg/mL) 
Low 25-OHD < 75 nmol/L
§
 
(n = 92) 
High 25-OHD ≥ 75 nmol/L§ 
(n = 78) 
P
 Ϫ
 
 
Median (Inter-Quartile Range)  
IL-1ß 0.24 (0.80) 0.20 (0.67) 0.68 
IL-2 1.06 (1.58) 1.09 (1.71) 0.93 
IL-4 4.45 ( 5.37) 4.15 ( 5.55) 0.32 
IL-5 0.16 (0.21) 0.20 (0.22) 0.48 
IL-6 2.01 (2.90) 1.79 (3.64) 0.36 
IL-7 1.14 (2.27) 1.22 (2.73) 0.89 
IL-8 1.56 (0.79) 1.57 (0.94) 0.58 
IL-10 10.28 (16.32) 12.03 (21.46) 0.30 
IL-12p70 3.01 (8.87) 2.91 (9.58) 0.88 
IL-13 1.88 (3.52) 1.73 (3.84) 0.77 
GM-CSF 2.93 (8.87) 2.33 (8.10) 0.66 
TNF-α 3.09 (2.90) 3.05 (3.20) 0.96 
IFN-γ 1.57 (3.03) 1.37 (3.10) 0.77 
hs-CRP (mg/L)
 ѣ
 0.80 (3.20) 0.80 (5.00) 0.76 
§ 
2.496 nmol/L = 1 ng/mL.  
Ϫ
 P-values compare groups using Mann-Whitney tests. 
Ѣ
 n = 168 for hs-CRP. 
Definition: Interleukin (IL), granulocyte-macrophage-colony-stimulating factor (GM-CSF), tumor 
necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and C-reactive protein (hs-CRP). 
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Table 29. Variations in Median and Inter-Quartile Range Distribution of Inflammatory Biomarkers  
by Waist Circumference (WC) Measurement 
 
Inflammatory Factor 
(pg/mL) 
Low WC < 80 cm 
(n = 176) 
High WC ≥ 80 cm 
(n = 89) 
P
 Ϫ
 
 
Median (Inter-Quartile Range)  
IL-1ß 1.17 (2.40) 0.24 (0.83) < 0.01 
IL-2 1.52 (2.25) 1.20 (2.09) 0.37 
IL-4 5.38 ( 5.60) 5.98 ( 7.36) 0.58 
IL-5 0.17 (0.22) 0.21 (0.26) 0.18 
IL-6 2.15 (2.60) 2.58 (3.83) 0.08 
IL-7 2.49 (3.66) 1.01 (3.03) < 0.01 
IL-8 1.76 (1.28) 1.69 (1.09) 0.67 
IL-10 9.92 (11.56) 13.48 (16.26) 0.08 
IL-12p70 3.29 (6.05) 3.98 (12.61) 0.29 
IL-13 2.29 (2.66) 2.28 (3.84) 0.62 
GM-CSF 11.63 (24.47) 2.95 (8.22) < 0.01 
TNF-α 5.18 (6.02) 3.22 (3.24) < 0.01 
IFN-γ 2.70 (3.61) 1.70 (4.09) 0.11 
hs-CRP (mg/L)
 ѣ
 0.70 (3.55) 0.90 (3.30) 0.95 
Ϫ
 P-values compare groups using Mann-Whitney tests. 
Ѣ
 n = 171 for hs-CRP. 
Definition: Interleukin (IL), granulocyte-macrophage-colony-stimulating factor (GM-CSF), tumor 
necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and C-reactive protein (hs-CRP). 
 
  
   193 
 
Table 30. Variations in Median and Inter-Quartile Range Distribution of Inflammatory Biomarkers  
by Body Mass Index (BMI) 
 
Inflammatory Factor 
(pg/mL) 
Low BMI < 25 kg/m
2
 
(n = 208) 
High BMI ≥ 25 kg/m2 
(n = 57) 
P
 Ϫ
 
 
Median (Inter-Quartile Range)  
IL-1ß 0.80 (2.32) 0.25 (2.06) 0.08 
IL-2 1.50 (2.24) 1.20 (1.85) 0.36 
IL-4 5.49 ( 6.10) 5.63 ( 6.37) 0.85 
IL-5 0.18 (0.24) 0.20 (0.22) 0.95 
IL-6 2.06 (3.02) 2.97 (4.57) 0.02 
IL-7 2.13 (3.83) 1.57 (3.43) 0.24 
IL-8 1.72 (1.12) 1.75 (0.75) 0.55 
IL-10 10.02 (16.34) 12.99 (12.16) 0.16 
IL-12p70 3.33 (6.05) 4.60 (13.21) 0.13 
IL-13 2.29 (3.05) 2.28 (3.49) 0.52 
GM-CSF 7.86 (23.36) 3.37 (16.04) 0.05* 
TNF-α 4.86 (5.79) 3.87 (4.80) 0.55 
IFN-γ 2.46 (3.80) 2.16 (3.86) 0.61 
hs-CRP (mg/L)
 ѣ
 0.80 (3.90) 0.60 (1.30) 0.10 
Ϫ
 P-values compare groups using Mann-Whitney tests. 
Ѣ
 n = 171 for hs-CRP. 
*  
Estimated P-value is borderline significant (P = 0.049). 
Definition: Interleukin (IL), granulocyte-macrophage-colony-stimulating factor (GM-CSF), tumor 
necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and C-reactive protein (hs-CRP). 
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Table 31. Variations in Median and Inter-Quartile Range Distribution of Inflammatory Biomarkers  
by Total Body Fat Percentage (TBF %):  
 
Inflammatory Factor  
(pg/mL) 
Low TBF < 32 % 
(n = 131) 
High TBF ≥ 32% 
(n = 139) 
P
 Ϫ
 
 
Median (Inter-Quartile Range)  
IL-1ß 0.85 (2.34) 0.56 (2.16) 0.22 
IL-2 1.45 (2.01) 1.51 (2.30) 0.55 
IL-4 5.36 ( 5.38) 5.89 ( 6.83) 0.34 
IL-5 0.18 (0.24) 0.19 (0.24) 0.51 
IL-6 2.06 (2.46) 2.55 (3.69) 0.03 
IL-7 2.35 (4.11) 1.77 (3.44) 0.46 
IL-8 1.71 (1.08) 1.75 (1.01) 0.42 
IL-10 9.91 (11.64) 11.72 (17.92) 0.14 
IL-12p70 3.25 (6.03) 4.01 (11.83) 0.34 
IL-13 2.13 (2.26) 2.41 (3.70) 0.15 
GM-CSF 8.47 (23.23) 5.47 (20.03) 0.34 
TNF-α 4.57 (5.98) 4.74 (4.93) 0.92 
IFN-γ 2.63 (3.87) 2.20 (3.88) 0.42 
hs-CRP (mg/L)
 ѣ
 0.80 (4.40) 0.80 (2.90) 0.56 
Ϫ
 P-values compare groups using Mann-Whitney tests. 
Ѣ
 n = 171 for hs-CRP. 
Definition: Interleukin (IL), granulocyte-macrophage-colony-stimulating factor (GM-CSF), tumor 
necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and C-reactive protein (hs-CRP). 
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Table 32. Median Inflammatory Biomarker Concentration by Categories of Oral Contraceptive Use, Smoking Status and 
Alcohol Intake 
 
 Oral Contraceptive Use  Smoking Status  Alcohol Intake  
Inflammatory 
Factor (pg/mL) No (152) 
 
Yes (113) 
 
No (249) 
 
Yes (15) 
 
No ( 112) 
 
Yes(59) 
 
 
Median  
(Inter-Quartile Range) 
P
 Ϫ
 Median  
(Inter-Quartile Range) 
P
 Ϫ
 Median  
(Inter-Quartile Range) 
P
 Ϫ
 
IL-1ß 0.64 (2.41) 0.74 (2.21) 0.81 0.72 (2.32) 0.43 (0.72) 0.57 0.77 (2.24) 0.70 (2.34) 0.62 
IL-2 1.38 (2.00) 1.52 (2.21) 0.33 1.47 (2.16) 1.48 (1.55) 0.84 1.02 (2.17) 1.53 (2.18) 0.07 
IL-4 5.61 (6.40) 5.45 (5.61) 0.67 5.45 (5.97) 6.57 (7.63) 0.36 4.15 (6.57) 5.97 (6.15) 0.05 
IL-5 0.17 (0.24) 0.19 (0.23) 0.52 0.18 (0.23) 0.17 (0.36) 0.64 0.18 (0.26) 0.19 (0.22) 0.96 
IL-6 2.04 (2.86) 2.64 (3.29) 0.08 2.21 (2.96) 2.47 (5.19) 0.59 2.01 (3.18) 2.37 (2.99) 0.40 
IL-7 1.85 (3.72) 2.17 (3.62) 0.24 2.11 (3.75) 1.70 (3.02) 0.82 2.17 (3.51) 1.97 (4.15) 0.78 
IL-8 1.72 (1.08) 1.75 (1.04) 0.86 1.72 (1.02) 1.54 (2.24) 0.88 1.68 (0.98) 1.74 (1.13) 0.73 
Ϫ
 P-values compare groups using Mann-Whitney tests. 
Definition: Interleukin (IL), granulocyte-macrophage-colony-stimulating factor (GM-CSF), tumor necrosis factor-alpha 
(TNF-α), interferon-gamma (IFN-γ), and C-reactive protein (hs-CRP). 
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Table 32. Continued  
 
 
  
 Oral Contraceptive Use  Smoking Status  Alcohol Intake  
Inflammatory  
Factor (pg/mL)    No ( 152) 
 
    Yes (113) 
 
      No (249) 
 
    Yes (15 ) 
 
No ( 112) 
 
Yes( 59) 
 
 
Median  
(Inter-Quartile Range) 
  P
 Ϫ
 Median  
(Inter-Quartile Range) 
P
 Ϫ
 Median  
(Inter-Quartile Range) 
P
 Ϫ
 
IL-10 11.07 (13.43) 9.91 (16.69) 0.59 10.52 (14.26) 9.92 (18.03) 0.89 10.04 (20.24) 10.92 (13.41) 0.81 
IL-12p70 3.25 (5.80) 4.19 (10.23) 0.24 3.37 (7.44) 4.65 (11.39) 0.62 3.57 (8.54) 3.55 (7.27) 0.77 
IL-13 2.23 (3.21) 2.40 (3.13) 0.50 2.28 (3.16) 2.49 (3.86) 0.79 1.77 (2.10) 2.43 (3.25) 0.06 
GM-CSF 6.35 (23.22) 7.59 (21.35) 0.59 7.15 (23.15) 5.31 (11.77) 0.91 7.29 (19.87) 6.96 (23.54) 0.35 
TNF-α 4.24 (5.57) 5.09 (5.36) 0.09 4.82 (5.75) 3.67 (3.51) 0.44 4.35 (5.30) 4.83 (5.85) 0.93 
IFN-γ 2.18 (3.96) 2.96 (3.49) 0.05 2.36 (3.88) 2.29 (3.15) 0.95 2.16 (4.35) 2.43 (3.84) 0.69 
hs-CRP (mg/L)
 ѣ
 0.75 (3.80) 0.90 (2.80) 0.91 0.80 (3.30) 0.60 (1.50) 0.67 1.00 (4.50) 0.60 (2.45) 0.19 
Ϫ
 P-values compare groups using Mann-Whitney tests. 
Ѣ
 n = 171 for hs-CRP. 
Definition: Interleukin (IL), granulocyte-macrophage-colony-stimulating factor (GM-CSF), tumor necrosis factor-alpha (TNF-α), 
interferon-gamma (IFN-γ), and C-reactive protein (hs-CRP). 
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Table 33. Pearson Product Correlations between Log Transformed Inflammatory Factors  
 
 log 
il_1ß 
log  
il_2 
log  
il_4 
log 
 il_5 
log 
 il_6 
log 
 il_7 
log  
il_8 
log 
il_10 
log 
il_12 
log 
il_13 
log 
gm_csf 
log 
tnf_α 
log 
ifn_γ 
log  
hs-crp 
log il_1ß ---              
log il_2 0.65
* 
---             
log il_4 0.54
*
 0.63
*
 ---            
log il_5 0.37
*
 0.43
*
 0.37
*
 ---           
log il_6 0.27
*
 0.44
*
 0.36
*
 0.29
*
 ---          
log il_7 0.78
*
 0.63
*
 0.53
*
 0.43
*
 0.55
*
 ---         
log il_8 0.41
*
 0.45
*
 0.49
*
 0.32
*
 0.41
*
 0.48
*
 ---        
log il_10 0.25
*
 0.43
*
 0.33
*
 0.46
*
 0.65
*
 0.51
*
 0.40
*
 ---       
log il_12 0.31
*
 0.57
*
 0.40
*
 0.36
*
 0.80
*
 0.57
*
 0.36
*
 0.69 ---      
log il_13 0.47
*
 0.60
*
 0.53
*
 0.45
*
 0.61
*
 0.71
*
 0.43
*
 0.57
*
 0.66
*
 ---     
log gm_csf 0.93
*
 0.66
*
 0.53
*
 0.34
*
 0.26
*
 0.77
*
 0.38
*
 0.20
*
 0.29
*
 0.46
*
 ---    
log tnf_α 0.85* 0.53* 0.43* 0.34* 0.27* 0.72* 0.41* 0.19* 0.23* 0.39* 0.82* ---   
log ifn_γ 0.71* 0.76* 0.60* 0.48* 0.45* 0.74* 0.45* 0.41* 0.50* 0.66* 0.71* 0.62* ---  
log hs-crp 0.02 
(0.76) 
0.01 
(0.85) 
0.10 
(0.19) 
0.04 
(0.64) 
0.004 
(0.96) 
-0.04 
(0.63) 
0.13 
(0.11) 
0.01 
(0.89) 
0.02 
(0.77) 
-0.01 
(0.92) 
0.03 
(0.66) 
-0.004 
(0.96) 
0.02 
(0.80) 
--- 
 
  All values in parentheses are P-values 
* 
Indicates
  
P-values are significant at P < 0.001.  
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   Table 34. Correlations between Log Transformed Inflammatory Factors and Serum 25-OHD Levels  
 
Inflammatory Factor (pg/mL) 
Serum 25-OHD Levels 
Correlation Coefficient (r) 
 
P-value 
log IL-1ß -0.03 0.72 
log IL-2 -0.07 0.34 
log IL-4 -0.05 0.56 
log IL-5  0.04 0.58 
log IL-6 -0.07 0.33 
log IL-7 -0.01 0.85 
log IL-8  0.02 0.80 
log IL-10  0.08 0.29 
log IL-12p70 -0.03 0.66 
log IL-13 -0.04 0.67 
log GM-CSF -0.09 0.26 
log TNF-α -0.003 0.97 
log IFN-γ -0.04 0.63 
log hs-CRP (mg/L)
 ѣ
   0.10 0.21 
Ϫ
 
₸
 r (Correlation Coefficient) and P-value for significance estimated using Pearson’s Product.  
Ѣ
 n = 171 for hs-CRP. 
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Table 35. Mean Serum 25-OHD Concentration across Categories of High Sensitive C - Reactive Protein  
(hs-CRP) Measures 
 
hs-CRP Concentration (mg/L) 
 
             < 1 mg/L (n = 94)      ≥ 1 mg/L (n = 74) 
 Mean ± Standard Deviation P-value
 ⱶ
 
Serum 25-OHD, nmol/L 76.7 ±  32.1 82.8 ± 33.0 0.23 
 
 
             < 3 mg/L (n = 119)      ≥ 3 mg/L (n = 49) 
 Mean ± Standard Deviation P-value
 ⱶ
 
Serum 25-OHD, nmol/L 77.1 ±  32.2 85.1 ± 33.0 0.15 
 
 
                 < 5 mg/L (n = 135)      ≥ 5 mg/L (n = 33) 
                                     Mean ± Standard Deviation                   P-value
 ⱶ
 
Serum 25-OHD, nmol/L 76.4 ±  31.1 91.6 ± 35.8           0.02 
ⱶ
 P-values compare groups using student t-tests 
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Figure 21. Lowess Regression Curve for the Association between High Sensitive C - Reactive Protein (hs-CRP) and Serum 25-OHD 
Concentration 
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Figure 22. Lowess Regression Curve for the Association between Interleukin-1β (IL-1β) and Serum 25-OHD Concentration 
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Figure 23. Lowess Regression Curve for the Association between Interleukin-2 (IL-2) and Serum 25-OHD Concentration 
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Figure 24. Lowess Regression Curve for the Association between Interleukin-4 (IL-4) and Serum 25-OHD Concentration 
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Figure 25. Lowess Regression Curve for the Association between Interleukin-5 (IL-5) and Serum 25-OHD Concentration 
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Figure 26. Lowess Regression Curve for the Association between Interleukin-6 (IL-6) and Serum 25-OHD Concentration 
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Figure 27. Lowess Regression Curve for the Association between Interleukin-7 (IL-7) and Serum 25-OHD Concentration 
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Figure 28. Lowess Regression Curve for the Association between Interleukin-8 (IL-8) and Serum 25-OHD Concentration 
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Figure 29. Lowess Regression Curve for the Association between Interleukin-10 (IL-10) and Serum 25-OHD Concentration 
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Figure 30. Lowess Regression Curve for the Association between Interleukin-12 (IL-12p70) and Serum 25-OHD Concentration 
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Figure 31. Lowess Regression Curve for the Association between Interleukin-13 (IL-13) and Serum 25-OHD Concentration 
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Figure 32. Lowess Regression Curve for the Association between Granulocyte Macrophage Colony Stimulating Factor  
(GM-CSF) and Serum 25-OHD Concentration 
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Figure 33. Lowess Regression Curve for the Association between Tumor Necrosis Factor Alpha (TNF-α) and Serum 25-OHD 
Concentration 
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Figure 34. Lowess Regression Curve for the Association between Interferon Gamma (IFN-γ) and Serum 25-OHD Concentration 
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Table 36. Univariate Linear Relationship between
 
log Transformed Inflammatory Biomarkers and Other Parameters  
  
                   log hs-CRP                          log IL-1β  
 
Predictor 
Unadjusted 
ß ± SE 
 
P-value 
Unadjusted 
ß ± SE 
 
P-value 
Age,  y
 
-0.04 ± 0.04 0.32 -0.02 ± 0.03 0.57 
Body Mass Index, kg/m
2
 -0.04 ± 0.04 0.26 -0.03 ± 0.03 0.28 
Total Body Fat, % -0.01 ± 0.01 0.68 -0.01 ± 0.01 0.34 
Waist Circumference, cm -0.01 ± 0.01 0.59 -0.02 ± 0.01 0.03 
Waist to Height Ratio -1.05 ± 2.35 0.66 -3.66 ± 1.63 0.03 
Education 
a 
- 0.06 ± 0.30 0.83 - 0.21 ± 0.23 0.37 
Season of blood draw 
 b
 -0.67 ± 0.30 0.03 -0.08 ± 0.24 0.73 
Smoking status 
c 
0.27 ± 0.53 0.61 0.21 ± 0.38 0.58 
Alcohol intake 
c 
-0.35 ± 0.25 0.16 -0.30 ± 0.20 0.88 
Oral Contraceptive use 
c 
-0.04 ± 0.25 0.88 -0.05 ± 0.18 0.77 
Physical activity level, MET-hrs/week
 
0.002 ± 0.003 0.54 -0.02 ± 0.002 0.41 
Multivitamin intake, g/day 
c 
-0.20 ± 0.24 0.40 -0.34 ± 0.18 0.06 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using simple linear regressions. 
Beta coefficient represents change in inflammatory factor level per unit change in predictor. 
a 
Dummy variable (0 =  Some College, 1= College Graduate) 
b 
Dummy variable (0 = winter/ 1 = non-winter, i.e. Spring, Summer, Fall). 
c 
Dummy variable (0 = no / 1 = yes). 
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Table 36. Continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                         log IL-2                           log IL-4  
 
Predictor 
Unadjusted 
ß ± SE 
 
P-value 
Unadjusted 
ß ± SE 
 
P-value 
Age,  y
 
-0.02 ± 0.03 0.37 -0.01 ± 0.03 0.77 
Body Mass Index, kg/m
2
 0.01 ± 0.02 0.56 0.04 ± 0.02 0.09 
Total Body Fat, % 0.01 ± 0.01 0.20 0.02 ± 0.01 0.06 
Waist Circumference, cm -0.001 ± 0.01 0.87 0.01 ± 0.01 0.16 
Waist to Height Ratio -4.62 ± 1.48 0.76 -1.55 ± 1.34 0.25 
Education 
a 
- 0.24 ± 0.21 0.25 - 0.12 ± 0.19 0.54 
Season of blood draw 
 b
 -0.33 ± 0.22 0.13 -0.05 ± 0.20 0.80 
Smoking status 
c 
0.28 ± 0.34 0.40 0.24 ± 0.31 0.44 
Alcohol intake 
c 
0.17 ± 0.18 0.34 0.16 ± 0.16 0.34 
Oral Contraceptive use 
c 
0.13 ± 0.16 0.40 -0.01 ± 0.14 0.97 
Physical activity level, MET-hrs/week
 
-0.002 ± 0.002 0.19 -0.001 ± 0.002 0.38 
Multivitamin intake, g/day 
c 
-0.20 ± 0.16 0.22 -0.24 ± 0.15 0.10 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using simple linear regressions. 
Beta coefficient represents change in inflammatory factor level per unit change in predictor. 
a 
Dummy variable (0 =  Some College, 1= College Graduate) 
b 
Dummy variable (0 = winter/ 1 = non-winter, i.e. Spring, Summer, Fall). 
c 
Dummy variable (0 = no / 1 = yes). 
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Table 36. Continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                       log IL-5                            log IL-6  
 
Predictor 
Unadjusted 
ß ± SE 
 
P-value 
Unadjusted 
ß ± SE 
 
P-value 
Age,  y
 
-0.03 ± 0.02 0.13 0.03 ± 0.03 0.30 
Body Mass Index, kg/m
2
 0.01 ± 0.02 0.67 0.08 ± 0.02 < 0.01 
Total Body Fat, % 0.01 ± 0.01 0.26 0.03 ± 0.01 < 0.01 
Waist Circumference, cm 0.01 ± 0.01 0.32 0.02 ± 0.01 0.03 
Waist to Height Ratio -0.82 ± 0.99 0.41 3.10 ± 1.53 0.04 
Education 
a 
-0.20 ± 0.14 0.16 0.12 ± 0.22 0.57 
Season of blood draw 
 b
 0.01 ± 0.15 0.94 0.21 ± 0.23 0.36 
Smoking status 
c 
-0.03 ± 0.23 0.89 0.17 ± 0.35 0.62 
Alcohol intake 
c 
0.004 ± 0.12 0.98 0.01 ± 0.19 0.96 
Oral Contraceptive use 
c 
0.07 ± 0.11 0.54 0.18 ± 0.17 0.28 
Physical activity level, MET-hrs/week
 
0.001 ± 0.001 0.43 -0.002 ± 0.002 0.26 
Multivitamin intake, g/day 
c 
-0.20 ± 0.11 0.07 -0.09 ± 0.17 0.58 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using simple linear regressions. 
Beta coefficient represents change in inflammatory factor level per unit change in predictor. 
a 
Dummy variable (0 =  Some College, 1= College Graduate) 
b 
Dummy variable (0 = winter/ 1 = non-winter, i.e. Spring, Summer, Fall). 
c 
Dummy variable (0 = no / 1 = yes). 
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Table 36. Continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                          log IL-7                           log IL-8  
 
Predictor 
Unadjusted 
ß ± SE 
 
P-value 
Unadjusted 
ß ± SE 
 
P-value 
Age,  y
 
0.001 ± 0.03 0.97 -0.01 ± 0.02 0.44 
Body Mass Index, kg/m
2
 0.003 ± 0.03 0.90 0.02 ± 0.01 0.09 
Total Body Fat, % 0.002 ± 0.01 0.83 0.01 ± 0.01 0.37 
Waist Circumference, cm -0.01 ± 0.01 0.11 0.01 ± 0.01 0.07 
Waist to Height Ratio -2.16 ± 1.55 0.16 1.30 ± 0.83 0.12 
Education 
a 
- 0.16 ± 0.22 0.46 - 0.03 ± 0.11 0.83 
Season of blood draw 
 b
 0.17 ± 0.23 0.47 -0.05 ± 0.12 0.68 
Smoking status 
c 
0.24 ± 0.35 0.50 0.48 ± 0.19 0.01 
Alcohol intake 
c 
0.35 ± 0.19 0.86 -0.10 ± 0.10 0.34 
Oral Contraceptive use 
c 
0.24 ± 0.17 0.15 0.03 ± 0.09 0.72 
Physical activity level, MET-hrs/week
 
-0.003 ± 0.002 0.15 0.001 ± 0.001 0.58 
Multivitamin intake, g/day 
c 
-0.18 ± 0.17 0.29 -0.03 ± 0.09 0.70 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using simple linear regressions. 
Beta coefficient represents change in inflammatory factor level per unit change in predictor. 
a 
Dummy variable (0 =  Some College, 1= College Graduate) 
b 
Dummy variable (0 = winter/ 1 = non-winter, i.e. Spring, Summer, Fall). 
c 
Dummy variable (0 = no / 1 = yes). 
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Table 36. Continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                        log IL-10                             log IL-12p70  
 
Predictor 
Unadjusted 
ß ± SE 
 
P-value 
Unadjusted 
ß ± SE 
 
P-value 
Age,  y
 
0.03 ± 0.02 0.24 0.01 ± 0.04 0.81 
Body Mass Index, kg/m
2
 0.05 ± 0.02 0.02 0.07 ± 0.04 0.05 
Total Body Fat, % 0.02 ± 0.01 0.06 0.02 ± 0.01 0.09 
Waist Circumference, cm 0.01 ± 0.01 0.10 0.01 ± 0.01 0.35 
Waist to Height Ratio 1.90 ± 1.27 0.14 1.53 ± 2.17 0.48 
Education 
a 
0.11 ± 0.18 0.54 - 0.02 ± 0.31 0.94 
Season of blood draw 
 b
 -0.08 ± 0.19 0.69 0.10 ± 0.32 0.76 
Smoking status 
c 
-0.05 ± 0.28 0.86 0.22 ± 0.49 0.65 
Alcohol intake 
c 
-0.02 ± 0.16 0.91 -0.01 ± 0.27 0.97 
Oral Contraceptive use 
c 
-0.05 ± 0.14 0.69 0.19 ± 0.23 0.41 
Physical activity level, MET-hrs/week
 
0.0003 ± 0.002 0.83 -0.0003 ± 0.003 0.93 
Multivitamin intake, g/day 
c 
-0.02 ± 0.14 0.88 -0.34 ± 0.23 0.15 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using simple linear regressions. 
Beta coefficient represents change in inflammatory factor level per unit change in predictor. 
a 
Dummy variable (0 =  Some College, 1= College Graduate) 
b 
Dummy variable (0 = winter/ 1 = non-winter, i.e. Spring, Summer, Fall). 
c 
Dummy variable (0 = no / 1 = yes). 
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Table 36. Continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                         log IL-13                            log GM-CSF  
 
Predictor 
Unadjusted 
ß ± SE 
 
P-value 
Unadjusted 
ß ± SE 
 
P-value 
Age,  y
 
-0.003 ± 0.03 0.93 -0.03 ± 0.03 0.38 
Body Mass Index, kg/m
2
 0.06 ± 0.03 0.03 -0.03 ± 0.03 0.27 
Total Body Fat, % 0.03 ± 0.01 0.02 -0.01 ± 0.01 0.66 
Waist Circumference, cm 0.01 ± 0.01 0.40 -0.02 ± 0.01 0.02 
Waist to Height Ratio 1.63 ± 1.61 0.31 -4.28 ± 1.78 0.02 
Education 
a 
-0.20 ± 0.23 0.38 - 0.28 ± 0.25 0.27 
Season of blood draw 
 b
 0.31 ± 0.24 0.19 -0.05 ± 0.27 0.86 
Smoking status 
c 
0.16 ± 0.37 0.67 0.03 ± 0.41 0.93 
Alcohol intake 
c 
0.19 ± 0.20 0.32 0.26 ± 0.22 0.23 
Oral Contraceptive use 
c 
0.16 ± 0.17 0.36 0.16 ± 0.19 0.41 
Physical activity level, MET-hrs/week
 
-0.003 ± 0.002 0.13 -0.003 ± 0.002 0.26 
Multivitamin intake, g/day 
c 
-0.24 ± 0.17 0.17 -0.23 ± 0.20 0.23 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using simple linear regressions. 
Beta coefficient represents change in inflammatory factor level per unit change in predictor. 
a 
Dummy variable (0 =  Some College, 1= College Graduate) 
b 
Dummy variable (0 = winter/ 1 = non-winter, i.e. Spring, Summer, Fall). 
c 
Dummy variable (0 = no / 1 = yes). 
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Table 36. Continued  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                       log TNF-α                          log IFN-γ 
 
Predictor 
Unadjusted 
ß ± SE 
 
P-value 
Unadjusted 
ß ± SE 
 
P-value 
Age,  y
 
-0.01 ± 0.02 0.50 -0.01 ± 0.03 0.82 
Body Mass Index, kg/m
2
 0.001 ± 0.01 0.93 -0.004 ± 0.03 0.87 
Total Body Fat, % 0.002 ± 0.01 0.68 0.0003 ± 0.01 0.97 
Waist Circumference, cm -0.01 ± 0.01 0.33 -0.01 ± 0.01 0.19 
Waist to Height Ratio -0.82 ± 0.86 0.34 -2.05 ± 1.65 0.21 
Education 
a 
- 0.08 ± 0.12 0.52 - 0.14 ± 0.23 0.55 
Season of blood draw 
 b
 0.04 ± 0.13 0.76 -0.15 ± 0.25 0.53 
Smoking status 
c 
-0.14 ± 0.20 0.47 0.40 ± 0.38 0.29 
Alcohol intake 
c 
0.01 ± 0.11 0.90 -0.02 ± 0.20 0.93 
Oral Contraceptive use 
c 
0.16 ± 0.09 0.08 0.36 ± 0.18 0.05 
Physical activity level, MET-hrs/week
 
-0.0001 ± 0.001 0.91 -0.0003 ± 0.002 0.90 
Multivitamin intake, g/day 
c 
-0.08 ± 0.09 0.42 -0.10 ± 0.18 0.59 
ϖ 
Regression coefficients (ß) ± standard errors (SE). All analyses were estimated using simple linear regressions. 
Beta coefficient represents change in inflammatory factor level per unit change in predictor. 
a 
Dummy variable (0 =  Some College, 1= College Graduate) 
b 
Dummy variable (0 = winter/ 1 = non-winter, i.e. Spring, Summer, Fall). 
c 
Dummy variable (0 = no / 1 = yes). 
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Table 37. Association
 
of Serum 25-OHD Concentrations with Log Transformed Inflammatory Biomarkers (Beta ± SE)
§
  
in Young Women: UMass Amherst Vitamin D Status Study, 2006 – 2011 
 
Y =  log (high sensitive C-Reactive Protein Concentration, mg/L) 
 25-OHD, nmol/L 
All women (n = 168) 
25-OHD < 75 nmol/L 
 (n = 90) 
25-OHD ≥ 75 nmol/L  
(n = 78) 
ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 
Model 1
Ж 
0.005 ± 0.004 0.21  0.014 ± 0.012 0.23 0.008 ± 0.007 0.31 
Model 2
 ╧
 0.004 ± 0.004 0.27 0.013 ± 0.011 0.27 0.008 ± 0.007 0.29 
Model 3
 ₸
 0.004 ± 0.004 0.33 0.014 ± 0.011 0.22 0.009 ± 0.008 0.26 
 
Y =  log (Interleukin-1ß Concentration, pg/mL) 
 25-OHD, nmol/L 
All women (n = 170) 
25-OHD < 75 nmol/L 
 (n = 92) 
25-OHD ≥ 75 nmol/L  
(n = 78) 
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 
Model 1
Ж 
-0.001 ± 0.003 0.72  -0.013 ± 0.010 0.19 -0.002 ± 0.006 0.76 
Model 2
 ┴
 -0.002 ± 0.003 0.54 -0.013 ± 0.009 0.17 -0.002 ± 0.006 0.80 
Model 3
 ┬
 -0.001 ± 0.003 0.67 -0.013 ± 0.009 0.15 -0.003 ± 0.006 0.64 
ϖ 
Regression coefficients: Beta (ß) ± standard errors (SE). Beta coefficient represents change in inflammatory factor level 
per 1-nmol/L change in serum 25-OHD concentration. 
Ϫ 
P-values estimated using simple or multiple linear regressions. 
Ж 
Model 1: Unadjusted. 
╧
 Model 2: Adjusted for season and body mass index. 
₸
 Model 3: Adjusted for season and body mass index, multivitamin intake, alcohol intake and physical activity level. 
┴
 Model 2: Adjusted for season and waist circumference. 
┬
 Model 3: Adjusted for season, waist circumference, multivitamin intake, smoking status and physical activity level. 
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Table 37. Continued 
 
 
 
 
 
Y =  log (Interleukin-2 Concentration, pg/mL) 
 25-OHD, nmol/L 
All women (n = 170) 
25-OHD < 75 nmol/L 
 (n = 92) 
25-OHD ≥ 75 nmol/L  
(n = 78) 
ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 
Model 1
Ж 
-0.003 ± 0.003 0.34  -0.021 ± 0.010  0.05
* 
-0.006 ± 0.006 0.33 
Model 2
 ╧
 -0.004 ± 0.003 0.20 -0.020 ± 0.010 0.05 -0.006 ± 0.006 0.35 
Model 3
 ₸
 -0.003 ± 0.003 0.32 -0.021± 0.010 0.04 -0.006 ± 0.006 0.36 
 
Y =  log (Interleukin-4 Concentration, pg/mL) 
Model 1
Ж 
-0.002 ± 0.003 0.54  -0.005 ± 0.010 0.60 -0.003 ± 0.005 0.61 
Model 2
 ╧
 -0.002 ± 0.003 0.38 -0.005 ± 0.010 0.65 -0.002 ± 0.005 0.64 
Model 3
 ₸
 -0.002 ± 0.003 0.49 -0.004 ± 0.011 0.69 -0.003 ± 0.005 0.49 
ϖ 
Regression coefficients: Beta (ß) ± standard errors (SE). Beta coefficient represents change in inflammatory factor level 
per 1-nmol/L change in serum 25-OHD concentration. 
Ϫ 
P-values estimated using simple or multiple linear regressions. 
*  
Esitmated
 
P-value is borderline significant (P = 0.049). 
Ж 
Model 1: Unadjusted. 
╧
 Model 2: Adjusted for season and total body fat percentage. 
₸
 Model 3: Adjusted for season and total body fat percentage, multivitamin intake, alcohol intake and physical activity level. 
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Table 37. Continued 
  
Y =  log (Interleukin-5 Concentration, pg/mL) 
 25-OHD, nmol/L 
All women (n = 170) 
25-OHD < 75 nmol/L 
 (n = 92) 
25-OHD ≥ 75 nmol/L  
(n = 78) 
ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 
Model 1
Ж 
0.001 ± 0.002 0.58  0.006 ± 0.006 0.32 -0.003 ± 0.004 0.45 
Model 2
 ╧
 0.001 ± 0.002 0.64 0.006 ± 0.006 0.32 -0.003 ± 0.004 0.46 
Model 3
 ₸
 0.001 ± 0.002 0.80 0.006 ± 0.006 0.33 -0.004 ± 0.004 0.34 
 
Y =  log (Interleukin-6 Concentration, pg/mL) 
Model 1
Ж 
-0.003 ± 0.003 0.33  -0.020 ± 0.010 0.05 -0.013 ± 0.007 0.85 
Model 2
 ┴
 -0.004 ± 0.003 0.23 -0.020 ± 0.010  0.05
* 
-0.003 ± 0.007 0.69 
Model 3
 ┬
 -0.003 ± 0.003 0.41 -0.020 ± 0.010 0.05 -0.003 ± 0.007 0.68 
ϖ 
Regression coefficients: Beta (ß) ± standard errors (SE). Beta coefficient represents change in inflammatory factor level per 
1-nmol/L change in serum 25-OHD concentration. 
Ϫ 
P-values estimated using simple or multiple linear regressions. 
*  
Esitmated
 
P-value is borderline significant (P = 0.048). 
Ж 
Model 1: Unadjusted. 
╧
 Model 2: Adjusted for season and waist circumference. 
₸
 Model 3: Adjusted for season, waist circumference, multivitamin intake, smoking status and physical activity level. 
┴
 Model 2: Adjusted for season and waist circumference. body mass index 
┬ 
Model 3: Adjusted for season, waist circumference, multivitamin intake, oral contraceptive use and physical activity level. 
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Table 37. Continued 
 
 
 
 
Y =  log (Interleukin-7 Concentration, pg/mL) 
 25-OHD, nmol/L 
All women (n = 170) 
25-OHD < 75 nmol/L 
 (n = 92) 
25-OHD ≥ 75 nmol/L  
(n = 78) 
ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 
Model 1
Ж 
-0.001 ± 0.003 0.85  -0.019 ± 0.010 0.06 0.002 ± 0.006 0.81 
Model 2
 ╧
 -0.001 ± 0.003 0.76 -0.019 ± 0.010 0.06 0.002 ± 0.007 0.80 
Model 3
 ₸
 -0.001 ± 0.003 0.87 -0.020 ± 0.010 0.05 0.002 ± 0.007 0.77 
 
Y =  log (Interleukin-8 Concentration, pg/mL) 
Model 1
Ж 
0.005 ± 0.002 0.80  -0.005 ± 0.007 0.45 0.005 ± 0.003 0.15 
Model 2
 ┴
 0.0001 ± 0.002 0.94 -0.005 ± 0.007 0.45 0.004 ± 0.003 0.16 
Model 3
 ┬
 0.001 ± 0.002 0.60 -0.004 ± 0.006 0.49 0.004 ± 0.003 0.22 
ϖ 
Regression coefficients: Beta (ß) ± standard errors (SE). Beta coefficient represents change in inflammatory factor level per 1-
nmol/L change in serum 25-OHD concentration. 
Ϫ 
P-values estimated using simple or multiple linear regressions. 
Ж 
Model 1: Unadjusted. 
╧
 Model 2: Adjusted for season and waist circumference. 
₸
 Model 3: Adjusted for season and waist circumference, multivitamin intake, oral contraceptive use and physical activity level. 
┴ 
Model 2: Adjusted for season and waist circumference. 
┬ 
Model 3: Adjusted for season, waist circumference, multivitamin intake, smoking status and physical activity level. 
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Table 37. Continued 
 
 
 
 
 
Y =  log (Interleukin-10 Concentration, pg/mL) 
 25-OHD, nmol/L 
All women (n = 170) 
25-OHD < 75 nmol/L 
 (n = 92) 
25-OHD ≥ 75 nmol/L  
(n = 78) 
ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 
Model 1
Ж 
0.003 ± 0.003 0.29  -0.002 ± 0.008 0.80 0.002 ± 0.005 0.72 
Model 2
 ╧
 0.002 ± 0.003 0.36 -0.002 ± 0.008 0.81 0.002 ± 0.005 0.78 
Model 3
 ₸
 0.003 ± 0.003 0.31 -0.002 ± 0.008 0.85 0.002 ± 0.006 0.75 
 
Y =  log (Interleukin-12 Concentration, pg/mL) 
Model 1
Ж 
-0.002 ± 0.005 0.67  -0.019 ± 0.015 0.21 -0.009 ± 0.010 0.36 
Model 2
 ╧
 -0.003 ± 0.005 0.55 -0.018 ± 0.015 0.21 -0.011 ± 0.010 0.29 
Model 3
 ₸
 -0.003 ± 0.005 0.58 -0.019 ± 0.015 0.21 -0.012 ± 0.010 0.25 
ϖ 
Regression coefficients: Beta (ß) ± standard errors (SE). Beta coefficient represents change in inflammatory factor level per 
1-nmol/L change in serum 25-OHD concentration. 
Ϫ 
P-values estimated using simple or multiple linear regressions. 
Ж 
Model 1: Unadjusted. 
╧
 Model 2: Adjusted for season and body mass index. 
₸
 Model 3: Adjusted for season and body mass index, multivitamin intake, oral contraceptive use and physical activity level. 
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Table 37. Continued 
 
 
 
 
Y =  log (Interleukin-13 Concentration, pg/mL) 
 25-OHD, nmol/L 
All women (n = 170) 
25-OHD < 75 nmol/L 
 (n = 92) 
25-OHD ≥ 75 nmol/L  
(n = 78) 
ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 
Model 1
Ж 
-0.002 ± 0.004 0.65  -0.007 ± 0.011 0.53 -0.002 ± 0.007 0.83 
Model 2
 ╧
 -0.002 ± 0.004 0.58 -0.005 ± 0.011 0.55 -0.002 ± 0.007 0.82 
Model 3
 ₸
 -0.001 ± 0.004 0.84 -0.006 ± 0.012 0.63 -0.002 ± 0.008 0.77 
 
Y =  log (GM-CSF Concentration, pg/mL) 
Model 1
Ж 
-0.004 ± 0.004 0.26  -0.021 ± 0.010 0.06 -0.003 ± 0.007 0.66 
Model 2
 ┴
 -0.005 ± 0.004 0.17 -0.022 ± 0.011 0.04 -0.003 ± 0.007 0.70 
Model 3
 ┬
 -0.004 ± 0.004 0.27 -0.022 ± 0.011 0.04
 
-0.003 ± 0.007 0.65 
ϖ 
Regression coefficients: Beta (ß) ± standard errors (SE). Beta coefficient represents change in inflammatory factor level 
per 1-nmol/L change in serum 25-OHD concentration. 
Ϫ 
P-values estimated using simple or multiple linear regressions. 
Ж 
Model 1: Unadjusted. 
╧
 Model 2: Adjusted for season and total body fat percentage. 
₸ 
Model 3: Adjusted for season, total body fat percentage, multivitamin intake, alcohol intake and physical activity level. 
┴ 
Model 2: Adjusted for season and waist to height ratio. 
┬ 
Model 3: Adjusted for season, waist to height ratio, multivitamin intake, alcohol intake and physical activity level. 
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Table 36. Continued 
 
 
 
 
 
 
Y =  log (TNF-α Concentration, pg/mL) 
 25-OHD, nmol/L 
All women (n = 170) 
25-OHD < 75 nmol/L 
 (n = 92) 
25-OHD ≥ 75 nmol/L  
(n = 78) 
ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 ß ± SE
ϖ
 P
 Ϫ
 
Model 1
Ж 
-0.0004 ± 0.002 0.97  -0.009 ± 0.005 0.09 -0.001 ± 0.003 0.77 
Model 2
 ╧
 -0.0004 ± 0.002 0.79 -0.009 ± 0.005 0.10 -0.001 ± 0.003 0.82 
Model 3
 ₸
 -0.0005 ± 0.002 0.77 -0.008 ± 0.005 0.10 -0.001 ± 0.003 0.81 
 
Y =  log (IFN-γ Concentration, pg/mL) 
Model 1
Ж 
-0.002 ± 0.004 0.63  -0.018 ± 0.012 0.13 -0.002 ± 0.007 0.75 
Model 2
 ╧
 -0.002 ± 0.004 0.58 -0.019 ± 0.012 0.14 -0.002 ± 0.007 0.79 
Model 3
 ₸
 -0.003 ± 0.004 0.47 -0.018 ± 0.012 0.15 -0.002 ± 0.007 0.79 
ϖ 
Regression coefficients: Beta (ß) ± standard errors (SE). Beta coefficient represents change in inflammatory factor level 
per 1-nmol/L change in serum 25-OHD concentration. 
Ϫ 
P-values estimated using simple or multiple linear regressions. 
Ж 
Model 1: Unadjusted. 
╧
 Model 2: Adjusted for season and waist circumference. 
₸
 Model 3: Adjusted for season, waist circumference, multivitamin intake, oral contraceptive use and physical activity level. 
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CHAPTER 6 
SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Summary and Conclusions 
We conducted a cross-sectional analysis among two hundred and seventy 18- to 30-year 
old female participants in the UMass Amherst Vitamin D Status Study (n = 270) to assess 
the extent to which dietary intakes of calcium and vitamin D are associated with obesity 
markers. We also evaluated the association between serum 25-OHD concentrations and 
both adiposity and inflammatory biomarkers. To our knowledge, ours is the first study to 
examine these associations in healthy young women using multiple measures of 
adiposity.  
Study participants were mostly Caucasian women (84.5%) with a normal BMI, 
although about half of women had high adiposity (total body fat ‘TBF’ ≥ 32%). Most 
women (83.3%) had total vitamin D intakes less than the current RDA of 600 IU/day 
(FNB/IOM, 2010), and about 40% of women had inadequate total calcium intakes (< 
RDA of 1000 mg/day). These findings confirm that large proportions of young women 
likely have inadequate intakes of both calcium and vitamin D.  
In multivariable analyses, women reporting adequate intakes of calcium (≥ 1000 
mg/day) but low intakes of vitamin D (< 600 IU/day) were more than twice as likely to 
have a high percentage of TBF compared to women with adequate intakes of both 
calcium and vitamin D.  The odds of being overweight/obese (BMI ≥ 25 kg/m2) also 
increased in a linear manner across tertiles of decreasing supplemental calcium intake 
(Ptrend = 0.02). In addition, multivariable logistic regression analyses showed that women 
with lower calcium intake from supplements were twice as likely to have a waist 
circumference ≥ 80 cm (OR = 2.04; 95% CI: 1.04 – 3.99) compared to women in the 
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highest tertile of calcium intake. The magnitude of this association is important since 
among young women 18-30 years old, a waist circumference greater than 80 cm indicates 
central obesity and suggests increased visceral adiposity, which contributes to 
hyperlipidemia and other obesity-related chronic conditions (Zhu et al., 2002; Shields et 
al., 2012; Clark et al., 2012). Additional studies are needed to better characterize the 
association between supplemental calcium and central adiposity and to determine 
whether calcium supplementation can influence subsequent disease risk.  
Among all women, total vitamin D, food vitamin D, and supplemental vitamin D 
intake were not associated with serum 25-OHD concentration (P > 0.05). However, 
among supplement users only, intake of vitamin D supplements was positively correlated 
with serum 25-OHD levels (ß = 0.03 ± 0.01 nmol/L, P = 0.05). Vitamin D insufficiency 
(25-OHD < 75 nmol/L) was common (53.4%), but serum 25-OHD was not significantly 
correlated with adiposity measures. These findings support the notion that serum levels of 
25-OHD are influenced by other factors besides the vitamin D content of foods, including 
the use of vitamin D supplements. They also suggest that, contrary to reports in obese 
populations, 25-OHD levels are not associated with adiposity among women with 
relatively normal body composition.  
Serum 25-OHD concentration tended to be correlated with hs-CRP levels (r = 
0.14, P = 0.06), but was not significantly associated with other inflammatory biomarkers. 
Mean 25-OHD levels were greater among women with high inflammation (hs-CRP ≥ 5 
mg/L) as compared to women with low inflammation. We also found significant 
associations between markers of obesity and inflammatory factors. Serum levels of IL-
1β, IL-7, GM-CSF, and TNF-α were higher in women with high waist circumference 
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(WC < 80 cm, P < 0.01). In multivariable analyses, we found that among women with 
low 25-OHD (< 75 nmol/L), serum 25-OHD level was inversely associated with IL-2 and 
GM-CSF concentrations, and marginally associated with IL-6 and IL-7 concentrations. 
Among these women, an increase of 1 nmol/L in serum 25-OHD concentration would be 
associated with a 2% reduction in IL-2, IL-6, IL-7 and GM-CSF concentrations. 
Additional prospective studies in more heterogeneous populations will help to 
characterize the relationship between vitamin D status, inflammation and obesity.  
A major strength of our study is the use of dual energy x-ray absorptiometry 
(DXA) to objectively quantify adiposity. We also assessed dietary intake using a 
comprehensive and validated food frequency questionnaire that captured the frequency of 
dietary intake in the previous two months. In addition to dietary vitamin D intake, we 
assessed serum vitamin D status with a biomarker (25-OHD). Assays were also available 
for several inflammatory biomarkers. We controlled for several factors known to be 
associated with adiposity, serum 25-OHD levels, and inflammation; however, it is still 
possible that there may be residual confounding by other unknown factors.  
Some limitations of our study include the homogeneity of our population and the 
cross-sectional design of our study. Our population comprised mostly of Caucasian 
women who were non-obese and between 18 to 30 years. Our findings are therefore 
limited to such populations and may not be generalizable to women in other age groups, 
BMI categories, or ethnicities. In addition, because all exposures and outcome variables 
were assessed at one time-point, temporal and/or causal associations cannot be inferred 
from our findings.  
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To the best of our knowledge, this research is among the first to assess 
associations between vitamin D status, adiposity and inflammation in a general 
population of pre-dominantly non-obese physically active young women. Since health 
risks tend to rise with increases in adiposity, identifying modifiable dietary and lifestyle 
factors could significantly impact adiposity in young women. Information pertaining to 
associations between vitamin D status and inflammatory factors in young women could 
also be vital in identifying their susceptibility to future life-altering chronic conditions. 
 
6.2 Future Directions 
Obesity is a growing public health concern, and the possibility that central obesity 
risk in young women may be influenced by a high intake of calcium, especially calcium 
obtained from dietary supplements, warrants additional study. Our study design was 
cross-sectional, which means that we cannot make any causal inferences on the nature of 
association between calcium/vitamin D intakes and adiposity. Prospective studies with 
dietary intakes and adiposity assessed at several time points are needed to establish causal 
and/or temporal relations. For instance, we will be able to tell whether high waist 
circumference somehow influences calcium supplement intake or whether the reverse is 
true.  
In our study, serum 25-OHD levels were not associated with adiposity measures 
in young women (ages 18-30 years). We recommend that additional studies be done to 
corroborate our findings. We also advise that future studies consider using a prospective 
study design as this will help to determine whether low serum 25-OHD concentration is a 
consequence of high adiposity or if it is in some way involved in its development. Larger 
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sample sizes may also guarantee a wider range of adiposity, and this will help to 
determine whether serum 25-OHD status differs among women with relatively little 
adiposity. 
We found that IL-2, GM-CSF, IL-6, and IL-7 levels may be reduced in young 
women with low levels of 25-OHD (< 75 nmol/L). However, information on exposure 
and outcome were assessed simultaneously, making it impossible for us to determine 
whether 25-OHD status causes changes in inflammation, or whether inflammation 
influences 25-OHD levels. Prospective studies are necessary to investigate whether low 
25-OHD status plays a causal role in the development of inflammation in young women. 
Future research should also consider enrolling larger cohorts as this will help improve the 
precision and power of analyses.  
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APPENDIX A 
PERMISSION TO ACCESS DATA 
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APPENDIX B 
NORMALITY AND DISTRIBUTION OF COVARIATES 
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APPENDIX C 
LINEARITY AND SPLINE MODEL FIT FOR DIETARY INTAKES 
*Y =TOTAL BODY FAT; X = Total Calcium Intakes 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Total 
Body Fat Percentage and Total Calcium Intake 
 
 
* Lacking specific knots – Define knots using evenly spaced percentiles 
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100       4600.61         4600.61     4600.61*
                               75      1504.128        1393.055     1601.13
                               50      1142.665        1051.204    1221.064
                               25        776.58        719.6616    851.1368
        calc       270          0        224.27          224.27      224.27*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* Note: Above suggests knots at p25=224.27, p50=776.58 and p75=1504.13  
 
* LINEAR MODEL – Fit  
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is not significant (null not rejected)* 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
   
                                                                              
       _cons     32.90039   1.105806    29.75   0.000     30.72322    35.07756
        calc    -.0006695   .0008093    -0.83   0.409     -.002263    .0009239
                                                                              
total_bf_p~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    17946.8751   269  66.7170077           Root MSE      =  8.1728
                                                       Adj R-squared = -0.0012
    Residual    17901.1601   268  66.7953733           R-squared     =  0.0025
       Model    45.7150077     1  45.7150077           Prob > F      =  0.4088
                                                       F(  1,   268) =    0.68
      Source         SS       df       MS              Number of obs =     270
ehat_linea~c      270    0.99155      1.639     1.154    0.12417
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
* Normality of residuals check is not significant (null not rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
   
                                                                              
       _cons     62.38243   12.60157     4.95   0.000     37.57006    87.19479
knot_calcp75    -1.27e-08   7.42e-09    -1.72   0.087    -2.74e-08    1.87e-09
knot_calcp50     1.55e-07   6.17e-08     2.51   0.013     3.36e-08    2.76e-07
knot_calcp25    -1.43e-06   5.70e-07    -2.51   0.013    -2.55e-06   -3.07e-07
       calc3     1.29e-06   5.14e-07     2.50   0.013     2.74e-07    2.30e-06
       calc2    -.0006498   .0002607    -2.49   0.013    -.0011632   -.0001365
        calc            0  (omitted)
                                                                              
total_bf_p~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    17946.8751   269  66.7170077           Root MSE      =  8.1346
                                                       Adj R-squared =  0.0082
    Residual    17469.3118   264  66.1716355           R-squared     =  0.0266
       Model    477.563292     5  95.5126585           Prob > F      =  0.2090
                                                       F(  5,   264) =    1.44
      Source         SS       df       MS              Number of obs =     270
ehat_splin~c      270    0.99360      1.242     0.507    0.30614
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
 
 
 
* Note: Spline prediction looks good. Biggest cook’s distance is still less than 1 
 
 
-2
-1
0
1
2
3
S
tu
d
e
n
ti
z
e
d
 r
e
s
id
u
a
ls
25 30 35 40 45
Linear prediction
Jacknife Residuals v Predicted
Restricted Cubic Splines Model
0
.2
.4
.6
.8
1
C
o
o
k
's
 D
0 100 200 300
subj_id
Cook Distances
Restricted Cubic Splines Model
   247 
 
* Compare Linear (1) and Splines (2) side-by-side  
 
 
* Partial F-test of Departure from Linearity*  
 
* Note: Departure from linearity is marginally significant. Proceed with the linear 
model 
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        8.173           8.135   
Adjusted R-squared         -0.001           0.008   
R-squared                   0.003           0.027   
Observations                  270             270   
                                                    
                          (1.106)         (12.60)   
Constant                    32.90***        62.38***
                                       (7.42e-09)   
knot_calcp75                            -1.27e-08   
                                       (6.17e-08)   
knot_calcp50                          0.000000155*  
                                     (0.000000570)   
knot_calcp25                          -0.00000143*  
                                     (0.000000514)   
calc3                                  0.00000129*  
                                       (0.000261)   
calc2                                   -0.000650*  
                                              (.)   
o.calc                                          0   
                       (0.000809)                   
calc                    -0.000670                   
                                                    
                     total_bf_p~t    total_bf_p~t   
                              (1)             (2)   
                                                    
            Prob > F =    0.0967
       F(  3,   264) =    2.13
       Constraint 4 dropped
       Constraint 2 dropped
 ( 5)  knot_calcp75 = 0
 ( 4)  knot_calcp50 = 0
 ( 3)  knot_calcp25 = 0
 ( 2)  calc3 = 0
 ( 1)  calc2 = 0
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*Y =TOTAL BODY FAT; X = Food Calcium Intake 
/* Lowess Regression Curve and Linear Prediction Fit for the Association between Total 
Body Fat Percentage and Food Calcium Intake 
 
 
 
* Lacking specific knots – Define knots using evenly spaced percentiles 
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100       4600.61         4600.61     4600.61*
                               75       1335.74        1282.706    1410.184
                               50       979.645        891.4725    1063.545
                               25      714.8375        665.6529    768.2664
     calc_wo       270          0         179.7           179.7       179.7*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* Note: Above suggests knots at p25=714.84, p50=979.65 and p75=1335.74  
 
* LINEAR MODEL – Fit  
 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is NOT significant (null not rejected)* 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
  
                                                                              
       _cons     32.76177   1.061827    30.85   0.000     30.67119    34.85235
     calc_wo    -.0006221   .0008602    -0.72   0.470    -.0023156    .0010714
                                                                              
total_bf_p~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    17946.8751   269  66.7170077           Root MSE      =  8.1753
                                                       Adj R-squared = -0.0018
    Residual    17911.9149   268  66.8355033           R-squared     =  0.0019
       Model    34.9601664     1  34.9601664           Prob > F      =  0.4702
                                                       F(  1,   268) =    0.52
      Source         SS       df       MS              Number of obs =     270
ehat_linea~o      270    0.99178      1.596     1.091    0.13755
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
  
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
 
-2
-1
0
1
2
3
S
tu
d
e
n
ti
z
e
d
 r
e
s
id
u
a
ls
30 30.5 31 31.5 32 32.5
Linear prediction
Jacknife Residuals v Predicted
Linear Model
0
.2
.4
.6
.8
1
C
o
o
k
's
 D
0 100 200 300
subj_id
Cook Distances
Linear Model
   251 
 
*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
 
 
* Normality of residuals check is NOT significant (null not rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
  
                                                                                 
          _cons     70.31099   17.43537     4.03   0.000     35.98032    104.6417
knot_calc_wop75    -1.56e-08   2.54e-08    -0.61   0.540    -6.55e-08    3.44e-08
knot_calc_wop50    -1.48e-08   9.90e-08    -0.15   0.881    -2.10e-07    1.80e-07
knot_calc_wop25     1.97e-07   1.70e-07     1.16   0.248    -1.38e-07    5.31e-07
       calc_wo3    -1.68e-07   1.00e-07    -1.68   0.095    -3.65e-07    2.94e-08
       calc_wo2     .0003268    .000178     1.84   0.068    -.0000237    .0006773
        calc_wo    -.2010608   .0996081    -2.02   0.045    -.3971916     -.00493
                                                                                 
total_bf_perc~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                 
       Total    17946.8751   269  66.7170077           Root MSE      =  8.1418
                                                       Adj R-squared =  0.0064
    Residual    17434.0507   263  66.2891663           R-squared     =  0.0286
       Model    512.824331     6  85.4707219           Prob > F      =  0.2623
                                                       F(  6,   263) =    1.29
      Source         SS       df       MS              Number of obs =     270
ehat_splin~o      270    0.99172      1.606     1.107    0.13415
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
 
  
 
* Note: Spline prediction looks good. Biggest cook’s distance is still less than 1 
 
-2
-1
0
1
2
3
S
tu
d
e
n
ti
z
e
d
 r
e
s
id
u
a
ls
25 30 35 40 45
Linear prediction
Jacknife Residuals v Predicted
Restricted Cubic Splines Model
0
.2
.4
.6
.8
1
C
o
o
k
's
 D
0 100 200 300
subj_id
Cook Distances
Restricted Cubic Splines Model
   253 
* Compare Linear (1) and Splines (2) side-by-side  
 
 
* Partial F-test of Departure from Linearity 
 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
 
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        8.175           8.142   
Adjusted R-squared         -0.002           0.006   
R-squared                   0.002           0.029   
Observations                  270             270   
                                                    
                          (1.062)         (17.44)   
Constant                    32.76***        70.31***
                                       (2.54e-08)   
knot_calc_wop75                         -1.56e-08   
                                       (9.90e-08)   
knot_calc_wop50                         -1.48e-08   
                                     (0.000000170)   
knot_calc_wop25                       0.000000197   
                                     (0.000000100)   
calc_wo3                             -0.000000168   
                                       (0.000178)   
calc_wo2                                 0.000327   
                       (0.000860)        (0.0996)   
calc_wo                 -0.000622          -0.201*  
                                                    
                     total_bf_p~t    total_bf_p~t   
                              (1)             (2)   
                                                    
            Prob > F =    0.1223
       F(  4,   263) =    1.84
       Constraint 4 dropped
       Constraint 3 dropped
 ( 6)  knot_calc_wop75 = 0
 ( 5)  knot_calc_wop50 = 0
 ( 4)  knot_calc_wop25 = 0
 ( 3)  calc_wo3 = 0
 ( 2)  calc_wo2 = 0
 ( 1)  calc_wo = 0
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*Y =TOTAL BODY FAT; X = Supplemental Calcium Intake 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Total 
Body Fat Percentage and Supplemental Calcium Intake 
  
 
  
* Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=162, p50=362 and p75=500  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100          1334            1334        1334*
                               75           500        499.9483    600.0162
                               50           362          257.14         450
                               25           162        90.69199         200
 calc_supplr        93          0         11.43           11.43       11.43*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit 
 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is NOT significant (null not rejected) 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
  
 
                                                                              
       _cons     32.97654   1.526441    21.60   0.000     29.94445    36.00862
 calc_supplr     -.002084   .0032266    -0.65   0.520    -.0084932    .0043252
                                                                              
total_bf_p~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    7246.47309    92  78.7660118           Root MSE      =  8.9033
                                                       Adj R-squared = -0.0064
    Residual     7213.4048    91  79.2681846           R-squared     =  0.0046
       Model    33.0682854     1  33.0682854           Prob > F      =  0.5200
                                                       F(  1,    91) =    0.42
      Source         SS       df       MS              Number of obs =      93
ehat_linea~r       93    0.97752      1.747     1.233    0.10883
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
  
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
 
* Normality of residuals check is marginally significant (null not rejected) 
 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
  
                                                                                     
              _cons     30.14036   5.712494     5.28   0.000      18.7843    41.49642
knot_calc_supplrp75     6.27e-07   9.50e-07     0.66   0.511    -1.26e-06    2.51e-06
knot_calc_supplrp50    -7.67e-07   1.91e-06    -0.40   0.688    -4.55e-06    3.02e-06
knot_calc_supplrp25    -1.82e-06   5.29e-06    -0.34   0.732    -.0000123    8.70e-06
       calc_supplr3     2.03e-06   4.38e-06     0.46   0.644    -6.68e-06    .0000107
       calc_supplr2    -.0009688   .0017825    -0.54   0.588    -.0045122    .0025746
        calc_supplr     .1243309     .20635     0.60   0.548    -.2858794    .5345411
                                                                                     
   total_bf_percent        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                     
       Total    7246.47309    92  78.7660118           Root MSE      =  9.0794
                                                       Adj R-squared = -0.0466
    Residual    7089.53102    86  82.4364072           R-squared     =  0.0217
       Model    156.942066     6   26.157011           Prob > F      =  0.9263
                                                       F(  6,    86) =    0.32
      Source         SS       df       MS              Number of obs =      93
ehat_splin~r       93    0.97590      1.873     1.386    0.08280
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
  
 
* Note: Generally looks good. One observation has cook’s distance is >1  
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* Compare Linear (1) and Splines (2) side-by-side 
 
 
/* Partial F-test of Departure from Linearity 
  
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        8.903           9.079   
Adjusted R-squared         -0.006          -0.047   
R-squared                   0.005           0.022   
Observations                   93              93   
                                                    
                          (1.526)         (5.712)   
Constant                    32.98***        30.14***
                                     (0.000000950)   
knot_calc_supplrp75                   0.000000627   
                                     (0.00000191)   
knot_calc_supplrp50                  -0.000000767   
                                     (0.00000529)   
knot_calc_supplrp25                   -0.00000182   
                                     (0.00000438)   
calc_supplr3                           0.00000203   
                                        (0.00178)   
calc_supplr2                            -0.000969   
                        (0.00323)         (0.206)   
calc_supplr              -0.00208           0.124   
                                                    
                     total_bf_p~t    total_bf_p~t   
                              (1)             (2)   
                                                    
            Prob > F =    0.8789
       F(  5,    86) =    0.35
       Constraint 3 dropped
 ( 6)  knot_calc_supplrp75 = 0
 ( 5)  knot_calc_supplrp50 = 0
 ( 4)  knot_calc_supplrp25 = 0
 ( 3)  calc_supplr3 = 0
 ( 2)  calc_supplr2 = 0
 ( 1)  calc_supplr = 0
   260 
*Y =TOTAL BODY FAT; X = Total Vitamin D Intake 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Total 
Body Fat Percentage and Total Vitamin D Intake 
 
 
 
* Lacking specific knots – Define knots using evenly spaced percentiles 
 
 
* Note: Above suggests knots at p25=162.59, p50=299.45 and p75=533.79  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100       1806.07         1806.07     1806.07*
                               75      533.7875        488.6483    571.3427
                               50        299.45        257.0065    340.6129
                               25        162.59        133.8724    188.4364
        vitd       270          0          3.37            3.37        3.37*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
   261 
* LINEAR MODEL – Fit 
 
 
/* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is NOT significant (null not rejected) 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
    
 
                                                                              
       _cons     33.02869   .7978986    41.39   0.000     31.45774    34.59963
        vitd    -.0025179   .0016649    -1.51   0.132    -.0057958      .00076
                                                                              
total_bf_p~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    17946.8751   269  66.7170077           Root MSE      =  8.1486
                                                       Adj R-squared =  0.0048
    Residual    17794.9998   268  66.3992532           R-squared     =  0.0085
       Model    151.875213     1  151.875213           Prob > F      =  0.1316
                                                       F(  1,   268) =    2.29
      Source         SS       df       MS              Number of obs =     270
ehat_linea~d      270    0.99119      1.710     1.253    0.10516
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances") 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
* Normality of residuals check is marginally significant (null not rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
    
                                                                              
       _cons     25.42006   4.050045     6.28   0.000     17.44542     33.3947
knot_vitdp75     2.20e-09   1.67e-07     0.01   0.989    -3.26e-07    3.30e-07
knot_vitdp50     6.43e-07   8.92e-07     0.72   0.472    -1.11e-06    2.40e-06
knot_vitdp25    -5.17e-06   3.23e-06    -1.60   0.111    -.0000115    1.20e-06
       vitd3     4.52e-06   2.57e-06     1.76   0.080    -5.38e-07    9.58e-06
       vitd2    -.0019495   .0010471    -1.86   0.064    -.0040113    .0001123
        vitd     .2434721   .1247986     1.95   0.052    -.0022595    .4892037
                                                                              
total_bf_p~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    17946.8751   269  66.7170077           Root MSE      =  8.1558
                                                       Adj R-squared =  0.0030
    Residual    17494.0071   263  66.5171374           R-squared     =  0.0252
       Model    452.867931     6  75.4779886           Prob > F      =  0.3424
                                                       F(  6,   263) =    1.13
      Source         SS       df       MS              Number of obs =     270
ehat_splin~d      270    0.99068      1.809     1.384    0.08321
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
 
 
* Note: Spline prediction looks good. Biggest cook’s distance is exactly 1 for one 
observation 
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* Compare Linear (1) and Splines (2) side-by-side 
 
* Partial F-test of Departure from Linearity 
 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        8.149           8.156   
Adjusted R-squared          0.005           0.003   
R-squared                   0.008           0.025   
Observations                  270             270   
                                                    
                          (0.798)         (4.050)   
Constant                    33.03***        25.42***
                                     (0.000000167)   
knot_vitdp75                             2.20e-09   
                                     (0.000000892)   
knot_vitdp50                          0.000000643   
                                     (0.00000323)   
knot_vitdp25                          -0.00000517   
                                     (0.00000257)   
vitd3                                  0.00000452   
                                        (0.00105)   
vitd2                                    -0.00195   
                        (0.00166)         (0.125)   
vitd                     -0.00252           0.243   
                                                    
                     total_bf_p~t    total_bf_p~t   
                              (1)             (2)   
                                                    
            Prob > F =    0.4208
       F(  5,   263) =    1.00
       Constraint 3 dropped
 ( 6)  knot_vitdp75 = 0
 ( 5)  knot_vitdp50 = 0
 ( 4)  knot_vitdp25 = 0
 ( 3)  vitd3 = 0
 ( 2)  vitd2 = 0
 ( 1)  vitd = 0
   266 
*Y =TOTAL BODY FAT; X = Food Vitamin D Intake 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Total 
Body Fat Percentage and Food Vitamin D Intake 
 
 
  
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=110.43, p50=188.03 and p75=306.70 
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100        1006.2          1006.2      1006.2*
                               75       306.695        279.1118    341.1421
                               50       188.025        169.6337    204.1505
                               25      110.4275        86.71537    128.0679
     vitd_wo       270          0          3.37            3.37        3.37*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit  
 
 
* LINEAR MODEL – Diagnostics 
 
* Normality of residuals check is NOT significant (null not rejected) 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
  
 
 
 
                                                                              
       _cons     33.01862   .8043631    41.05   0.000     31.43495    34.60229
     vitd_wo    -.0040631   .0027509    -1.48   0.141    -.0094793     .001353
                                                                              
total_bf_p~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    17946.8751   269  66.7170077           Root MSE      =  8.1502
                                                       Adj R-squared =  0.0044
    Residual    17801.9648   268  66.4252418           R-squared     =  0.0081
       Model    144.910253     1  144.910253           Prob > F      =  0.1408
                                                       F(  1,   268) =    2.18
      Source         SS       df       MS              Number of obs =     270
ehat_linea~o      270    0.99165      1.620     1.127    0.12987
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 * Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
 
* Normality of residuals check is NOT significant (null not rejected)  
 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
  
 
                                                                                 
          _cons     30.73728   3.827989     8.03   0.000     23.19987    38.27468
knot_vitd_wop75    -2.19e-07   1.05e-06    -0.21   0.835    -2.28e-06    1.84e-06
knot_vitd_wop50     1.09e-06   4.77e-06     0.23   0.819    -8.29e-06    .0000105
knot_vitd_wop25    -4.28e-06   .0000124    -0.35   0.730    -.0000287    .0000201
       vitd_wo3     3.39e-06   8.92e-06     0.38   0.704    -.0000142    .0000209
       vitd_wo2    -.0009759   .0023706    -0.41   0.681    -.0056438    .0036919
        vitd_wo     .0834572   .1829118     0.46   0.649    -.2767008    .4436151
                                                                                 
total_bf_perc~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                 
       Total    17946.8751   269  66.7170077           Root MSE      =  8.2199
                                                       Adj R-squared = -0.0127
    Residual    17770.0634   263  67.5667812           R-squared     =  0.0099
       Model    176.811614     6  29.4686023           Prob > F      =  0.8544
                                                       F(  6,   263) =    0.44
      Source         SS       df       MS              Number of obs =     270
ehat_splin~o      270    0.99197      1.558     1.036    0.15006
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
  
 
* Note: Spline prediction looks good. Biggest cook’s distance is still less than 1 
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* Compare Linear (1) and Splines (2) side-by-side 
 
 
* Partial F-test of Departure from Linearity 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        8.150           8.220   
Adjusted R-squared          0.004          -0.013   
R-squared                   0.008           0.010   
Observations                  270             270   
                                                    
                          (0.804)         (3.828)   
Constant                    33.02***        30.74***
                                     (0.00000105)   
knot_vitd_wop75                      -0.000000219   
                                     (0.00000477)   
knot_vitd_wop50                        0.00000109   
                                      (0.0000124)   
knot_vitd_wop25                       -0.00000428   
                                     (0.00000892)   
vitd_wo3                               0.00000339   
                                        (0.00237)   
vitd_wo2                                -0.000976   
                        (0.00275)         (0.183)   
vitd_wo                  -0.00406          0.0835   
                                                    
                     total_bf_p~t    total_bf_p~t   
                              (1)             (2)   
                                                    
            Prob > F =    0.8544
       F(  6,   263) =    0.44
 ( 6)  knot_vitd_wop75 = 0
 ( 5)  knot_vitd_wop50 = 0
 ( 4)  knot_vitd_wop25 = 0
 ( 3)  vitd_wo3 = 0
 ( 2)  vitd_wo2 = 0
 ( 1)  vitd_wo = 0
   272 
*Y =TOTAL BODY FAT; X = Supplemental Vitamin D Intake 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Total 
Body Fat Percentage and Supplemental Vitamin D Intake 
  
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=228.57, p50=400 and p75=400  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100          1400            1400        1400*
                               75           400             400    555.0903
                               50           400          228.57         400
                               25        228.57           57.15      228.57
 vitd_supplr       110          0         28.57           28.57       28.57*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit 
 
* LINEAR MODEL – Diagnostics 
 
* Normality of residuals check is NOT significant (null not rejected) 
 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
    
 
                                                                              
       _cons     32.74697   1.307738    25.04   0.000      30.1548    35.33913
 vitd_supplr    -.0022811   .0029098    -0.78   0.435    -.0080488    .0034866
                                                                              
total_bf_p~t        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    7572.06558   109  69.4684916           Root MSE      =  8.3496
                                                       Adj R-squared = -0.0035
    Residual    7529.22232   108  69.7150215           R-squared     =  0.0057
       Model    42.8432637     1  42.8432637           Prob > F      =  0.4348
                                                       F(  1,   108) =    0.61
      Source         SS       df       MS              Number of obs =     110
ehat_linea~r      110    0.98746      1.121     0.255    0.39918
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
 
* Note: Looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
 
* Normality of residuals check is NOT significant (null not rejected)  
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
  
 
                                                                                     
              _cons     36.63863    11.2204     3.27   0.001     14.38815    58.88912
knot_vitd_supplrp75            0  (omitted)
knot_vitd_supplrp50     3.10e-07   7.87e-07     0.39   0.694    -1.25e-06    1.87e-06
knot_vitd_supplrp25     8.75e-08   3.61e-06     0.02   0.981    -7.08e-06    7.25e-06
       vitd_supplr3    -3.47e-07   2.91e-06    -0.12   0.905    -6.11e-06    5.42e-06
       vitd_supplr2     .0003081   .0016802     0.18   0.855    -.0030238      .00364
        vitd_supplr    -.0784632    .280821    -0.28   0.780    -.6353419    .4784154
                                                                                     
   total_bf_percent        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                     
       Total    7572.06558   109  69.4684916           Root MSE      =  8.4287
                                                       Adj R-squared = -0.0227
    Residual    7388.51461   104  71.0434097           R-squared     =  0.0242
       Model    183.550973     5  36.7101947           Prob > F      =  0.7631
                                                       F(  5,   104) =    0.52
      Source         SS       df       MS              Number of obs =     110
ehat_splin~r      110    0.98904      0.980    -0.044    0.51759
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
  
 
* Note: Looks good. Biggest cook’s distance is still less than 1 
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* Compare Linear (1) and Splines (2) side-by-side 
 
 
* Partial F-test of Departure from Linearity 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
  
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        8.350           8.429   
Adjusted R-squared         -0.004          -0.023   
R-squared                   0.006           0.024   
Observations                  110             110   
                                                    
                          (1.308)         (11.22)   
Constant                    32.75***        36.64** 
                                              (.)   
o.knot_vitd_suppl~75                            0   
                                     (0.000000787)   
knot_vitd_supplrp50                   0.000000310   
                                     (0.00000361)   
knot_vitd_supplrp25                      8.75e-08   
                                     (0.00000291)   
vitd_supplr3                         -0.000000347   
                                        (0.00168)   
vitd_supplr2                             0.000308   
                        (0.00291)         (0.281)   
vitd_supplr              -0.00228         -0.0785   
                                                    
                     total_bf_p~t    total_bf_p~t   
                              (1)             (2)   
                                                    
            Prob > F =    0.7150
       F(  4,   104) =    0.53
       Constraint 3 dropped
 ( 5)  knot_vitd_supplrp50 = 0
 ( 4)  knot_vitd_supplrp25 = 0
 ( 3)  vitd_supplr3 = 0
 ( 2)  vitd_supplr2 = 0
 ( 1)  vitd_supplr = 0
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APPENDIX D 
LINEARITY AND SPLINE MODEL FIT FOR ADIPOSITY MEASURES 
*Y =Serum 25-OHD; X = Total Body Fat Percentage 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Total Body Fat Percentage  
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100          56.6            56.6        56.6*
                               75        37.675        36.28157    39.54393
                               50          31.6        30.63828        32.8
                               25          26.1            25.2    27.63685
total_bf_p~t       270          0          14.8            14.8        14.8*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
   279 
* Note: Above suggests knots at p25=26.1, p50=31.6 and p75=37.68  
 
* LINEAR MODEL – Fit 
 
 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
    
                                                                                  
           _cons     73.25745   9.833621     7.45   0.000     53.84733    92.66756
total_bf_percent     .1862036   .2962134     0.63   0.530    -.3984777     .770885
                                                                                  
       serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                  
       Total    180403.813   173   1042.7966           Root MSE      =  32.349
                                                       Adj R-squared = -0.0035
    Residual    179990.301   172  1046.45524           R-squared     =  0.0023
       Model    413.511617     1  413.511617           Prob > F      =  0.5304
                                                       F(  1,   172) =    0.40
      Source         SS       df       MS              Number of obs =     174
ehat_linea~f      174    0.94879      6.770     4.369    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
* Normality of residuals check is significant (null rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
 
* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
                                                                                          
                   _cons    -850.0428   647.3483    -1.31   0.191    -2128.084    427.9981
knot_total_bf_percentp75     .0360661    .069492     0.52   0.604      -.10113    .1732622
knot_total_bf_percentp50    -.0162627   .1019666    -0.16   0.873    -.2175723     .185047
knot_total_bf_percentp25    -.0925775   .1116539    -0.83   0.408    -.3130124    .1278575
       total_bf_percent3     .0766644   .0562542     1.36   0.175    -.0343967    .1877255
       total_bf_percent2    -5.456412   3.891785    -1.40   0.163    -13.13985    2.227026
        total_bf_percent      125.535   87.95225     1.43   0.155    -48.10659    299.1766
                                                                                          
               serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                          
       Total    180403.813   173   1042.7966           Root MSE      =  31.881
                                                       Adj R-squared =  0.0253
    Residual    169736.693   167  1016.38738           R-squared     =  0.0591
       Model    10667.1193     6  1777.85322           Prob > F      =  0.1126
                                                       F(  6,   167) =    1.75
      Source         SS       df       MS              Number of obs =     174
ehat_splin~f      174    0.95906      5.413     3.858    0.00006
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
    
 
* Note: Spline prediction looks good. Biggest cook’s distance is still less than 1* 
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* Compare Linear (1) and Splines (2) side-by-side  
 
 
* Partial F-test of Departure from Linearity 
 
 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
  
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        32.35           31.88   
Adjusted R-squared         -0.004           0.025   
R-squared                   0.002           0.059   
Observations                  174             174   
                                                    
                          (9.834)         (647.3)   
Constant                    73.26***       -850.0   
                                         (0.0695)   
knot_total_bf_per~75                       0.0361   
                                          (0.102)   
knot_total_bf_per~50                      -0.0163   
                                          (0.112)   
knot_total_bf_per~25                      -0.0926   
                                         (0.0563)   
total_bf_percent3                          0.0767   
                                          (3.892)   
total_bf_percent2                          -5.456   
                          (0.296)         (87.95)   
total_bf_percent            0.186           125.5   
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.1126
       F(  6,   167) =    1.75
 ( 6)  knot_total_bf_percentp75 = 0
 ( 5)  knot_total_bf_percentp50 = 0
 ( 4)  knot_total_bf_percentp25 = 0
 ( 3)  total_bf_percent3 = 0
 ( 2)  total_bf_percent2 = 0
 ( 1)  total_bf_percent = 0
   284 
*Y =Serum 25-OHD; X = Body Mass Index 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Body Mass Index  
 
 
 
* Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=20.51, p50=22.36 and p75=24.49  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100         37.72           37.72       37.72*
                               75       24.4925        24.00263    25.10439
                               50         22.36        21.95531    22.92469
                               25       20.5125        20.20841    20.93369
         bmi       270          0         16.67           16.67       16.67*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit 
 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
   
 
                                                                              
       _cons     63.80506   17.36018     3.68   0.000     29.53863    98.07148
         bmi     .6725131   .7486518     0.90   0.370    -.8052148    2.150241
                                                                              
   serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    180403.813   173   1042.7966           Root MSE      =   32.31
                                                       Adj R-squared = -0.0011
    Residual    179561.397   172  1043.96161           R-squared     =  0.0047
       Model    842.415473     1  842.415473           Prob > F      =  0.3703
                                                       F(  1,   172) =    0.81
      Source         SS       df       MS              Number of obs =     174
ehat_linea~i      174    0.95022      6.581     4.305    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
  
 
 
* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics* 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
 
                                                                              
       _cons     -908.745   10655.77    -0.09   0.932    -21946.12    20128.63
 knot_bmip75     .4108644    .841773     0.49   0.626    -1.251024    2.072752
 knot_bmip50    -.4534833   2.048367    -0.22   0.825    -4.497515    3.590548
 knot_bmip25     .0448409   2.703609     0.02   0.987    -5.292817    5.382499
        bmi3     .1104872   1.441605     0.08   0.939    -2.735632    2.956606
        bmi2    -6.854677    84.4944    -0.08   0.935    -173.6695    159.9602
         bmi     142.1807   1645.947     0.09   0.931    -3107.364    3391.725
                                                                              
   serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    180403.813   173   1042.7966           Root MSE      =  32.686
                                                       Adj R-squared = -0.0245
    Residual    178417.375   167  1068.36752           R-squared     =  0.0110
       Model    1986.43746     6   331.07291           Prob > F      =  0.9312
                                                       F(  6,   167) =    0.31
      Source         SS       df       MS              Number of obs =     174
ehat_splin~i      174    0.95316      6.193     4.166    0.00002
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
 
    
* Note: Spline prediction looks good. Biggest cook’s distance is still less than 1 
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* Compare Linear (1) and Splines (2) side-by-side  
 
 
* Partial F-test of Departure from Linearity 
 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
 
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        32.31           32.69   
Adjusted R-squared         -0.001          -0.025   
R-squared                   0.005           0.011   
Observations                  174             174   
                                                    
                          (17.36)       (10655.8)   
Constant                    63.81***       -908.7   
                                          (0.842)   
knot_bmip75                                 0.411   
                                          (2.048)   
knot_bmip50                                -0.453   
                                          (2.704)   
knot_bmip25                                0.0448   
                                          (1.442)   
bmi3                                        0.110   
                                          (84.49)   
bmi2                                       -6.855   
                          (0.749)        (1645.9)   
bmi                         0.673           142.2   
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.9312
       F(  6,   167) =    0.31
 ( 6)  knot_bmip75 = 0
 ( 5)  knot_bmip50 = 0
 ( 4)  knot_bmip25 = 0
 ( 3)  bmi3 = 0
 ( 2)  bmi2 = 0
 ( 1)  bmi = 0
   290 
*Y =Serum 25-OHD; X = Waist Circumference 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Waist Circumference  
 
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=71.1, p50=76.2 and p75=83.35  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100         114.3           114.3       114.3*
                               75         83.35              80        85.1
                               50          76.2        74.93828        77.5
                               25          71.1            68.6        72.4
      wst_cm       270          0          58.4            58.4        58.4*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit 
 
 
 
* LINEAR MODEL – Diagnostics 
 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
  
                                                                              
       _cons     66.70997   21.97659     3.04   0.003     23.33143    110.0885
      wst_cm     .1593932   .2777336     0.57   0.567     -.388812    .7075983
                                                                              
   serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    180403.813   173   1042.7966           Root MSE      =  32.355
                                                       Adj R-squared = -0.0039
    Residual    180059.011   172  1046.85472           R-squared     =  0.0019
       Model     344.80124     1   344.80124           Prob > F      =  0.5668
                                                       F(  1,   172) =    0.33
      Source         SS       df       MS              Number of obs =     174
ehat_linea~t      174    0.94873      6.778     4.372    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
   
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
* Normality of residuals check is significant (null rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
  
                                                                                
         _cons     57404.21   41944.12     1.37   0.173    -25404.84    140213.3
knot_wst_cmp75     .0378234   .0305493     1.24   0.217    -.0224892     .098136
knot_wst_cmp50    -.1413803   .0981395    -1.44   0.152    -.3351343    .0523737
knot_wst_cmp25     .2840046   .1951372     1.46   0.147     -.101249    .6692582
       wst_cm3    -.1755514   .1269376    -1.38   0.169    -.4261605    .0750578
       wst_cm2     36.32253   26.36053     1.38   0.170     -15.7203    88.36536
        wst_cm    -2501.276   1822.423    -1.37   0.172    -6099.233     1096.68
                                                                                
     serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                
       Total    180403.813   173   1042.7966           Root MSE      =  32.612
                                                       Adj R-squared = -0.0199
    Residual    177616.543   167  1063.57211           R-squared     =  0.0155
       Model    2787.26946     6   464.54491           Prob > F      =  0.8535
                                                       F(  6,   167) =    0.44
      Source         SS       df       MS              Number of obs =     174
ehat_splin~t      174    0.94623      7.109     4.481    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
    
 
* Note: Spline prediction looks good. Cook’s distance is > 1 for one observation 
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* Compare Linear (1) and Splines (2) side-by-side  
 
 
* Partial F-test of Departure from Linearity  
 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        32.36           32.61   
Adjusted R-squared         -0.004          -0.020   
R-squared                   0.002           0.015   
Observations                  174             174   
                                                    
                          (21.98)       (41944.1)   
Constant                    66.71**       57404.2   
                                         (0.0305)   
knot_wst_cmp75                             0.0378   
                                         (0.0981)   
knot_wst_cmp50                             -0.141   
                                          (0.195)   
knot_wst_cmp25                              0.284   
                                          (0.127)   
wst_cm3                                    -0.176   
                                          (26.36)   
wst_cm2                                     36.32   
                          (0.278)        (1822.4)   
wst_cm                      0.159         -2501.3   
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.8535
       F(  6,   167) =    0.44
 ( 6)  knot_wst_cmp75 = 0
 ( 5)  knot_wst_cmp50 = 0
 ( 4)  knot_wst_cmp25 = 0
 ( 3)  wst_cm3 = 0
 ( 2)  wst_cm2 = 0
 ( 1)  wst_cm = 0
   296 
*Y =Serum 25-OHD; X = Arm Fat Percentage 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Arm Fat Percentage  
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles
 
* Note: Above suggests knots at p25=24.48, p50=29.6 and p75=38  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100          52.5            52.5        52.5*
                               75            38        36.58157    39.47197
                               50          29.6        28.09141    31.66172
                               25        24.475        22.65607    25.51843
arm_fat_pe~t       270          0           8.2             8.2         8.2*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit 
 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
 
 
                                                                                 
          _cons     77.70931   8.294727     9.37   0.000     61.33674    94.08187
arm_fat_percent     .0514622   .2657383     0.19   0.847    -.4730659    .5759902
                                                                                 
      serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                 
       Total    180403.813   173   1042.7966           Root MSE      =  32.383
                                                       Adj R-squared = -0.0056
    Residual    180364.486   172  1048.63073           R-squared     =  0.0002
       Model    39.3269831     1  39.3269831           Prob > F      =  0.8467
                                                       F(  1,   172) =    0.04
      Source         SS       df       MS              Number of obs =     174
ehat_linea~f      174    0.94866      6.788     4.375    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
  
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
   
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
     
                                                                                         
                  _cons    -202.7319   136.3584    -1.49   0.139    -471.9404    66.47647
knot_arm_fat_percentp75     .0351601   .0516609     0.68   0.497    -.0668324    .1371526
knot_arm_fat_percentp50     .0235405   .0676138     0.35   0.728    -.1099474    .1570284
knot_arm_fat_percentp25    -.0774471   .0613727    -1.26   0.209    -.1986134    .0437193
       arm_fat_percent3     .0420874   .0207216     2.03   0.044     .0011774    .0829974
       arm_fat_percent2    -2.551403    1.21711    -2.10   0.038    -4.954308   -.1484977
        arm_fat_percent      48.4344   22.85006     2.12   0.036     3.322193     93.5466
                                                                                         
              serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                         
       Total    180403.813   173   1042.7966           Root MSE      =    32.1
                                                       Adj R-squared =  0.0119
    Residual    172080.351   167  1030.42126           R-squared     =  0.0461
       Model    8323.46199     6  1387.24366           Prob > F      =  0.2394
                                                       F(  6,   167) =    1.35
      Source         SS       df       MS              Number of obs =     174
ehat_splin~f      174    0.95212      6.330     4.216    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
 
 
* Note: Spline prediction looks good. Biggest cook’s distance is still less than 1 
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* Compare Linear (1) and Splines (2) side-by-side  
 
 
* Partial F-test of Departure from Linearity 
 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
  
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        32.38           32.10   
Adjusted R-squared         -0.006           0.012   
R-squared                   0.000           0.046   
Observations                  174             174   
                                                    
                          (8.295)         (136.4)   
Constant                    77.71***       -202.7   
                                         (0.0517)   
knot_arm_fat_perc~75                       0.0352   
                                         (0.0676)   
knot_arm_fat_perc~50                       0.0235   
                                         (0.0614)   
knot_arm_fat_perc~25                      -0.0774   
                                         (0.0207)   
arm_fat_percent3                           0.0421*  
                                          (1.217)   
arm_fat_percent2                           -2.551*  
                          (0.266)         (22.85)   
arm_fat_percent            0.0515           48.43*  
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.2394
       F(  6,   167) =    1.35
 ( 6)  knot_arm_fat_percentp75 = 0
 ( 5)  knot_arm_fat_percentp50 = 0
 ( 4)  knot_arm_fat_percentp25 = 0
 ( 3)  arm_fat_percent3 = 0
 ( 2)  arm_fat_percent2 = 0
 ( 1)  arm_fat_percent = 0
   302 
*Y =Serum 25-OHD; X = Leg Fat Percentage 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Leg Fat Percentage  
 
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=30.18, p50=35.1 and p75=40.6  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100          54.2            54.2        54.2*
                               75          40.6        39.86315        41.2
                               50          35.1            34.3        36.2
                               25        30.175        28.82803        31.5
leg_fat_pe~t       270          0           8.7             8.7         8.7*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit 
 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
  
 
                                                                                 
          _cons       76.735   11.71084     6.55   0.000     53.61954    99.85046
leg_fat_percent     .0698886   .3190005     0.22   0.827    -.5597713    .6995485
                                                                                 
      serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                 
       Total    180403.813   173   1042.7966           Root MSE      =  32.382
                                                       Adj R-squared = -0.0055
    Residual    180353.483   172  1048.56676           R-squared     =  0.0003
       Model    50.3299067     1  50.3299067           Prob > F      =  0.8268
                                                       F(  1,   172) =    0.05
      Source         SS       df       MS              Number of obs =     174
ehat_linea~f      174    0.94908      6.732     4.356    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
   
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
. 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
    
                                                                                         
                  _cons     22.07104   143.3152     0.15   0.878     -260.872    305.0141
knot_leg_fat_percentp75     .0133673   .0986049     0.14   0.892    -.1813055    .2080401
knot_leg_fat_percentp50    -.0521618    .105227    -0.50   0.621    -.2599083    .1555847
knot_leg_fat_percentp25      .019731   .0641618     0.31   0.759    -.1069417    .1464037
       leg_fat_percent3     .0030541   .0139906     0.22   0.827    -.0245672    .0306754
       leg_fat_percent2    -.2746332   .9679993    -0.28   0.777    -2.185726     1.63646
        leg_fat_percent     7.315349   21.07453     0.35   0.729    -34.29149    48.92219
                                                                                         
              serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                         
       Total    180403.813   173   1042.7966           Root MSE      =  32.393
                                                       Adj R-squared = -0.0063
    Residual    175236.416   167  1049.31986           R-squared     =  0.0286
       Model    5167.39672     6  861.232786           Prob > F      =  0.5553
                                                       F(  6,   167) =    0.82
      Source         SS       df       MS              Number of obs =     174
ehat_splin~f      174    0.95324      6.182     4.162    0.00002
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
 
 
* Note: Spline prediction looks good. Cook’s distance > 1 for one observation* 
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* Compare Linear (1) and Splines (2) side-by-side 
 
 
* Partial F-test of Departure from Linearity 
 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
  
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        32.38           32.39   
Adjusted R-squared         -0.006          -0.006   
R-squared                   0.000           0.029   
Observations                  174             174   
                                                    
                          (11.71)         (143.3)   
Constant                    76.73***        22.07   
                                         (0.0986)   
knot_leg_fat_perc~75                       0.0134   
                                          (0.105)   
knot_leg_fat_perc~50                      -0.0522   
                                         (0.0642)   
knot_leg_fat_perc~25                       0.0197   
                                         (0.0140)   
leg_fat_percent3                          0.00305   
                                          (0.968)   
leg_fat_percent2                           -0.275   
                          (0.319)         (21.07)   
leg_fat_percent            0.0699           7.315   
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.5553
       F(  6,   167) =    0.82
 ( 6)  knot_leg_fat_percentp75 = 0
 ( 5)  knot_leg_fat_percentp50 = 0
 ( 4)  knot_leg_fat_percentp25 = 0
 ( 3)  leg_fat_percent3 = 0
 ( 2)  leg_fat_percent2 = 0
 ( 1)  leg_fat_percent = 0
   308 
*Y =Serum 25-OHD; X = Trunk Fat Percentage 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Trunk Fat Percentage 
 
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=25.28, p50=31 and p75=38.53  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100          60.7            60.7        60.7*
                               75        38.525            35.8        40.3
                               50            31        30.13828    32.22344
                               25        25.275            23.4    26.41843
trunk_fat_~t       270          0          11.7            11.7        11.7*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
    
 
                                                                                   
            _cons     72.08415   8.390594     8.59   0.000     55.52235    88.64594
trunk_fat_percent      .224919   .2521104     0.89   0.374    -.2727097    .7225477
                                                                                   
        serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                   
       Total    180403.813   173   1042.7966           Root MSE      =  32.311
                                                       Adj R-squared = -0.0012
    Residual    179572.847   172  1044.02818           R-squared     =  0.0046
       Model    830.965283     1  830.965283           Prob > F      =  0.3736
                                                       F(  1,   172) =    0.80
      Source         SS       df       MS              Number of obs =     174
ehat_linea~f      174    0.94909      6.731     4.356    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
* Normality of residuals check is significant (null rejected)* 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
    
 
                                                                                           
                    _cons     761.2512   305.5506     2.49   0.014     158.0114    1364.491
knot_trunk_fat_percentp75     .0690709   .0410088     1.68   0.094    -.0118916    .1500335
knot_trunk_fat_percentp50    -.1470753   .0667792    -2.20   0.029    -.2789156    -.015235
knot_trunk_fat_percentp25     .1641801   .0724989     2.26   0.025     .0210475    .3073126
       trunk_fat_percent3    -.0719512   .0333991    -2.15   0.033      -.13789   -.0060124
       trunk_fat_percent2     4.680598   2.161648     2.17   0.032     .4129187    8.948277
        trunk_fat_percent    -99.27567   45.27739    -2.19   0.030    -188.6655   -9.885824
                                                                                           
                serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                           
       Total    180403.813   173   1042.7966           Root MSE      =   31.74
                                                       Adj R-squared =  0.0339
    Residual    168240.785   167  1007.42985           R-squared     =  0.0674
       Model    12163.0274     6  2027.17124           Prob > F      =  0.0667
                                                       F(  6,   167) =    2.01
      Source         SS       df       MS              Number of obs =     174
ehat_splin~f      174    0.97659      3.095     2.581    0.00492
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
  
 
* Note: Spline prediction looks good. Biggest cook’s distance is still less than 1 
  
-4
-2
0
2
4
S
tu
d
e
n
ti
z
e
d
 r
e
s
id
u
a
ls
60 80 100 120
Linear prediction
Jacknife Residuals v Predicted
Restricted Cubic Splines Model
0
.2
.4
.6
.8
1
C
o
o
k
's
 D
0 100 200 300
subj_id
Cook Distances
Restricted Cubic Splines Model
   313 
* Compare Linear (1) and Splines (2) side-by-side  
 
 
 
* Partial F-test of Departure from Linearity  
 
* Note: Departure from linearity is marginally significant. Proceed with the linear 
model 
  
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        32.31           31.74   
Adjusted R-squared         -0.001           0.034   
R-squared                   0.005           0.067   
Observations                  174             174   
                                                    
                          (8.391)         (305.6)   
Constant                    72.08***        761.3*  
                                         (0.0410)   
knot_trunk_fat_pe~75                       0.0691   
                                         (0.0668)   
knot_trunk_fat_pe~50                       -0.147*  
                                         (0.0725)   
knot_trunk_fat_pe~25                        0.164*  
                                         (0.0334)   
trunk_fat_percent3                        -0.0720*  
                                          (2.162)   
trunk_fat_percent2                          4.681*  
                          (0.252)         (45.28)   
trunk_fat_percent           0.225          -99.28*  
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.0667
       F(  6,   167) =    2.01
 ( 6)  knot_trunk_fat_percentp75 = 0
 ( 5)  knot_trunk_fat_percentp50 = 0
 ( 4)  knot_trunk_fat_percentp25 = 0
 ( 3)  trunk_fat_percent3 = 0
 ( 2)  trunk_fat_percent2 = 0
 ( 1)  trunk_fat_percent = 0
   314 
*Y =Serum 25-OHD; X = Android Fat Percentage 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Android Fat Percentage 
 
 
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=26.48, p50=33.8 and p75=41.83  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100          62.9            62.9        62.9*
                               75        41.825        39.76315    44.37197
                               50          33.8            32.3        36.2
                               25        26.475            25.6    28.11843
android_fa~t       270          0          12.5            12.5        12.5*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
   315 
* LINEAR MODEL – Fit 
 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
    
 
                                                                                     
              _cons     72.50559   8.392461     8.64   0.000     55.94011    89.07107
android_fat_percent     .1941041    .231229     0.84   0.402    -.2623078    .6505159
                                                                                     
          serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                     
       Total    180403.813   173   1042.7966           Root MSE      =   32.32
                                                       Adj R-squared = -0.0017
    Residual     179667.73   172  1044.57983           R-squared     =  0.0041
       Model    736.082288     1  736.082288           Prob > F      =  0.4024
                                                       F(  1,   172) =    0.70
      Source         SS       df       MS              Number of obs =     174
ehat_linea~f      174    0.94868      6.785     4.374    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
     
                                                                                             
                      _cons     718.6123    304.954     2.36   0.020     116.5504    1320.674
knot_android_fat_percentp75     .0859876   .0390651     2.20   0.029     .0088624    .1631127
knot_android_fat_percentp50    -.1298347   .0500871    -2.59   0.010    -.2287202   -.0309492
knot_android_fat_percentp25     .1350824   .0548391     2.46   0.015     .0268152    .2433496
       android_fat_percent3    -.0626731   .0285218    -2.20   0.029    -.1189828   -.0063633
       android_fat_percent2     4.205491   1.947363     2.16   0.032     .3608691    8.050112
        android_fat_percent    -91.38856   42.97005    -2.13   0.035    -176.2231   -6.554043
                                                                                             
                  serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                             
       Total    180403.813   173   1042.7966           Root MSE      =  31.944
                                                       Adj R-squared =  0.0214
    Residual    170412.528   167   1020.4343           R-squared     =  0.0554
       Model    9991.28454     6  1665.21409           Prob > F      =  0.1412
                                                       F(  6,   167) =    1.63
      Source         SS       df       MS              Number of obs =     174
ehat_splin~f      174    0.96636      4.447     3.409    0.00033
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
 
 
* Note: Spline prediction looks good. Biggest cook’s distance is still less than 1 
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* Compare Linear (1) and Splines (2) side-by-side  
 
 
* Partial F-test of Departure from Linearity 
 
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
  
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        32.32           31.94   
Adjusted R-squared         -0.002           0.021   
R-squared                   0.004           0.055   
Observations                  174             174   
                                                    
                          (8.392)         (305.0)   
Constant                    72.51***        718.6*  
                                         (0.0391)   
knot_android_fat_~75                       0.0860*  
                                         (0.0501)   
knot_android_fat_~50                       -0.130*  
                                         (0.0548)   
knot_android_fat_~25                        0.135*  
                                         (0.0285)   
android_fat_percent3                      -0.0627*  
                                          (1.947)   
android_fat_percent2                        4.205*  
                          (0.231)         (42.97)   
android_fat_percent         0.194          -91.39*  
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.1412
       F(  6,   167) =    1.63
 ( 6)  knot_android_fat_percentp75 = 0
 ( 5)  knot_android_fat_percentp50 = 0
 ( 4)  knot_android_fat_percentp25 = 0
 ( 3)  android_fat_percent3 = 0
 ( 2)  android_fat_percent2 = 0
 ( 1)  android_fat_percent = 0
   320 
*Y =Serum 25-OHD; X = Gynoid Fat Percentage 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Gynoid Fat Percentage  
 
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
 
 
* Note: Above suggests knots at p25=36.28, p50=40.95 and p75=45.2  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100          59.9            59.9        59.9*
                               75          45.2        44.38158    45.97197
                               50         40.95        39.67656        41.9
                               25        36.275              35        37.2
gynoid_fat~t       270          0          16.1            16.1        16.1*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
   321 
* LINEAR MODEL – Fit 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
  
 
                                                                                    
             _cons      76.6577   14.78117     5.19   0.000     47.48185    105.8335
gynoid_fat_percent     .0634391   .3575743     0.18   0.859    -.6423598    .7692379
                                                                                    
         serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                    
       Total    180403.813   173   1042.7966           Root MSE      =  32.383
                                                       Adj R-squared = -0.0056
    Residual    180370.805   172  1048.66747           R-squared     =  0.0002
       Model    33.0079556     1  33.0079556           Prob > F      =  0.8594
                                                       F(  1,   172) =    0.03
      Source         SS       df       MS              Number of obs =     174
ehat_linea~f      174    0.94927      6.707     4.348    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
   
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
* Normality of residuals check is significant (null rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
     
                                                                                            
                     _cons     21.45657   373.3076     0.06   0.954    -715.5538    758.4669
knot_gynoid_fat_percentp75     .1124944   .1147833     0.98   0.328    -.1141191    .3391078
knot_gynoid_fat_percentp50      -.16901   .1459351    -1.16   0.248    -.4571254    .1191054
knot_gynoid_fat_percentp25     .0672372   .0796772     0.84   0.400    -.0900672    .2245416
       gynoid_fat_percent3    -.0009727   .0158987    -0.06   0.951     -.032361    .0304157
       gynoid_fat_percent2    -.0228067   1.405261    -0.02   0.987    -2.797172    2.751558
        gynoid_fat_percent     3.642658   40.26293     0.09   0.928    -75.84728    83.13259
                                                                                            
                 serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                            
       Total    180403.813   173   1042.7966           Root MSE      =  32.322
                                                       Adj R-squared = -0.0018
    Residual    174463.899   167  1044.69401           R-squared     =  0.0329
       Model    5939.91318     6  989.985531           Prob > F      =  0.4626
                                                       F(  6,   167) =    0.95
      Source         SS       df       MS              Number of obs =     174
ehat_splin~f      174    0.95981      5.314     3.816    0.00007
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
 
 
* Note: Spline prediction generally looks good. Cook’s distance > 1 for two 
observations 
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* Compare Linear (1) and Splines (2) side-by-side 
 
* Partial F-test of Departure from Linearity
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
  
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        32.38           32.32   
Adjusted R-squared         -0.006          -0.002   
R-squared                   0.000           0.033   
Observations                  174             174   
                                                    
                          (14.78)         (373.3)   
Constant                    76.66***        21.46   
                                          (0.115)   
knot_gynoid_fat_p~75                        0.112   
                                          (0.146)   
knot_gynoid_fat_p~50                       -0.169   
                                         (0.0797)   
knot_gynoid_fat_p~25                       0.0672   
                                         (0.0159)   
gynoid_fat_percent3                     -0.000973   
                                          (1.405)   
gynoid_fat_percent2                       -0.0228   
                          (0.358)         (40.26)   
gynoid_fat_percent         0.0634           3.643   
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.4626
       F(  6,   167) =    0.95
 ( 6)  knot_gynoid_fat_percentp75 = 0
 ( 5)  knot_gynoid_fat_percentp50 = 0
 ( 4)  knot_gynoid_fat_percentp25 = 0
 ( 3)  gynoid_fat_percent3 = 0
 ( 2)  gynoid_fat_percent2 = 0
 ( 1)  gynoid_fat_percent = 0
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*Y =Serum 25-OHD; X = Android to Gynoid Fat Ratio 
* Lowess Regression Curve and Linear Prediction Fit for the Association between Serum 
25-OHD Levels and Android to Gynoid Fat Ratio  
 
 
 
* Define knots - Lacking specific knots – Define knots using evenly spaced percentiles 
 
* Note: Above suggests knots at p25=0.72, p50=0.84 and p75=0.95  
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* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100      1.776397        1.776397    1.776397*
                               75      .9528462        .9280353    .9741237
                               50      .8389978        .8179142    .8581198
                               25       .721889        .7014008    .7700477
    ag_ratio       270          0      .4048913        .4048913    .4048913*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* LINEAR MODEL – Fit 
 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
    
 
 
                                                                              
       _cons     68.69532    12.1976     5.63   0.000     44.61906    92.77159
    ag_ratio       12.568   14.23693     0.88   0.379     -15.5336    40.66961
                                                                              
   serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    180403.813   173   1042.7966           Root MSE      =  32.313
                                                       Adj R-squared = -0.0013
    Residual    179590.132   172  1044.12868           R-squared     =  0.0045
       Model    813.680118     1  813.680118           Prob > F      =  0.3786
                                                       F(  1,   172) =    0.78
      Source         SS       df       MS              Number of obs =     174
ehat_linea~r      174    0.94686      7.026     4.454    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted") 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
 
 
* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
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*RESTRICTED CUBIC SPLINES – Fit  
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
* Normality of residuals check is significant (null rejected) 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals") 
  
 
                                                                                  
           _cons    -137.8501   786.9147    -0.18   0.861    -1691.433    1415.733
knot_ag_ratiop75    -11034.34   5248.039    -2.10   0.037    -21395.39    -673.288
knot_ag_ratiop50     16732.21   9261.342     1.81   0.073    -1552.194    35016.61
knot_ag_ratiop25    -9161.747   7917.894    -1.16   0.249    -24793.82    6470.321
       ag_ratio3     1788.044   3269.968     0.55   0.585    -4667.759    8243.846
       ag_ratio2    -2873.935   6209.942    -0.46   0.644    -15134.04    9386.173
        ag_ratio     1434.181   3864.864     0.37   0.711    -6196.108     9064.47
                                                                                  
       serum_25d        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                  
       Total    180403.813   173   1042.7966           Root MSE      =   32.13
                                                       Adj R-squared =  0.0101
    Residual    172395.403   167  1032.30781           R-squared     =  0.0444
       Model    8008.40907     6  1334.73485           Prob > F      =  0.2630
                                                       F(  6,   167) =    1.29
      Source         SS       df       MS              Number of obs =     174
ehat_splin~r      174    0.95249      6.282     4.198    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
    
  
* Note: Spline prediction generally appears good. Cook’s distance > 1 for one 
observation 
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* Compare Linear (1) and Splines (2) side-by-side 
 
 
* Partial F-test of Departure from Linearity  
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model 
  
                                                    
rmse                        32.31           32.13   
Adjusted R-squared         -0.001           0.010   
R-squared                   0.005           0.044   
Observations                  174             174   
                                                    
                          (12.20)         (786.9)   
Constant                    68.70***       -137.9   
                                         (5248.0)   
knot_ag_ratiop75                         -11034.3*  
                                         (9261.3)   
knot_ag_ratiop50                          16732.2   
                                         (7917.9)   
knot_ag_ratiop25                          -9161.7   
                                         (3270.0)   
ag_ratio3                                  1788.0   
                                         (6209.9)   
ag_ratio2                                 -2873.9   
                          (14.24)        (3864.9)   
ag_ratio                    12.57          1434.2   
                                                    
                        serum_25d       serum_25d   
                              (1)             (2)   
                                                    
            Prob > F =    0.2630
       F(  6,   167) =    1.29
 ( 6)  knot_ag_ratiop75 = 0
 ( 5)  knot_ag_ratiop50 = 0
 ( 4)  knot_ag_ratiop25 = 0
 ( 3)  ag_ratio3 = 0
 ( 2)  ag_ratio2 = 0
 ( 1)  ag_ratio = 0
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APPENDIX E 
LINEARITY AND SPLINE MODEL FIT FOR SERUM 25-OHD LEVELS 
*Y =Inflammation (hs-CRP); X = Serum 25-OHD  
* Lowess Regression Curve and Linear Prediction Fit for the Association between 
Inflammation and Serum 25-OHD Levels  
  
 
 
* Lacking specific knots – Define knots using evenly spaced percentiles 
 
 
-2
0
2
4
lo
g
 h
s
-C
 R
e
a
c
ti
v
e
 P
ro
te
in
(m
g
/L
)
0 50 100 150 200
Serum 25-OHD (nmol/L)
ths-crp_mgl lowess: ths-crp_mgl
Fitted values
bandwidth = .3
Lowess smoother
-2
0
2
4
lo
g
 h
s
-C
 R
e
a
c
ti
v
e
 P
ro
te
in
(m
g
/L
)
0 50 100 150 200
Serum 25-OHD (nmol/L)
ths-crp_mgl lowess: ths-crp_mgl
95% CI Fitted values
bandwidth = .3
Lowess smoother
* Lower (upper) confidence limit held at minimum (maximum) of sample
                              100         174.3           174.3       174.3*
                               75          97.3        90.27447         108
                               50          72.7        68.11087    77.24457
                               25        55.275        51.33308        60.6
   serum_25d       174          0          21.7            21.7        21.7*
                                                                           
    Variable       Obs  Percentile      Centile        [95% Conf. Interval]
                                                          Binom. Interp.   
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* Note: Above suggests knots at p25=55.28, p50=72.7 and p75=97.3  
* LINEAR MODEL – Fit 
 
* LINEAR MODEL – Diagnostics 
 
 
* Normality of residuals check is significant (null rejected) 
 
* Linear Model Fit – Plot of ("Normality of Residuals")  
  
                                                                              
       _cons    -.4428095   .3188431    -1.39   0.167     -1.07232    .1867008
   serum_25d     .0047232   .0037162     1.27   0.206    -.0026139    .0120603
                                                                              
    tcrp_mgl        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    409.857778   167  2.45423819           Root MSE      =  1.5637
                                                       Adj R-squared =  0.0037
    Residual    405.907787   166  2.44522763           R-squared     =  0.0096
       Model    3.94999093     1  3.94999093           Prob > F      =  0.2055
                                                       F(  1,   166) =    1.62
      Source         SS       df       MS              Number of obs =     168
ehat_lin~25d      168    0.96310      4.733     3.545    0.00020
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Linear Model Fit – Plot of ("Jacknife Residuals versus Predicted")   
 
 
 
 
* Linear Model Fit – Plot of ("Cook Distances")  
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* Note: Linear prediction looks good. Biggest cook’s distance is less than 1 
 
*RESTRICTED CUBIC SPLINES – Fit  
 
 
* RESTRICTED CUBIC SPLINES – Diagnostics 
 
 
 
* Normality of residuals check is significant (null rejected)* 
 
* Restricted Cubic Splines Fit - Plot of ("Normality of Residuals")  
 
                                                                                   
            _cons    -11.75217   8.533572    -1.38   0.170    -28.60434    5.099999
knot_serum_25dp75    -.0000269   .0000445    -0.60   0.547    -.0001149    .0000611
knot_serum_25dp50     .0001467   .0001098     1.34   0.183    -.0000702    .0003637
knot_serum_25dp25    -.0002547   .0001712    -1.49   0.139    -.0005928    .0000834
       serum_25d3     .0001393   .0000973     1.43   0.154    -.0000528    .0003315
       serum_25d2    -.0191812   .0136405    -1.41   0.162    -.0461186    .0077562
        serum_25d     .8396773   .6082801     1.38   0.169    -.3615592    2.040914
                                                                                   
         tcrp_mgl        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                                   
       Total    409.857778   167  2.45423819           Root MSE      =  1.5629
                                                       Adj R-squared =  0.0047
    Residual    393.259265   161  2.44260413           R-squared     =  0.0405
       Model    16.5985128     6   2.7664188           Prob > F      =  0.3458
                                                       F(  6,   161) =    1.13
      Source         SS       df       MS              Number of obs =     168
ehat_spl~25d      168    0.96700      4.233     3.290    0.00050
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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* Restricted Cubic Splines Fit - Plot of ("Jacknife Residuals versus Predicted")  
 
 
 
* Restricted Cubic Splines Fit - Plot of ("Cook Distances") 
    
 
* Note: Spline prediction looks good. One observation has Cook’s distance > 1 
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* Compare Linear (1) and Splines (2) side-by-side  
 
* Partial F-test of Departure from Linearity  
 
* Note: Departure from linearity is NOT significant. Proceed with the linear model. 
* p<0.05, ** p<0.01, *** p<0.001
Standard errors in parentheses
                                                    
rmse                        1.564           1.563   
Adjusted R-squared          0.004           0.005   
R-squared                   0.010           0.040   
Observations                  168             168   
                                                    
                          (0.319)         (8.534)   
Constant                   -0.443          -11.75   
                                      (0.0000445)   
knot_serum_25dp75                      -0.0000269   
                                       (0.000110)   
knot_serum_25dp50                        0.000147   
                                       (0.000171)   
knot_serum_25dp25                       -0.000255   
                                      (0.0000973)   
serum_25d3                               0.000139   
                                         (0.0136)   
serum_25d2                                -0.0192   
                        (0.00372)         (0.608)   
serum_25d                 0.00472           0.840   
                                                    
                         tcrp_mgl        tcrp_mgl   
                              (1)             (2)   
                                                    
            Prob > F =    0.3458
       F(  6,   161) =    1.13
 ( 6)  knot_serum_25dp75 = 0
 ( 5)  knot_serum_25dp50 = 0
 ( 4)  knot_serum_25dp25 = 0
 ( 3)  serum_25d3 = 0
 ( 2)  serum_25d2 = 0
 ( 1)  serum_25d = 0
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